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Abstract 
INTRODUCTION: Cardio-metabolic diseases (e.g. type 2 diabetes mellitus) are a major cause of 
mortality worldwide.  The incidence of cardio-metabolic diseases continues to increase, especially 
in low and middle income countries.  This “pandemic” is possibly brought about by a fairly 
universal shift towards a more “Westernized” diet.  High sugar consumption - a hallmark of the 
“Westernized” diet - may play a key role in the onset of cardio-metabolic diseases.  Accordingly, 
our research focus moved towards sugar-sweetened beverages (SSBs) as it is a major source of 
added dietary sugars.  The current study aimed to elucidate underlying mechanisms leading to the 
development of cardiometabolic diseases by exploiting a novel rat model of long-term SSB intake, 
and by focusing on the liver as a major metabolic organ.  Here we evaluated well-known systemic 
markers together with hepatic proteome analysis and downstream consequences.   
METHODS: Male Wistar rats ( 200 g) were gavaged with 3-5.1 mL SSB daily for three and six 
months, respectively.  The two control groups were gavaged with an iso-volumetric amount of 
water and iso-caloric amount of butter, respectively.  Body weight and systemic blood markers 
were measured.  A proteomic expression analysis was performed on the six-month liver 
samples.  The rest of our experimental work was guided by the proteomic results. Four markers 
for oxidative stress were evaluated: malondialdehyde, conjugated dienes, reduced:oxidized 
glutathioneand oxygen radical absorbance capacity.  The non-oxidative glucose pathways 
(NOGPs): polyol pathway, hexosamine biosynthetic pathway, advanced glycation end-products 
formation and protein kinase C activation; were measured as elevated activity could be 
indicative of impaired glycolytic flux. The liver histology was investigated with Hematoxylin and 
Eosin and Masson’s Trichrome stains, respectively.  Finally, Western blotting techniques were 
used to evaluate markers of inflammation.  
RESULTS:  SSB consumption had little effect on systemic markers of cardio-metabolic health. 
Our proteomic analysis revealed that the expression level of 140 proteins was significantly 
altered in the SSB group, with a major finding that SSB consumption induces hepatic 
endoplasmic reticulum (ER) stress.  Initially the liver adapted to SSB-mediated nutrient overload 
by increasing oxidative phosphorylation, suppressing protein transcription, degrading misfolded 




proteins and improving protein folding capacity.  However, due to prolonged stress liver  cells 
entered an ‘’alarm phase’’ marked by a decrease in mitocholdrial metabolism.   The proteomic 
results further revealed that SSB-induced effects are largely  attributed to excess caloric intake 
versus SSBs per se.  Surprisingly,  oxidative stress did not precede ER stress as there were no 
significant changes in any of the oxidative stress markers here evaluated.  The activity of the 
NOGPs did not increase significantly thus suggesting that moderate SSB intake did not 
suppress glucose metabolism and the glycolytic pathway in particular.  Conversely, SSB intake 
increased hepatic lipid storage while limited changes were detected between the groups 
regarding inflammation and stress signaling.   
 
CONCLUSION:  Frequent SSB consumption triggers metabolic changes in the liver, i.e. ER 
stress despite the lack of obvious manifestation of macroscopic “warning signs”.  Thus the 
current study identifies hepatic ER stress as a relatively early result of long-term SSB 









INLEIDING:  Kardiometaboliese siektes (bv. tipe 2 diabetes mellitus) is wêreldwyd ‘n hoofoorsaak 
van mortaliteit.  Die voorkoms van kardiometaboliese siektes neem voordurend toe, veral in lae- 
en middel-inkomste lande.  Hierdie “pandemie” word moontlik gedryf deur ‘n redelike universiële 
skuif na ‘n meer “Westerse” dieet.  Hoë suikerinname, ‘n kerneienskappe van die “Westerse” 
dieet, speel moontlik ‘n sleutelrol in die ontwikkeling van kardiometaboliese siektes.  Daarvolgens 
fokus ons navorsing op suiker-versoete drankies (SVDs), die hoofbron van ekstra suikers in die 
dieet.  Hierdie studie poog om insig te kry in die onderliggende meganismes wat die ontwikkeling 
van kardiometaboliese siekes dryf, deur ‘n nuwe rot model vir lang-termyn SVD inname te gebruik 
en op die lewer as hoof metaboliese orgaan te fokus.  Sistemiese merkers, veranderings in die 
hepatiese proteoom en die nagevolge daarvan is tydens die studie ondersoek.   
 
METODES:  Manlike Wistar rotte ( 200 g) is daagliks gevoer met 3-5.1 mL SVD deur orale 
toediening vir drie en ses maande, onderskeidelik.  Die kontrole groepe het onderskeidelik ‘n 
isovolumetriese hoeveelheid water ‘n isokaloriese hoeveelheid botter ontvang. Liggaamsgewig 
en sistemiese bloedmerkers is gemeet.  ‘n Proteomiese uitdrukkinganalise is op die ses maand 
lewerweefsel uitgevoer.  Die res van ons eksperimentele werk is deur die proteomika resultate 
gerig. Merkers vir oksidatiewe stres is geëvauleer (malonielaldehied, gekonjugeerde diëne, 
gereduseer tot geoksideerde glutatioonen suurstofradikaal absorbansie kapasiteit).  Die nie-
oksidatiewe glukosepaaie (poliolweg, heksosamien-biosinteseweg, vorming van gevorderde 
glukeringseindprodukte en proteïen kinase C aktivering) is geëvalueer aangesien verhoogde 
aktiwiteit ‘n teken van onderdrukte glikolise kan wees.  Die lewerhistologie is ondersoek deur 
“Hematoksilien en Eosien” en “Massons Trichroom” kleuringstegnieke. Westerse blottegnieke is 
gebruik om merkers van inflammasie te evalueer. 
 
RESULTATE: Matige SVD inname het min effek op sistemiese merkers vir kardiometaboliese 
gesondheid gehad.  Die proteomikaanalise wys dat die uitdrukking van 140 proteïene  
beduidend verander het in die SVD groep en dat SVD inname hepatiese endoplasmiese 
retikulum- (ER) stres veroorsaak.  Aanvanklik het die lewer aangepas by die SVD-bemiddelde 
voedingstofoorlading deur oksidatiewe fosforilasie te verhoog, transkripsie te verlaag en 
proteïenvouing en afbreking te bevorder.  Weens langdurige stres het die lewer selle egter ‘n 




“noodfase” betree, gekenmerk deur ‘n afname in mitokondriese metabolisme.   Verder dui die 
resultate dat die effek van SVDs grootliks aan die oormatige kalorieinname te wyte is, eerder as 
die SVD self. Dit lyk nie asof oksidatiewe stres die voorafgaande “kondisie” is wat ER-stres 
geïnisiëer het nie aangesien daar geen beduidende veranderings in oksidatiewe stres merkers 
waargeneem is nie.  Die aktiwiteit van die NOGPs het nie beduidend verhoog nie, dus is 
glukosemetabolisme en die glikolitiese pad in besonder nie onderdruk nie.  SVD inname het wel 
die stoor van lipiede in die lewer verhoog, maar nie inflammasie en stresseinpaaie geïnisiëer 
nie. 
  
GEVOLGTREKKING: Gereelde inname van SVDs lei tot metaboliese veranderings in die lewer 
soos ER-stres sonder duidelike manifesasie van klassieke vroeë makroskopiese gevaartekens.  
Die huidige studie indentifiseer hepatiese ER-stres as ‘n relatiewe vroeë resultaat van 
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Chapter 1: Literature Review  
1.1 Cardio-metabolic diseases  
Non-communicable diseases pose a major threat to public health worldwide.  During 2011 the 
United Nations announced that - for the first time – non-communicable diseases are a greater 
health risk than infectious diseases in both developed and developing countries (Lustig et al., 
2012).  According to the World Health Organization (WHO), non-communicable diseases result 
in 38 million deaths annually with cardio-metabolic diseases accounting for  19 million of these 
(WHO factsheet #355, 2015).  The umbrella term “cardio-metabolic diseases” describes both 
cardiovascular diseases (CVD) and metabolic conditions such as metabolic syndrome (MetS) 
and Type 2 diabetes mellitus (T2DM).  The increased prevalence of cardio-metabolic disorders 
is strongly associated with behavioral changes like urbanization, the adoption of a more 
sedentary lifestyle and the increasingly universal uptake of a “Westernized” diet (Caballero, 
2005).  This section will provide a brief overview of the prevalence of the major cardio-metabolic 
complications and associated pathophysiology. 
1.1.1 Obesity 
Obesity is one of the most prevalent metabolic conditions and is characterized by excessive fat 
accumulation.  Obesity leads to increased morbidity and mortality through its association with a 
range of pathological states including CVD, certain types of cancer and osteoarthritis (WHO 
Fact sheet #311, 2016).  Furthermore, obesity is robustly linked to insulin resistance, a chief 
underlying cause of MetS and T2DM (Fezeua et al., 2007).  
The prevalence of obesity is increasing on a global scale - in 2014 the WHO reported its 
doubling (since 1980) with more than 600 million adults globally burdened with this condition 
(WHO Fact sheet #311, 2016).  Obesity is also becoming more prevalent amongst children.  It is 
estimated that the percentage of pre-school children in the United States (US) suffering from 
obesity increased from 5% to 9.5% during the period 1970 to 2008 (Garnett et al., 2012).  
Global estimates report that  41 million children (under the age of 5 years) were classified as 
overweight or obese in 2014 (WHO Fact sheet #311, 2016). Moreover, obesity which was once 
considered to be exclusive to high-income countries, is now increasingly emerging as a health 
issue in low- and middle-income countries.  For example the number of obese children in Africa 
has doubled over the past  25 years (WHO Fact sheet #311, 2016).   




1.1.2  MetS  
MetS refers to a cluster of metabolic conditions including obesity, impaired glucose tolerance 
and dyslipidemia that manifest concurrently in an individual and serves as a prognostic tool for 
the future development of T2DM and CVD.  Individuals with MetS are about 5 times more likely 
to develop T2DM compared to matched controls, and about twice as likely to develop CVD 
(Park et al., 2003).  MetS is also associated with several other complications including non-
alcoholic fatty liver disease and polycystic ovary syndrome (reviewed by Baranova et al., 2011).  
There are currently four definitions for MetS, stipulated by the International Diabetes Federation 
(IDF), WHO, European Group for Study of Insulin Resistance (EGIR) and the National 
Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). The NCEP ATP III 
definition is very similar to that of the IDF (refer to Table 1.1.1), while impaired glucose tolerance 
and elevated insulin levels are mandatory conditions for the WHO and EGIR definitions (Parikh 
& Mohan, 2012).  Although the prevalence of MetS varies depending on the diagnostic criteria 
used, this condition remains a pressing global health issue.  Almost  37% of US adults 
exhibited MetS according to criteria stipulated by the IDF (Ford, 2005).  Furthermore, in most 
European countries the average prevalence of MetS in adults exceeds 20%, with some 
countries reaching a staggering 40% (reviewed by Grundy, 2008; Tanner et al., 2012).  There is 
a similar tendency in Africa with some populations showing a prevalence of up to  50% 
(reviewed by Okafor, 2012).  Here it is important to note that none of the available definitions of 
MetS has been fully optimized for African ethnicity.  MetS also has a high prevalence amongst 
children and adolescents which Grundy (2008) argues to be directly linked to increased obesity 
levels in younger populations.   
  


































Waist circumference (ethnic-specific): 
Europids; Sub-Saharan Africans; Middle East; 
Eastern Mediterranean 
 ≥ 94 cm (males) 
 ≥ 80 cm (females) 
South Asian; Chinese; Japanese; South and 
Central Americans 
 ≥ 90 cm (males) 
 ≥ 80 cm (females)  
Raised triglycerides (TGs) ≥ 1.7 mmol/L or on treatment for lipid abnormality 
Reduced high-density 
lipoprotein (HDL) cholesterol 
< 1  mmol/L (males) 
<1.3 mmol/L (females) 
Increased blood pressure Systolic ≥ 130 mmHg 
Diastolic ≥ 85 mmHg 
Or on treatment for previously diagnosed 
hypertension 
Elevated fasting blood glucose  ≥ 5.6 mmol/L or previously diagnosed with T2DM 
Table 1.1.1: IDF Global MetS definition (Alberti et al., 2009) 




Figure 1.1.1:  IDF projections for the global increase of T2DM (2014 and 2035) are 
53%.  The prevalence of diabetes in Africa, Asia and South America is expected to 
increase more rapidly than in Europe, North-America and the Caribbean (adapted from 
IDF Diabetes Atlas, 2014).    
 
 
1.1.3   T2DM  
There are two major categories of diabetes mellitus, namely type 1 and type 2.  Type 1, which 
accounts for ~5-10% of cases, is an auto-immune condition characterized by damaged 
pancreatic β-cells that result in insufficient insulin secretion.  On the contrary, poor dietary 
choices can lead to reduced insulin sensitivy and are thus a major contributing factor to the 
development of T2DM (90-95% of all diabetic cases) (Marcovecchio et al., 2011).  
 
↑53% 
Africa - ↑93% 
Middle East and North Africa - ↑85% 
South East Asia - ↑64% 
South and Central America - ↑55% 
Western Pacific - ↑46% 
Europe - ↑33% 
North America and Caribbean - ↑30% 




 A study on the international burden of T2DM (1995 – 2025) projected that the global prevalence 
of diabetes will rise to  300 million by 2025 (King et al., 1998), but this figure was already 
exceeded in 2011.  It is now estimated that  422 million people are currently suffering from 
T2DM globally and it is predicted that the prevalence of T2DM will increase to  642 million by 
2040 (IDF Diabetes atlas, 2015; WHO Global Diabetes Report, 2016).  This will elevate 
diabetes to the seventh leading cause of death worldwide (WHO Fact sheet #312, 2016) with 
the majority of such mortalities occurring in low- and middle-income countries where the 
incidence of T2DM is rapidly increasing (IDF Diabetes Atlas, 2014; WHO Fact sheet #312, 
2016).  South Africa is not unique in this regard – here metabolic disorders already account for 
 6% of all mortalities (StatsSA, 2013).  The picture remains bleak as the IDF predicts that Africa 
will suffer the highest increase globally in terms of T2DM incidence (2014 to 2035) with an 
estimated increase of  93% versus  53% expected globally (Figure 1.1.1).  Moreover, an 
increasing number of T2DM cases (together with obesity and MetS) are now also reported for 
children and adolescents (Vivian, 2006).  Together these data raise concerns as to whether this 
growing prevalence will taper down in the foreseeable future. 
In order to determine the T2DM burden of disease it is necessary to also consider conditions 
that likely result from this condition, e.g. neuropathy, chronic kidney disease, end-stage renal 
failure, retinopathy and CVD (DeFronzo et al., 1992).  Such conditions are largely caused by 
micro- and macro-vascular dysfunction induced by chronic hyperglycemia associated with 
T2DM and can be equally fatal (Ha et al., 2008).  The IDF Diabetes Atlas estimated that 40 000 
– 100 000 deaths in South Africa during 2011 were attributed to diabetic complications alone 
(IDF Diabetes Atlas, 2011).  Additionally, T2DM is also a primary risk factor for CVD, the 
number one killer worldwide.   
 
1.1.4 CVDs 
CVDs are the leading cause of death worldwide.  In 2012 it accounted for  17.5 million 
mortalities and it is estimated to increase to 23.3 million by 2030 (WHO factsheet #317, 2016).  
As with the other condition, future projections indicate that low- and middle-income countries will 
be most severely affected by CVD (WHO factsheet #317, 2016).  In South Africa CVDs caused 
17% of all deaths in 2013 (StatsSA, 2013). Ischemic heart disease accounts for the largest 
percentage of such mortalities, followed by hypertension-related heart diseases (WHO 




Factsheet #317, 2016).  Ischemic heart disease is characterized by an insufficient blood supply 
and nutrients to the heart through the coronary arteries, resulting in myocardial infarction.  
Hypertensive heart disease refers to a state where chronic hypertension caused pathological 
cardiac hypertrophy and cardiac inefficiency (Guyton & Hall, 2011).   
In summary, the statistics and projections regarding the prevalence of cardio-metabolic 
diseases serve as motivation for comprehensive research into the underlying molecular 
mechanisms driving these diseases. Although a variety of detrimental lifestyle choices such as a 
sedentary behavior, smoking, high intake of salt and processed foods all contribute to the 
cardio-metabolic pandemic, excess sugar consumption has been identified as one of the most 
prominent global dietary changes observed during the past few decades and a primary driver of 
cardio-metabolic diseases  (Fagherazzi et al., 2013) (Figure 1.1.2).  A study conducted in the 
US over four years (2005 - 2009) established that 74% of the 85, 451 different edible products 
on the market contained added sugars; these products include mainly cereals, energy bars and 
beverages (Ng et al., 2011).  Sugar-sweetened beverages (SSBs) are proposed to be the main 
culprit with estimates indicating that  46% of added sugars are consumed through SSBs (US 
Department of Agriculture & US Department of Health and Human Services, 2010).  For this 
reason, the focus of cardio-metabolic research gradually shifted to SSBs as a leading source of 
sugar-derived calories.  Section 1.2 concentrates on the consumption trends and health risks 
associated with SSBs.  




Figure 1.1.2:  Global trends in sugar consumption expressed as the amount of 
teaspoons of sugar consumed per person per day (only selected countries are displayed 
here).  Sugar consumption in low- and middle-income countries globally is on the rise, refer 
e.g. Mexico and Brazil.  This trend is equally prominent in Africa where sugar intake in most 
southern African countries is above the recommended daily amount put forward by the 
World Health Organization in 2015 (no more than six teaspoons per day, see * on diagram).  




1.2 Sugar-sweetened beverages  
The emphasis on SSBs as a source of sugar has increased since the latter has been identified 
as a key factor in the cardio-metabolic “pandemic”.  SSB consumption increased drastically in 
the last 30 years of the twentieth century.  The ingestion of SSBs leads to excessive sugar and 
calorie intake and it is associated with general unhealthy lifestyle choices e.g. frequent fast-food 
intake (Miller et al., 2013).  This section explores global trends in SSB consumption, as well as 
the association between SSB intake and cardio-metabolic disease risk.    




1.2.1  SSB consumption 
The first SSB was produced and consumed in the 1800s, but only gained popularity during 
World War II when free Coca Cola™ products were donated to the US army (reviewed by 
Pendergrast, 2000, Wolf et al., 2008).  The consumption of all SSBs types including carbonated, 
sports, fruit drinks and vitamin waters increased significantly between 1970 and 2000, and 
continued to increase in the 2000s in most parts of the world (reviewed by Basu et al., 2013).     
Interestingly, there has been a modest decrease in SSB consumption in the US since the turn of 
the millennium (Hert et al., 2014; Welsh et al., 2011).  Despite the decrease, SSB consumption 
in the US still exceeds the recommended daily allowance as stated by the WHO.  The WHO 
recently released a bulletin (2015) suggesting that added sugar consumption should be kept 
below 5% of total caloric intake ( six teaspoons) and not 10% ( 12 teaspoons) as stated in the 
2003 dietary guideline  (Guideline: Sugars intake for adults and children, 2015). According to 
the US National Health and Nutrition Examination Survey (NHANES) (2005-2008) a quarter of 
the US population consumed at least 1.5 cans of SSB daily ( 10% of total recommended 
calories) and  5% consume at least 4 cans per day (> 25% of total recommended calories) 
(Ogden et al., 2011).  On average SSBs account for  9.2% of total caloric intake in the US 
(Miller et al., 2013) with the highest being among low-income individuals such as African-
Americans and Hispanics who also show an inordinate prevalence of obesity and related 
diseases (Hu, 2013).  SSB-related behavioral patterns are also dependent on age and gender.  
Data from the US reveal that children and adolescents obtain  11% of their total daily caloric 
intake from SSB-derived sugar consumption (Wang et al., 2008) and 12% (294 kcal) in the case 
of male adolescents (Miller et al., 2013).  Alarmingly, it has also been reported that  50% of 2-
year olds US consume SSBs on a weekly basis (Garnett et al., 2012).  
Despite the decrease in SSB consumption in the US, research suggests that it is still on the rise 
globally as reported in a recent study evaluating SSB intake in 75 countries (Basu et al., 2013).  
Additional support comes from country-specific studies, e.g. in the United Kingdom  the amount 
of SSB consumed per capita per week has doubled since 1975 and continues to increase (Ng et 
al., 2012).  This also reflects in SSB-derived calories that increased from 113 (1986-1987) to 
155 KJ/capita/day (2000-2001) and further to 209 KJ/capita/day by 2008-2009 (Ng et al., 2012).   
Likewise, in South Korea the prevalence in SSB consumption between 2001 and 2009 
increased with 7%, 3%, 7% and 18% amongst adolescents, young adults, adults and aged 
groups, respectively (Han et al., 2013). Here the highest prevalence of consumption manifested 




in the adult group (70%).  Of note, this study included sweetened tea/coffee that are generally 
not considered to be SSBs.  SSB sales are also rapidly increasing in low- and middle-income 
countries such as China where the trading of Coca Cola™ and PepsiCo™ products increased 
by 145% and 127%, respectively, between 2000 and 2010 (Kleiman et al., 2012).  Similarly, 
SSB sales increased between 1999 and 2012 in Mexico (Stern et al., 2014).  Here consumption 
of caloric beverages increased drastically (1999-2006) amongst Mexican children e.g. pre-
schoolers derives 27.8% of their daily caloric intake from beverages.  However, this is possibly 
an overestimation as it includes non-sweetened caloric beverages such as milk (Barquera et al., 
2010).  Of particular interest is a South African-based study where 1,233 subjects (rural and 
urban communities in the Western Cape) completed a 5-year follow up study (Vorster et al., 
2014).  Lifestyle questionnaires revealed that the proportion of participants who consume SSBs 
increased from 25% to 56% and 33% to 63% in males and females, respectively, over the 
period of the study.  Moreover, the percentage of participants who consumed more than 10% of 
their daily caloric intake from added sugars increased from 18% to 40% (males) and 29% to 
46% (females) (Vorster et al., 2014).  
1.2.2 The problem with SSB consumption 
Why is it so concerning that SSB consumption is increasing on a global scale?  Frequent SSB 
intake may contribute to the onset of cardio-metabolic diseases – one important mechanism is 
by increasing total calorie intake (Miller et al., 2013).  In support, a US-based study examining a 
dietary survey and recall of 488 adults, found that the daily caloric intake of SSB consumers is 
 572 kcal higher compared to non-consumers (Ruff et al., 2014).  Groundbreaking work by 
Mattes (1996, 2006) and Rolls et al. (1990) provide a possible explanation for this increase.  
Here they found that liquids that are high in energy but have a very low viscosity e.g. SSBs 
trigger a limited sensation of satiety despite a high caloric count. Thus subsequent food 
consumption is not reduced to compensate for the SSB-derived calories and hence extra 
calories are likely to be consumed.     
Another explanation is that SSB intake often occurs together with other poor lifestyle choices, 
e.g. SSB consumers are more likely to consume unhealthy foods (e.g. pizza, hamburgers and 
savory snacks) compared to non-consumers (Mathias et al., 2013).  Another study that explored 
dietary preferences found that SSBs are most often paired with calorie-dense food (Cornwell & 
McAlister, 2013).  These data are supported by a cross-sectional study (9,433 subjects) that 
found SSB consumption is associated with higher intake of fast foods, savory snacks, iced 




puddings and total sugar in an adolescent cohort (Collison et al., 2010).   These findings also 
revealed that significantly more vegetables are consumed when meals are accompanied by 
water instead of SSBs (Cornwell & McAlister, 2013).  In agreement, SSB consumers of all ages 
are more prone to snacking between meals than their counterparts, resulting in a higher calorie 
intake (Bleich & Wolfson, 2015).   Frequent SSB consumption is also associated with other 
unhealthy lifestyle choices such as smoking and lack of exercise (Kristal et al., 2015).  Together 
these studies indicate the SSB consumption is often not an isolated problem, but instead  
associated with several wide-ranging unhealthy dietary choices that ultimately leads to the onset                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
of cardio-metabolic diseases. 
Besides overall calorie consumption and unhealthy lifestyle, the sugar used for sweetening 
SSBs may also directly induce pathological molecular events.  Additionally, the ‘type’ of sugar 
could also play a significant role in the consequences of SSB consumption (Aerberli et al., 
2011). Commercially available SSBs in the US are generally sweetened with sucrose or high 
fructose corn syrup (HFCS) (Aerberli et al., 2011).  HFCS is the preferred choice of sweetener 
since the higher fructose content provides a sweeter taste (Bray et al., 2004).  Bray et al. (2004) 
found that the consumption of fructose (mainly in the form of HFCS) increased by almost 30% 
during the last three decades and is considered a major culprit in the onset of metabolic 
perturbations. There is no set formula for HFCS. Generally HFCS contains 42% or 55% 
fructose, but Ventura et al. (2011) demonstrated that HFCS-sweetened SSBs contain an 
average of 59% fructose, while some leading US brands contained up to 65% fructose.  HFCS 
has been named and shamed both in popular media and academic circles, yet to date there is 
not sufficient evidence that HFCS has more severe health consequences compared to sucrose 
(reviewed by Rippe & Angelopoulos, 2016). 
In South Africa SSBs are usually sweetened with sucrose (also known as table sugar) (Vorster 
et al., 2014).  Sucrose is a disaccharide consisting of equal amounts of glucose and fructose 
molecules (Maersk et al., 2012) and is sometimes considered to be a “healthier option”.  
However, it is still strongly related to greater weight gain and obesity risk (Ventura et al., 2011).  
The manifestation of chronic SSB consumption is thus determined by both the amount and 
content of the ingested sweetener (Aerberli et al., 2011).  Although a theoretical approach 
provides convincing concerns regarding SSB consumption, it requires support from observed 
and experimental data.  The following section explores epidemiological and clinical data on the 
link between frequent SSB intake and disease risk.  




1.2.3  Metabolic derangements and disease risk  
There is considerable observational data linking higher SSB consumption to increased risk for 
the development of obesity,  MetS, T2DM, CVDs (reviewed by Malik et al., 2010) non-alcoholic 
fatty liver disease (Abid et al. 2009) and chronic kidney disease (Yuzbashian et al., 2015).  Yet 
the question whether sugar consumption actually leads to the onset of cardio-metabolic disease 
remains controversial (Stanhope, 2015).  The subsequent sections will elaborate on the merits 
and limitations of current epidemiological and (limited) clinical data linking SSB consumption to 
cardio-metabolic diseases. 
1.2.3.1  Weight gain and obesity  
Although epidemiological studies are often criticized, there are ample large-scale long-term 
cohort studies that provide considerable statistical evidence to prove the positive association 
between SSBs and weight gain and the eventual risk of developing obesity (Malik et al., 2010).  
For example, Shulze et al. (2004) followed more than 50, 000 female nurses for 2  four-year 
periods and established that participants consuming one or more SSB serving per day gained 
significantly more weight (8 kg) than those consuming less than 1  SSB serving per week (2.8 
kg). In agreement, others evaluated the weight gain of more than 40, 000 African American 
females for six years and found the largest gain in the group where consumption increased to 
more than one SSB serving per day (Palmer et al., 2008).  Moreover, the lowest weight gain 
was observed in the group who reduced their SSB consumption.  Similar results were also 
observed in a cohort of > 43, 000 Singaporean males and females where significant weight gain 
was observed in participants consuming ≥ 2 SSB servings per week compared to those who 
rarely consumed SSBs (Odegaard et al., 2010).  A South African-based study also reported a 
positive association between SSB consumption and obesity by evaluating waist circumference, 
body mass index (BMI) and lipid profile (Vorster et al., 2010).  After a 5-year follow-up period, 
participants who consume ≥ 10% of daily caloric intake from added sugars (of which SSBs are a 
significant source) displayed larger waist circumferences, higher BMIs as well as lower levels of 
HDL-cholesterol (Vorster et al., 2010).  Observational data further showed that decreasing SSB 
intake can lead to weight loss.  The Clinical Trial of Comprehensive Lifestyle Modification for 
Blood Pressure Control (PREMIER) study showed that decreasing SSB consumption by one 
serving daily resulted in weight loss within a 6-month time frame (Chen et al., 2009).  A similar 
study was conducted in obese adolescents where the lowering of SSB consumption for one 
year resulted in significant decreases in weight and BMI (Ebbeling et al., 2006; Ebbeling et al., 




2012).  However, no significant differences were observed between the two groups a year later, 
proving the complexity of such interventions (particularly within the school system). 
Due to the popularity of SSBs amongst children and the increasing prevalence of childhood 
obesity, cross-sectional and longitudinal epidemiological studies also explored the correlation 
between SSB intake and weight gain in children (Malik et al., 2010).  Data gathered from across 
the globe support the notion that frequent SSB consumption in children leads to significant 
weight gain.  For example, the European Youth Heart Study monitored 358 children for 6 years 
and concluded that SSB consumption is directly associated with an increased body fat 
percentage in children and adolescents (Zheng et al., 2015).  In accordance, Chinese children 
(n > 6, 900) who regularly consume SSBs exhibited significantly higher BMIs and waist 
circumferences compared to regular milk consumers and have an increased risk of developing 
obesity (Shang et al., 2012).  A cross-sectional study confirmed the positive correlation between 
SSB intake and the prevalence of obesity amongst Chinese children and adolescents (n = 702) 
(Jia et al., 2012).  An earlier study where more than 2, 000 Canadian toddlers (2.5 years of age) 
were monitored for three years reported that those who frequently consumed SSBs between 
meals were  2.4  more likely to be overweight than their counterparts (Dubois et al., 2007).  
Research by DeBoer et al. (2013) also found a positive association between SSB consumption 
and weight gain in children as young as two years old.  Although the BMI z-score did not differ 
significantly between groups at the two year-old age, a prospective analysis showed that 
frequent consumption in this group resulted in a significant increase in BMI compared to 
infrequent/non-consumers over the following two years (DeBoer et al., 2013). Furthermore, 
frequent SSB consumption is associated with a high risk of developing obesity in five-year old 
children (DeBoer et al., 2013).  A significant association between SSB intake and obesity was 
also observed in a cohort of Mexican American children (aged 8 – 10) (Beck et al., 2014) and 
Australian children and adolescents (Grimes et al., 2013). Here participants consuming more 
than one SSB serving daily exhibited a 26% increased risk of developing obesity (Relative risk 
[RR]: 1.26, 95 % CI: 1.03-1.53).  Moreover, a Spanish study that used a matched case-control 
design (comparing 174 obese children/adolescents to 174 healthy body weight controls) found 
that the obese cohort consumed significantly more SSBs compared to the healthy cohort.  The 
cases and controls were age and gender matched (Martin-Calvo et al., 2014).  Together these 
studies demonstrate a robust positive correlation between SSB intake and weight gain in 
children and adolescents.  Additionally, a recent clinical study used functional magnetic 
resonance imaging to evaluate sugar-induced brain perfusion (Jastreboff et al., 2016).  The 




patterns detected in obese adolescents were markedly different from lean adolescents and may 
indicate that the obese participants have developed a sugar addiction, thus perpetuating a 
vicious cycle (Bray, 2016).  In light of these studies, it has been recommended that pediatricians 
and parents should strongly discourage SSB consumption by children (DeBoer et al., 2013) 
However promising this may be, there are still some studies that produced negative or neutral 
results.  In a cohort of school-aged Saudi Arabian boys (n = 5, 033) and girls (n = 4, 400) SSB 
intake showed a positive correlation to BMI and waist-circumference in the male, but not the 
female cohort after the adjustment for potential confounders (Collison et al., 2010).  Others also 
found no significant association between SSB consumption and body fat percentage in a cohort 
of British children (Johnson et al., 2007).  Of note, the SSBs consumed for this study only 
accounted for  3% of the daily calorie intake and may explain this surprising outcome.  Despite 
these studies, the weight of evidence strongly support the notion that frequent SSB 
consumption leads to an increased risk of weight gain and obesity in young and adult 
populations.  Some of the inconsistency in the data may be due to variation in methodology and 
study design (Poppitt, 2015).  For example, the lack of standardization of measurements used 
to assess obesity make it difficult to interpret the results of various studies (Poppitt, 2015).  
While some studies only measured weight gain, others measured BMI, waist-to-hip ratio or 
skinfold thickness (all markers of obesity).  In a cohort of 2, 045 Costa Rican adults, (Rhee et 
al., 2012) found that frequent SSB consumption was associated with a significant increase in 
BMI and waist-to-hip ratio, but not skinfold thickness, showing variability between various 
markers.  Another concern is that many findings do not take the sex of participants into account 
although it is evident that this factor may contribute to complexity of the results.  A study of a 
large German cohort (n > 17, 000) found a significant relationship between SSB consumption 
and obesity in males, but not females after a four-year follow up period (Shulze et al., 2002).  By 
contrast, a cross-sectional survey of Chinese males (n = 2, 295) and females (n = 2, 334) found 
that the frequency of SSB consumption as an independent risk factor for obesity in females, 
while a sedentary lifestyle, a meat-rich diet and smoking were better predictors of obesity in 
males (Ko et al., 2010).  All things considered, epidemiological data strongly suggest that 
frequent SSB intake is linked to weight gain and obesity.  Nonetheless, researchers should take 
care when selecting study design, parameters and a cohort. 




1.2.3.2  MetS and T2DM   
High SSB consumption is also considered to be a risk factor for the onset of MetS and T2DM 
(Malik et al., 2010).  Dhingra et al. (2007) investigated the development of MetS in an adult 
cohort (n > 6, 000) over a four-year period and concluded that consuming one or more SSB 
serving daily increased the risk for developing MetS by  44%.  They further elucidated the 
effects of SSBs on the respective components of MetS.  Here subjects consuming ≥ 1 SSB 
serving/day displayed an increased prevalence of obesity (RR: 1.31; 95 % CI: 1.02–1.68), 
greater waist circumference (RR: 1.30; 95 % CI: 1.09-1.56), hypertension (RR: 1.18; 95 % CI: 
0.96–1.44), elevated fasting glucose (RR: 1.25; 95 % CI: 1.05–1.48), hypertriglyceridemia (RR: 
1.25; 95 % CI: 1.04–1.51) and decreased HDL-cholesterol (RR: 1.32; 95 % CI: 1.06–1.64) 
compared to those who did not consume SSBs on a daily basis (Dhingra et al., 2007).  In 
agreement, data from an adult Mexican cohort (n > 5, 200) also demonstrated that frequent 
SSB consumption leads to increased risk for all the attributes of MetS (Denova-Gutiérrez, et al., 
2010).  Others focused specifically on the effects of SSB consumption on insulin resistance by 
using the homeostasis model assessment for insulin resistance (HOMA-IR) as an indicator 
(Kondaki et al., 2012).   For this cohort (546 European adolescents) they found that the HOMA-
index is significantly higher in participants consuming SSBs at least 5-6 times/week compared 
to those consuming less than one SSB per week (Kondaki et al., 2012).  Besides the studies 
described here there are limited epidemiological data available to support the association 
between SSB consumption and the development of MetS as most of the research focused on 
T2DM instead.      
Murphy et al. (2015) investigated the link between SSB consumption and T2DM by collecting 
data from a diabetic cohort (n = 580).  Here 49% of the participants consumed SSBs on a daily 
basis and  9% consumed four or more servings per day.  These data show that diabetic 
individuals do not follow health guidelines by abstaining from SSB consumption despite being 
diagnosed with T2DM.  The bigger question is, however, how many SSBs were consumed prior 
to the diagnosis and whether SSB intake actually contributed to T2DM onset?  A follow-up study 
of 8 years found that participants consuming ≥ 1 SSB/day were  83% more likely to develop 
T2DM compared to those whose intake were less than one per month (Schulze et al., 2004).  
However, this study did not adjust the data for BMI variations as is the general practice.  
Similarly, another study found a significant association between SSB intake and T2DM risk in a 
cohort of > 43, 000 Singaporeans (Odegaard et al., 2010).  Here the consumption of as little as 
≥ 2 SSB servings/week caused a 34% increase in disease risk compared to non- or infrequent 




consumers, while consumption of ≥ 2 fruit juice servings per week was also associated with a 
24% higher risk (Odegaard et al., 2010).  Bhupathiraju et al. (2013) undertook a long term study 
with a pooled cohort of over > 110,000 participants and confirmed that frequent SSB intake 
increased the risk for developing T2DM regardless of whether the SSB is caffeinated or not.  
Recently, Teshima et al., (2015) also found that frequent SSB consumers had more than twice 
the risk to develop T2DM to non-consuming counterparts  Lastly, a number of smaller studies 
also provide support for the positive association between SSB consumption and the 
development of T2DM (De Koning et al., 2011; Nettleton et al., 2009; The InterAct Consortium, 
2013). 
However, not all of the studies found a positive correlation between SSB intake and T2DM 
onset.  For example, Palmer et al. (2008) established that participants who consumed two or 
more SSBs daily were more prone to developing T2DM than those consuming one or less per 
month, but the results were not significant after adjustments for BMI.  These data therefore 
indicate that obesity was the biggest contributor to T2DM in this instance.  Paynter et al. (2006) 
also rejected the notion that SSB consumption is significantly associated with an increased risk 
of developing T2DM.  In addition, there should also be a consideration for the role of ethnicity.  
For example, a cohort of more than 2, 037 middle-aged Japanese males (followed for 7 years) 
displayed no significant association between any of the SSB categories and the development of 
T2DM, although the consumption of diet soda was positively linked to the onset of T2DM 
(Sakurai et al., 2014).  
Most studies discussed used intervals of SSB consumption (lowest: < 1 SSB per month; 
highest: ≥ 1 SSB per day) but Fagherazzi et al. (2013) designed a model to describe the 
continuous correlation between SSB consumption and T2DM development.  In this instance the 
consumption of SSBs (0 – 1, 000 mL per week) is directly related to a greater T2DM risk (RR: 
1.3; 95 % CI: 1.03–1.66).  However, when volumes larger than 1, 000 mL is consumed the 
frequency of consumers and statistical power are too low to make meaningful conclusions.  
Similarly, an analysis with pooled data attempted to determine the dose-dependent correlation 
between SSB consumption and T2DM risk.  Here it was established that every 330 mL SSB 
serving (per day) relates to a 20% increase in the risk of developing T2DM, thus clearly 
indicating a positive relation between disease risk and SSB intake (Greenwood et al., 2014) 
(see Figure 1.2.1).   
 













Table 1.2.1 provides a brief summary of the epidemiological studies investigating the 
association between SSB consumption and T2DM.  We conclude that SSBs may play a central 
role in the onset of MetS and T2DM although some controversy still exists. Clinical data are 
required to confirm these findings and elucidate possible molecular mechanisms involved.
Figure 1.2.1: The association between daily SSB intake and the risk of 
developing T2DM.   Data from five publications were combined and show the risk of 
developing T2DM increase in a dose-dependent manner – the pooled RR increase by 
20% (95 % CI 1·12, 1·29 indicated by the dotted lines) for every 330 mL SSB serving 
consumed daily (Greenwood et al., 2014).     
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Study II; US 
> 91, 000; F; 
24 – 44 
8 
1.83 (1.42– 2.36), 
≥ 1 serving/day vs. <1/month 




Health Study; China 
> 43, 000; F ; 45-
74 
5.7 
1.34 (1.17, 1.52), 
≥ 2 serving/week vs. rarely 
< 0.001 Yes / No 
Palmer et al., 
2008 
Black Women’s 
Health Study, US 
> 43, 000; 10 
1.24 (1.06– 1.45), 
≥ 2 serving/day vs. ≤ 1/month 
0.0002 Yes / No 
Sakurai et al., 
2014 
Japan 
> 2, 000; M; 35-
55 
7 
1.34 (0.72– 2.36), 
≥ 1 serving/day vs. rare/never 




> 66, 000; F; 53 
  7 
14 
1.30 (1.02– 1.66), 
359 mL/week vs. never 











Daily intake vs. never 
0.0198 Yes / No 
Nettleton et 
al., 2009 
Multi-Ethnic Study of 
Atherosclerosis; US 
> 5, 000; M & F; 
45 – 84 
5 
1.38 (1.04–1.82), 
≥ 1 serving/day vs. rare/never: 







> 15, 000; M; 
Mean age 55.6 
6.9 
1.29 (1.02– 1.63), 
≥ 1 serving/day vs. <1/month 
0.013 Yes / Yes 
Bhupathiraju 




Follow-up Study; US 
> 39, 000; M; 40-
75 
22 
1.37 (1.08– 1.74), 
≥ 1 serving/day vs. < 1/month 
0.002 Yes / Yes 
Bhupathiraju 
et al., 2013  
The Nurses’ Health 
Study I; US 
> 74,000; M; 30-
55 
24 
1.20 (1.01– 1.42), 
≥ 1 serving/day vs. < 1/month 
0.05 Yes / Yes 
de Koning 
et al., 2011 
US 
> 40,000; M; 40-
75 
20 
1.24 (1.09– 1.40) 
4.5 servings/week to 7.5/day 
vs. never 
< 0.01 Yes / Yes 
Table 1.2.1: Studies investigating the link between SSB consumption and T2DM risk (adapted from Greenwood et al., 2014 and 
Wang et al., 2015). 
 
Stellenbosch University  https://scholar.sun.ac.za





SSB intake is considered to be a risk factor for CVD (independent of BMI changes) (reviewed by 
Richelsen, 2013) and literature suggests that it contributes to such conditions by promoting 
hypertension, triggering inflammation and altering the lipid profile (Malik et al., 2010).  As 
hypertension is a component of MetS and a major risk factor for CVD, an immediate question 
that arises relates to the link between SSB intake and hypertension.  Several studies 
established a positive correlation between SSB consumption and hypertension (Nettleton et al., 
2009). For example, the NHANES (2003 – 2006, > 3, 000 adults) found no correlation between 
overall sugar intake and blood pressure, but the daily consumption of SSBs (≥ 1 to < 3 servings) 
caused a 43% increase in the risk for developing hypertension (Kim et al., 2012).  The NHANES 
also indicated that every additional SSB serving consumed daily ( 240 mL) caused a 0.16 mm 
Hg upsurge in systolic blood pressure (1999 – 2004; n > 6, 5000) (Bremer et al., 2009).  In 
agreement, Nguyen et al. (2009) used a similar dataset from the NHANES (1999-2004; n > 4, 
500) and affirmed a correlation between SSB consumption and increased systolic blood 
pressure in adolescents.  However, the latter conclusion has been criticized because published 
adult norms were directly applied to an adolescent cohort (White, 2009).  A study that used a 
dataset from the International Study of Macro and Micronutrients and Blood Pressure 
(INTERMAP) (1996-1999; n > 2, 500)  linked daily SSB consumption (≥ 360 mL) to a 1.6 mm Hg 
increase in systolic blood pressure (Brown et al., 2011).  Others, however, found the exact 
opposite, i.e. SSB intake is rather a good indicator of increased diastolic blood pressure (Tayel 
et al., 2013).    
Prospective data from the Coronary Artery Risk Development in Young adults (CARDIA) study 
(n > 2, 500) revealed that frequent SSB consumption causes a marginal increase (6%) in the 
risk of developing hypertension (Duffey et al., 2010).    Furthermore,  a pooled analysis from 
three prospective cohorts (The Nurses’ Health Study [NHS] I and II as well as the Health 
Professionals Follow-up study [HPFS]; total n > 220, 000) and found that there is a 13% (RR: 
1.13; 95 % CI: 1.09–1.17) higher incidence of hypertension in the population consuming ≥ 1 
SSB serving/day compared to non-consumers (Cohen et al., 2012).  The association between 
carbonated drinks and hypertension was significantly stronger compared to non-carbonated 
ones in all three cohorts while the consumption of cola-containing SSBs also indicated a 
stronger link to hypertension compared to non-cola SSBs (NHS I; HPFS).  Increased SSB-
derived fructose intake also showed a robust association with the development of hypertension 
(NHS I; NHS II).  Similarly, Winkelmayer et al. (2005) used data from the NHS I and II (total n > 




230, 000) in a multivariate adjusted model with the follow-up period spanning 18 months to 38 
years.  Here daily SSB consumption was associated with a 9% and 13% increased risk of 
developing hypertension in the two cohorts, respectively, and the risk increased linearly with a 
higher amount of daily servings. 
The Framingham Offspring Study generated conflicting results as they established that 
participants (n > 6000) consuming ≥ 1 SSB serving/day displayed a 18% adjusted risk ratio for 
developing hypertension compared to infrequent consumers, but this trend was not significant 
(P = 0.1) (Dhingra et al., 2007). Similarly, the outcome of an Australian adolescent cohort (n > 1, 
400) was also insignificant after multivariate adjustments were made to the data (Ambrosini et 
al., 2013).  Nevertheless they found that increased SSB consumption altered lipid profiles (in 
boys and girls) and resulted in a greater overall cardio-metabolic risk (girls only) (Ambrosini et 
al., 2013). How does the lowering of SSB intake impact on systolic and diastolic blood 
pressure? A  randomized controlled trial conducted for 18 months (n = 810) found that reducing 
SSB intake by 310 mL/daily resulted in a decrease of 1.8 mm Hg (95 % CI: 1.2–2.4) and 1.1 
mm Hg (95 % CI: 0.7–1.4) in systolic and diastolic blood pressure, respectively, after adjustment 
for potential confounders (Chen et al., 2010). This result is considered to be particularly 
noteworthy for understanding the association between SSB intake and blood pressure 
(reviewed by Malik et al., 2014). All the relevant studies on the effect of SSB consumption on 
blood pressure are summarized in Table 1.2.2. However, at present the epidemiological data 
are not convincing and there is a lack in intervention studies to ‘swing the vote’.  Further 
research is required to provide greater insights regarding this intriguing question.  
SSB consumption can also contribute to CVD by triggering a pathologic lipid profile (Stanhope, 
2015).  Data suggest that individuals consuming SSBs on a daily basis are  22% more likely to 
suffer from hypertriglyceridemia and have an imbalance between HDL and low-density 
lipoproteins (LDL) levels compared to non-consumers (Dhingra et al, 2007). Moreover, higher 
SSB consumption was associated with significantly decreased HDL levels in children (n = 4, 
880; 3 - 11 years), while total cholesterol, TGs and LDL levels remained unaltered (Kosova et 
al., 2013).  Dhingra et al. (2007) also investigated the influence of gender and age in this regard, 
but only observed a positive association between SSB consumption and higher LDL levels in 
young girls (3-5 years).  
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Table 1.2.2: Studies investigating the link between SSB consumption and hypertension (adapted from Malik et al., 2014). 
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SSB consumption is also a risk factor for the development of coronary heart disease (CHD) 
(Malik et al., 2010).  A 22 year follow-up study established a link between SSB consumption and 
CHD risk (De Koning et al., 2012). Here SSB consumption led to an increase of several 
inflammatory markers such as C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis 
factor (TNF) receptors 1 and 2, while  HDL, lipoprotein A and leptin levels were lower.  In 
support, Kosova et al., (2013) found that increased SSB consumption by children is associated 
with higher CRP levels, irrespective of gender.  Others established the incidence of vascular 
events (stroke, myocardial ischemia) in a US sample group (n > 2, 500) during a 10-year follow 
up period (Gardener et al., 2012).  These data revealed that daily SSB consumption is 
associated with an increased risk for vascular events after controlling for multiple potential 
confounders (RR = 1.43, 95% CI = 1.06–1.94) compared to regular or ‘’light’’ consumers 
(Gardener et al., 2012).  However, this study did not discriminate between genders.  Others 
found that frequent SSB consumption resulted in a worse outcome in females compared to 
males in a Japanese cohort (n > 39, 000) with a follow-up period of 18 years (Eshak et al., 
2012).  Fung et al. (2009) evaluated the effect of SSBs on CHD in the NHS cohort (n > 88, 500) 
during a 24-year follow-up study with subjects divided into five categories of SSB consumption 
(with increasing frequency).  An increase in risk for CHD was observed for all categories, with 
the highest (≥ 2 SSB servings/day) displaying a 35% higher risk compared to the lowest 
category (< 1 SSB serving/month) (HR = 135, 95% CI = 1.07–1.69).  A meta-analysis on four of 
the above-mentioned studies concluded that daily SSB consumption results in a 17% higher risk 
for developing CHD and that every additional serving per day further increase the risk by 16% 
(Huang et al., 2014).  Here they suggest that insulin resistance, inflammation and β-cell 
dysfunction induced by high glycemic loads may be key mechanisms driving the onset of CHD 
and metabolic perturbations.   




1.2.3.4  Summary of metabolic complications  
Epidemiological studies are not sufficient to establish causality between SSB consumption and 
the development of cardio-metabolic diseases. Thus there is a great need for clinical 
intervention studies supporting epidemiological findings.  Clinical studies could also reveal 
plausible molecular mechanisms – a necessary step in establishing causality between SSB 
consumption and cardio-metabolic pathophysiology (Stanhope, 2015).  Unfortunately there are 
limited clinical data available and most of the available studies have some drawbacks.  In order 
to summarize current knowledge, this section will discuss clinical studies from the past decade 
where SSB intervention groups were compared to SSB naïve groups.  In a recent review article 
Stanhope (2015) explained that SSB consumption could potentially contribute to cardio-
metabolic complications though direct or indirect mechanisms. SSBs are energy dense and their 
consumption is associated with excessive caloric intake (Miller et al., 2013) and subsequent 
weight gain.  Indirectly, the increased caloric load and body mass can induce cardio-metabolic 
perturbations.  However, SSB consumption may also have direct metabolic effects independent 
of body weight and energy balance.   
The indirect mechanism, i.e. the effect of SSB intake on body weight and obesity, will be 
discussed first.  De Ruyter et al. (2012) conducted a small clinical study (final n = 477) to 
establish whether SSB consumption actually induced weight gain in a clinical setting.  Here 
children of normal weight (4 to 11 years old) were assigned to either experimental or control 
groups in a double-blinded manner and were expected to consume 250 mL SSB or artificially 
sweetened beverage, respectively, on a daily basis.  After the 18 month intervention period 
body weight, BMI, waist circumference, waist-to-hip ratio and body fat percentage increased 
significantly in the SSB group compared to the artificially sweetened group.   However, a similar 
study did not support the link between SSB consumption and weight gain (Maersk et al., 2012).  
This could perhaps be explained by the shorter intervention period (6 months) although the 
intervention itself was more severe (1 L sucrose-sweetened beverage/day compared to 250 
mL/day).  Aerberli et al. (2011) considered various anthropometric markers of obesity (i.e. body 
weight, BMI, waist circumference and waist-to-hip) in participants consuming glucose-, fructose- 
or sucrose-sweetened drinks, respectively (400-800 mL/day for three weeks).  A significant 
increase in body weight and BMI was observed only in the group consuming glucose-
sweetened beverages, while sucrose and fructose-sweetened drinks induced changes in waist 
circumference and waist-to-hip, but body weight and BMI did not increase.  Of note, Stanhope 
et al., [2011] and Swarbrick et al., [2008] observed a decline in body weight and BMI in fructose-




consuming participants.  These findings may provide some insight into the mechanisms in play 
and possibly explain why the previous study failed to detect changes in body weight.  Aerberli et 
al. (2011) explained that increased glucose consumption stimulates an intensified insulin 
response.  Insulin mediates the activity of insulin-dependent lipoprotein lipase that in turn 
promotes the deposition of subcutaneous fat thereby increasing the BMI.  By contrast, fructose 
(and sucrose to some extent) has a lower glycemic load and does not trigger the release of 
insulin to the same extent as glucose.  Thus the activity of lipoprotein lipase is reduced and the 
deposition of visceral fat is favored resulting in an increase in waist circumference and waist-to-
hip ratio (also concluded by Stanhope et al., 2011).  Waist circumference and waist-to-hip ratio 
are markers of abdominal obesity - a key feature of MetS – indicating that SSB consumption 
has detrimental metabolic consequences even if it does not always reflect in body weight.   
This brings us to the direct effect of SSB consumption.   Black et al. (2006) showed that SSBs 
can induce cardio-metabolic perturbations in a more direct manner, independent of weight gain.  
Their experimental groups followed an energy-balanced diet to prevent weight changes, yet 
they show significant increases in total cholesterol and LDL levels.  This outcome is possibly 
indicative of atherosclerosis risk.  In support, another study found that iso-caloric fructose 
restriction decreased diastolic blood pressure, lactate levels, TGs and LDL-cholesterol. There 
was also an improvement in glucose tolerance and reduced insulin levels (Lustig et al., 2015). 
Of note, this study is not included in Table 1.2.3 because the restricted fructose did not come 
exclusively from SSBs. To elaborate further of the effect of SSBs on lipid profiles, Stanhope et 
al. (2015) observed an increase in LDL levels that were induced by the intake of fructose-
sweetened beverages.  Glucose- and sucrose-sweetened beverages also lead to elevated LDL 
levels (sub classes IIb and IIIa) (Aerberli et al., 2011).   Here it was also observed that sucrose- 
and fructose sweetened beverages reduced the size of LDL particles – a characteristic in men 
with borderline hypertension (Kazumi, 2002).  Thus the clinical data strongly support the link 
between SSB consumption and dyslipidemia.  
Besides dyslipidemia, hypertension and inflammation are also risk factors for the onset of CVD. 
Although none of the studies supported the link between SSB consumption and the onset of 
hypertension (Aerberli et al., 2011; Black et al., 2006; Maersk et al., 2012; Stanhope et al., 
2011;  Swarbrick et al., 2008)  there is some clinical support for the link between SSB intake 
and  inflammation.  For example, Aerberli et al. (2011) observed an increase in CRP levels of 
young men consuming SSB quantities for a 3-week period (here the specific sweetener did not 




play a role). The consumption of fructose-sweetened beverages also increased uric acid levels 
(Stanhope et al., 2015), a risk factor for the onset of CVDs (Stanhope, 2015). 
Some studies also provide insight into the effect of SSB consumption on glucose handling, e.g. 
participants consuming glucose- or fructose-sweetened drinks display elevated fasting blood 
glucose levels after the intervention (Aerberli et al., 2011; Stanhope et al., 2011;   Swarbrick et 
al., 2008).  This is an interesting result considering that such beverages have no effect on 
fasting insulin levels and opposite effects on postprandial insulin secretion.  Here glucose 
consumption spiked an increase in insulin (Stanhope et al., 2011) while fructose caused a 
decrease (Stanhope et al., 2011; Swarbrick et al., 2008).  In the Stanhope et al. (2011) study 
aged overweight males and females consumed either glucose- or fructose-sweetened 
beverages for 10 weeks (calories of the beverages accounted for  25% of their total daily 
calorie intake).  The fructose caused a  17% decrease in insulin sensitivity – explaining the rise 
in fasting blood glucose levels associated with fructose consumption. 
In summary, this section considered the link between SSB consumption and cardio-metabolic 
diseases.  The epidemiological data on this topic is well documented and the bulk of it suggest 
that frequent SSB intake will increase cardio-metabolic disease risk.  At this point there is not 
sufficient clinical data to confirm this association, fueling the ongoing controversies about the 
health consequences of SSB intake.  However, after carefully dissecting the eight available 
clinical studies, it is undeniable that SSB consumption does trigger some metabolic response 
e.g. the participants of some studies displayed increases in various makers of obesity.  This 
supports the data from section 1.2.3.1 concluding that SSB intake is associated with weight gain 
and obesity.  Some of the data also indicate that hepatic glucose handling and insulin sensitivity 
may be altered which may ultimately lead to SSB-induced onset of MetS and T2DM.  There are 
also signs of dyslipidemia and inflammation (known CVD risk factors) although there is no 
support for the development of hypertension. Finally, it seems as if glucose and fructose do not 
necessarily have similar metabolic effects.  More well-designed clinical studies would be of 
great value in the quest to fully understand the metabolic and health consequences of SSB 
consumption  

















▪ (A, F, G) 
↑ (A) 
▪ (A) 






↓ (C, D) 
Body fat (%) 
↑ (B) 




Waist circumference (cm) ↑ (A, B) ▪ (A) ▪ (A) 
Waist-to-hip ratio ↑ (A, B) ▪ (A) ↑ (A) 
Blood pressure (mmHg) ▪ (A, F, G) ▪ (A) ▪ (A; C, D) 
LDL size (nm) ↓ (A) ▪ (A) 
↓ (A) 
▪ (D) 
LDL level (%) 
↑ (G) 
↓s.c. I (A) 
↑ s.c. IIb (A) 
↑ s.c. IIIa (A) 




↓s.c. I (A) 
↑ s.c. IIb (A) 
↑ s.c. IIIa (A) 
Free fatty acids (µmol/L) ▪ (A) ▪ (A) ▪ (A) 





▪ (C, D) 
Total cholesterol (mg/dL) ↑ (F, G) ND ▪ (D) 
CRP (ng/mL) ↑ (A, ) ↑ (A) ↑ (A) 
Leptin (ng/mL) ▪ (A, F) ↑ (A) ▪ (A) 
Adiponectin (µg/mL) ▪ (A) ▪ (A) ▪ (A) 
Ghrelin (pg/mL) ▪ (A) ▪ (A) ▪ (A) 
Fasting glucose (mmol/L) ▪ (A, F, G) ↑ (A; C) ↑ (A; C; D) 






↓ (C, D) 
Fasting insulin (µU/mL) ▪ (F, G) ▪ (C) ▪ (C; D) 
Post prandial insulin 
(µU/mL) 
ND ↑ (C) ↓ (C; D) 
Uric acid  (mg/dL) ND ND ↑ (E) 
Table 1.2.3: SSB-induced perturbations in a clinical setting.  A:  Aerberli et al., 2011;       
B:  De Ruyter et al., 2012;  C: Stanhope et al., 2011;  D:  Swarbrick et al., 2008; E: Stanhope 
et al., 2015; F: Maersk et al., 2012; G: Black et al., 2006.  ↑: significant increase;                  
↓: significant decrease;  ▪ measured but no significant change; ND : not determined; s.c.: 
subclass 




1.2.4 Reducing SSB consumption: Strategies and obstacles 
Many interventions have been used in an attempt to reduce SSB consumption with varying 
results.  One such strategy that has been making headlines in recent years is sugar/SSB 
taxation.  Some argue that a sugar tax would have a significant effect in terms of overall, daily 
calorie consumption with the added benefit of securing a generous source of revenue that could 
be used for public health initiatives (Barry et al., 2013).  For example, Andreyeva et al. (2011) 
argued that an additional taxation of a penny-per-ounce ( 12c / 30 mL) in the US would lead to 
a  110 mL decrease in daily SSB consumption per capita.  This has led many countries such 
as France (Sparks, 2011), Mexico (Rodriguez, 2013), the United Kingdom (Gander, 2016) and 
some cities in the US to introduce sugar/SSB taxation strategies (Nadolny, 2016).  In South 
Africa it was also announced in the 2016 national budget speech that a sugar tax will be levied 
from 1 April 2017 aiming to significantly curb the incidence of obesity in South Africa (Ismail, 
2016).  This is supported by research by the University of Witwatersrand (South Africa) that 
established that a 20% tax would reduce the prevalence of obesity by 2.4% in females and 
3.8% in males.  Altogether these projections suggest that there could be more than 220, 000 
less obese adults in South Africa (Manyema et al., 2014).   
Despite the potential benefits of sugar/SSB taxation the consequences are not entirely 
predictable and may have other repercussions.  For example, while many countries are 
considering such a tax, Denmark repealed its long-standing SSB tax in 2014 after deeming it 
ineffective and detrimental to the economy (Scott-Thomas, 2013). It is also difficult to determine 
what the net effect of SSB taxation will be on public health as consumers may opt to buy non-
taxed alternative beverages like diet sodas, fruit juices and alcoholic beverages that may not 
necessarily a be healthier option.  Consumers may even choose to purchase cheaper and 
unhealthier food products in order to sustain well-established SSB habits (Edwards, 2011).  
Early data from Mexico indicated that there was an average decrease of 6% in SSB sales in the 
first year after a  10% price increase through taxation.  This translates to roughly 12 
mL/capita/day (Colchero et al, 2016).  Although this is a statistically significant decrease and the 
decline accelerated towards the end of the year, it is difficult to determine the long term clinical 
relevance.    It is projected that a 10% decrease in SSB consumption would result in 189, 300 
fewer T2DM and 20, 400 fewer stroke and myocardial infarction incidences over a 10 year 
period (2013-2022) (Sánchez-Romero et al., 2016).  Ultimately, 18,900 fewer deaths will occur 
and the government would spend 983 million international dollars less on healthcare.  Although 
it sounds promising, such projections based on a number of assumptions e.g. it is assumed that 




a 10% increase in tax will result in a 10% increase in retail price i.e. that retailers and 
manufacturers will not absorb the cost of the added tax (Nakhimovsky et al., 2016).  A second 
assumption in this particular study is that a 10% increase in tax can achieve and maintain a 
10% decrease in SSB intake (Sánchez-Romero et al., 2016).  Additionally, it is assumed that 
only 39% of the reduced (SSB-derived) calories will be replaced by the consumption of other 
foods.  Due to the complexity of the matter Colchero et al. (2016) could not establish causality 
between taxation and a decrease in SSB consumption.  There have also been attempts by the 
food industry to counter such taxation initiatives, e.g. by using aggressive marketing strategies 
(Colchero et al, 2016).  Furthermore, policies to increase SSB tax generally do not enjoy public 
support.  A survey conducted in a large representative US sample revealed that such taxation 
was regarded as overwhelmingly negative (Barry et al., 2013, Gollust et al., 2014). To conclude, 
Nakhimovsky et al. (2016) performed a meta-analysis to determine the effect of sugar/SSB 
taxation on health outcomes, specifically in middle-income countries (Brazil, Ecuador, India, 
Mexico, South Africa and Peru).  Here they found that at least a 20% tax increase is required in 
order to halt the growing prevalence of obesity in middle income countries.  Additionally they 
conclude that it is unlikely that sugar/SSB tax alone will have a permanent effect on the overall 
body weight of the population     
Another and perhaps more implementable strategy is to improve public awareness regarding 
SSB sugar content and the associated health risks (Adams et al., 2014). There are several 
problems with current food labeling procedures, e.g.  nutritional labels are often printed in a 
relatively small font and can easily be overlooked.  Food labels also present information in a 
relatively abstract manner, e.g. grams of sugar/100 mL SSB that makes it hard to relate how 
much the sugar content actually amounts to.  However, some found that displaying sugar 
content in a more “user-friendly” manner (e.g. images displaying sugar content in a sugar cube 
pyramid) significantly reduced the “attractiveness” of SSBs as well as the intention for 
consumption (Adams et al., 2014).  The US Food and Drug Administration recently announced 
that nutritional labels have to adhere to new requirements within the next two to three years.  
One of the major amendments is that new labels must disclose the amount of “added sugars” as 
a percentage of the daily recommended allowance (10% of a 2000 Kcal diet or 12 teaspoons) 
(Malik et al., 2016).  This decision was criticized by the food industry based on the argument the 
all calories are similar despite its source.  The FDA also adjusted serving sizes and general 
issues regarding appearance, visibility and interpretability (Malik et al., 2016).  An additional 
limitation of the current food labeling system is that it does not indicate the composition of sugar 




content, i.e. the fructose to glucose ratio thus withholding crucial information from the consumer 
that impacts upon informed decision making (Ventura et al., 2011).  Adams et al. (2014) also 
found that health messages displayed on SSB cans caused participants to rather choose water.  
This strategy was recently acknowledged in San Francisco, California (Malik et al., 2016).   
Other possible interventions include restricting SSB quantities (Gollust et al., 2014) and 
regulating availability and sales in schools (Hebden et al., 2013).  
To conclude this section, there is a lot of epidemiologic data indicating that frequent SSB 
consumption leads to increased risk of disease onset.  At this point, however, the limited clinical 
studies are not sufficient to make a compelling argument for or against the consumption of 
SSBs, or to elucidate possible mechanisms involved.   Nevertheless, many countries have used 
strategies to restrict SSB consumption in the hope of curbing the prevalence of obesity and 
other cardio-metabolic diseases.  This has proved to be a complex task, and the best strategy 
forward is still to be determined.  As the focus of this preclinical study is on SSB-mediated 
metabolic changes in the liver, the emphasis now shifts to liver metabolism 
1.3  Summary and Aims  
Cardio-metabolic diseases like T2DM are a major global burden of disease due to the rapid 
increase in prevalence over the past few decades.  Projections indicate that low- and middle-
income countries will be affected the most by cardio-metabolic diseases in years to come. For 
example, the IDF estimates that T2DM will increase with 93% in Africa between 2014 and 2035 
compared to the average global increase of 53%. The global projections regarding obesity, MetS 
and CVD are equally calamitous.  These projections necessitate research to improve the 
understanding of the underlying factors driving this “pandemic” 
It is argued that the increase in cardio-metabolic disease is caused by a fairly universal shift 
towards a more “Westernized” diet.  The consumption of an excessive amount of added sugars, a 
hallmark of the “Westernized” diet, is proposed to play a key role in the onset of cardio-metabolic 
diseases.  Subsequently, the role of SSBs in the context of cardio-metabolic diseases has 
become increasingly relevant.  In light of this, the Cardio-Metabolic Research Group (CMRG) 
initiated a novel preclinical study in 2013 to evaluate metabolic perturbations induced by 
moderate, chronic SSB consumption in rats. The current study was based on this particular rat 
model and focused on the liver as a major metabolic organ.  Since our previous research focused 
on the heart, this was an investigative study.   We hoped to achieve the following aims and 




objectives in order to ultimately gain a greater understanding of molecular mechanisms underlying 
the onset of cardio-metabolic diseases: 
Aims: 
1. To evaluate the effects of long-term, moderate SSB intake on systemic cardio-metabolic health 
markers. 
2. To gain insight into changes induced in hepatic structure and function in response to long-term, 
moderate SSB consumption. 
Objectives 
1. Collect and characterize sample material from an established rat model of long-term, moderate 
SSB intake. 
2. Perform comprehensive proteomic analysis on liver samples after six months of SSB 
consumption (Objective 3 and 4 will be based on the findings of Objective 2). 
3.  Determine the molecular mechanism driving SSB-induced alterations in protein expression.   
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Chapter 2: Model overview  
2.1 Introduction 
There are various systemic markers that reveal valuable information about the overall cardio-
metabolic health of the organism e.g. insulin and uric acid.  The current model was established 
in 2013 by the CMRG and the effect of moderate SSB intake on glucose tolerance, total 
cholesterol and triglyceride levels has already been determined.  This section aims to build on 
these data to ultimately expand our holistic understanding of SSB-induced perturbations before 
we zoom in on a specific organ system.   
2.2 Materials and methods  
2.2.1  Experimental design and procedure  
This study was conducted with the permission of the Animal Ethics Committees of Stellenbosch 
University (South Africa) (Ethics # SU-ACUM13-00012) (Appendix A). All procedures and 
animal handling were in agreement with the Guide for the Care and Use of Laboratory Animals 
of the National Academy of Science (NIH publication No. 85-23, revised 1996).  
Healthy male Wistar rats weighing  200 g were randomly divided into three groups i.e. Control, 
Caloric (cal) control and SSB (n = 12 per group). Each treatment group was further subdivided 
into a three- and six-month time group (n = 6 per subgroup), respectively.  The rats were 
exposed to a 12 hour day-night cycle and had ad libitum access to standard chow and water.  
They were housed three per cage and familiarized with the environment, handlers and 
techniques for a week prior to the start of the experimental procedures.  
The rats were gavaged on a daily basis with an experimental dosage according to their 
respective group and current weight.  The SSB group received a dosage of Jive® (granadilla 
flavor) that was equivalent to 100 mL ( 54 calories) of soda for an adult weighing 60 kg. Here 
the body surface area of rats to humans was used to calculate the volume required for various 
weight categories (Reagan-Shaw et al., 2007).  Jive® was selected as the SSB of choice since 
it is locally produced and relatively inexpensive as compared to other brands, making it a 
popular choice for a large part of the South African population.  Additionally, Jive® contains 13 g 
sugar per 100 mL ( 54 calories).  The high sugar content allowed us to gavage smaller 




volumes to be gavaged. The Cal-control group received an iso-caloric amount of melted butter, 
while the Control group was gavaged with an iso-volumetric amount of water as stipulated in 
Table 2.1.1 below.  The rats were weighed once a week for the duration of the study (24 weeks) 





Group Treatment 250-300 g 300-350 g 350-400 g 400-450 g >450 g 
Control Water 2.4 2.9 3.4 3.8 4.4 
Cal-
control 
Butter 0.3 0.37 0.43 0.5 0.56 
SSB Jive® 2.4 2.9 3.4 3.8 4.4 
 
2.2.2  Blood and tissue collection  
At three and six months, respectively, the rats were fasted overnight and blood glucose levels 
measured.  A prick was made at the tip of the tail to collect a blood droplet on AccuChek® 
glucostrips (Roche Diagnostics, Risch-Rotkreuz, Switzerland) in the glucometer (Roche 
Diagnostics, Risch-Rotkreuz, Switzerland). Thereafter, the rats were sedated with 5% isoflurane 
(Piramal, Bethlehem PA) and pedal reflexes were tested before they were euthanized.  Blood 
Table 2.1.1: Treatment volume according to weight classification (mL) 
Figure 2.3.1: Experimental design  




was drawn from the abdominal aorta into serum-separating (gold) and EDTA (lavender) 
vacutainers (Guangzhou Improve Medical Instruments, Guangzhou, China).  Blood samples 
were stored at -80⁰C until it was sent to the National Health Laboratory Service at Tygerberg 
Hospital (Bellville, South Africa) for analysis - insulin, CRP, uric acid, glycated hemoglobin A1c 
(HbA1c) and alanine transaminase (ALT) levels were measured.  Next the heart, liver, visceral 
fat pad, kidney, gastrocnemius muscle and pancreas were harvested and weighed.  Tissues 
were either snap-frozen in liquid nitrogen and stored at -80°C or stored in formalin, depending 
on the nature of further analyses.  The entire experimental setup was implemented by the 
CMRG in our laboratories. 
2.2.3  Statistical analysis  
Statistica 13.0 (StatSoft Inc., Dell Software, Tulsa OK) was used for statistical analyses.  The 
weight gain data were analyzed with a repeated measures ANOVA test. The rest of the normally 
distributed data in this section were evaluated with one-way ANOVAs, while Kruskal-Wallis 
ANOVA and median tests were used in the case of non-parametric data. Outliers and extremes 
were detected using boxplots with an outlier coefficient of 2.2 and Levene’s tests were used to 
test for homogeneity of variances.  A p-value < 0.05 was considered significant. All the data 
were presented on Graphpad Prism 5.01 (Graphpad Software Inc., San Diego CA) as mean ± 
standard deviation (SD).  
2.3 Results  
2.3.1 Body weights 
The experimental design entailed weighing the rats on a weekly basis and weight gained by 
each rat compared to its own baseline weight was expressed as a percentage.  Here the Cal-
control group gained weight at a faster pace in the first 12 weeks of the study (P < 0.05 at week 
3 and weeks 5-12).  From week 13 onwards there were no significant differences between any 
of the groups and at the end of the study (six months) all the rats had gained a similar amount of 
weight regardless of treatment (refer to Figure 2.3.1).   







2.3.2 Organ weights 
Tissues samples were blotted dry before weighing. Thereafter the tissues were snap-frozen or 
stored in formaldehyde.  These included the entire liver and heart, the left gastrocnemius 
muscle, the right kidney and visceral fat pads around the right testicle.  A relative increase or 
decrease in organ weight could be indicative of pathological hypertrophy or atrophy in the 
respective organ.  The weights of various tissues (expressed as a percentage of the final body 
weight) are portrayed in Table 2.3.1. Here it was observed that liver weights and visceral fat pad 
mass of the Cal-control group increased (P < 0.05) compared to both the control and SSB 
groups.  This is a noteworthy finding although it is not directly relevant for the purpose of this 
study.  The SSB group did not show any significant changes for any of the tissues at three or six 
months.    
 
 
Figure 2.3.2: Percentage weight gain over 24 weeks (6 months).  Data are displayed as 
mean ± SD. For all groups n = 24 (weeks 1-12) and n = 12 (weeks 13-24).  Significance is 
shown as * P < 0.05 compared to Control and # P < 0.05 compared to SSB.    





Organ Months Control Cal-control SSB 
Liver (%) 
Three 2.347 ± 0.330 2.754 ± 0.298  * # 2.405 ± 0.264 
Six 2.446 ± 0.206 2.549 ± 0.194 2.439 ±0.22p 
Heart (%) 
Three 0.261 ±0.041 0.263 ± 0.018 0.240 ± 0.024 
Six 0.233 ± 0.018 0.236 ± 0.021 0.233 ± 0.020 
Muscle (%) 
Three 0.599 ± 0.070 0.621 ± 0.131 0.602 ± 0.117 
Six 0.462 ± 0.155 0.566 ± 0.043 0.542 ± 0.086 
Kidney (%) 
Three 0.285 ± 0.044 0.296 ± 0.037 0.270 ± 0.029 
Six 0.249 ± 0.020 0.2642 ± 0.030 0.263 ± 0.021 
Visceral fat 
pads (%) 
Three 1.001 ±0.447 1.337 ± 0.321 * # 0.967 ± 0.243 
Six 1.306 ± 0.253 1.546 ± 0.326 1.582 ± 0.500 
Data are displayed as mean ± SD 
N ≥ 11 for all  groups 
* Significantly different compared to Control group (P < 0.05) 
# Significantly different compared to SSB group (P < 0.05) 
 
2.3.3 Biochemical analyses 
Blood samples were collected from the tail and abdominal aorta and then analyzed for systemic 
markers (findings summarized in Table 2.3.2).  Uric acid levels increased in the Cal-control 
group compared to the Control and SSB groups (P<0.05).  ALT levels were measured as a 
marker for liver damage and levels were similar amongst all three groups at both time points.  
Insulin levels and CRP (a marker for systemic inflammation) were also measured but were 
below detectable levels in all samples.  
Different methods were used to determine blood glucose levels.  For example, blood collected 
by tail pricks was used to determine fasting blood glucose levels.  However, no significant 
changes were observed at time points investigated.  HbA1c levels were also measured 
(provides indication of average blood glucose levels over the past 8-12 weeks) and expressed 
according to three different systems.  The National Glycohemoglobin Standardization Program 
(NGSP) system is the most widely used and results are expressed as a percentage (Little & 
Sacks, 2009).  Here no significant changes were observed after three or six months versus 
controls.  The International Federation for Clinical Chemistry (IFCC) method relies on high 
performance liquid chromatography to separate glycated and non-glycated peptides.  Thereafter 
mass spectrometry or capillary electrophoresis is used in order to quantify each respective 
Table 2.3.1: Organ weights expressed as a percentage of final body mass.  




group.  This method generally yield a result 1.5-2% lower than the NGSP and is expressed in 
mmol/mol (Little & Sacks, 2009).  According to the IFCC method, the SSB group displayed 
elevated HBA1c levels compared to the Control group at both three and six months  (P < 0.05).  
Although the increase compared to the Cal-control is not significant, a definite trend is evident at 
three months (P = 0.077).  The last set of readings is the estimated average glucose (eAG) that 
is calculated with a regression equation and measured in mmol/L. Here the SSB group exhibited 
an increase (P < 0.05) compared to the Control group at three months but no other changes 
were detected.  It is important to note, however, that the validity of the eAG method is often 
contested (Little & Sacks, 2009).  
 
Marker Months Control Cal-control SSB 
Uric acid 
(mmol/L) 
Three 0.0617 ± 0.012 0.075 ± 0.010 0.062 ± 0.010 
Six 0.075 ± 0.014 0.043 ± 0.008* # 0.080 ± 0.015 
ALT (U/L) 
Three 61.60 ± 6.768 55.67 ± 6.088 53.50 ± 14.29 
Six 54.17 ± 6.494 46.50 ± 8.118 66.20 ± 17.02 
Fasting blood 
glucose (mmol/L) 
Three 4.717 ± 0.500 4.425 ± 0.347 4.400 ± 0.500 
Six 5.525 ± 0.890 5.417 ± 0.388 5.325 ± 0.723 
HbA1c [NGSP] 
(%) 
Three 3.233 ± 0.242 3.333 ± 0.225 3.500 ± 0.346 
Six 3.133 ± 0.320 3.317 ± 0.319 3.333 ± 0.207 
HbA1c [IFCC] 
(mmol/mol) 
Three 10.20 ± 1.304 11.50 ± 01.643 15.83 ± 2.787* 
Six 10.67 ± 3.143 12.83 ± 3.656 13.00 ± 12.530 * 
HbA1c [eAG] 
(mmol/L) 
Three 2.40 ± 0.268 2.70 ± 0.358 3.183 ± 0.407 * 
Six 2.417± 0.504 2.683 ± 0.504 2.70 ± 0.341 
Data are displayed as mean ± SD 
N ≥ 11 for all groups 
* Significantly different compared to Control group (P < 0.05) 
# Significantly different compared to SSB group (P < 0.05) 
 
2.4 Discussion  
The purpose of the initial part of this study was to establish the effects of SSB consumption on 
systemic markers related to cardio-metabolic disease states.  Here we considered weight gain, 
relative organ weight and various blood markers.  These data, together with data previously 
generated by the CMRG (Driescher, 2014), provides a comprehensive overview of systemic 
changes induced by moderate SSB intake.  
Table 2.3.2: Various blood markers at three and six months.  




 SSB consumption did not have a significant effect on weight gain in our model (Figure 2.3.1).  
This finding agrees with the majority of similar animal studies that did not report any differences 
between the SSB and control groups for body weight/weight gained (Diaz-Aguila et al., 2015; 
Figlewicz et al., 2009; Lozano et al., 2016; Rebollo et al., 2014, Sheludiakova et al., 2012). 
Despite relative consensus on this matter, there were a few studies with an opposite finding, 
e.g. in a study by Mamikutty et al. (2014) rats consuming SSBs gained significantly more weight 
compared to control rats.  However, the fact that  67% of the total calorie intake of this group 
was SSB-derived may possibly account for the exaggerated reaction.  Others found that HFCS 
led to excessive weight gain (Bocarsley et al., 2010).  We speculate that this is due to the 
intrinsic nature of HFCS bearing in mind that Light et al. (2009) evaluated the effect of sucrose, 
glucose, fructose and HFCS intake, respectively, and only observed significant changes in body 
weight in the HFCS group.  Some studies observed an increase in VAT (based on a combined 
measure of pericardial, peritoneal and gonadal fat pads), despite no significant increase in body 
weight (Diaz-Aguila et al., 2015).  For this reason we measured the relative weight of  gonadal 
fat pads as an indicator of VAT, but SSB consumption had no effect here (Table 2.3.1).  
However, the gonadal fat pad may not be a sensitive enough marker, as Bocarsley et al. (2010) 
found that HFCS significantly increased abdominal fat pad weight but not that of gonadal fat 
pads.   Additionally, none of the other studies measured only the gonadal fat pad as a marker of 
VAT.    
We also measured the relative weight of the heart, liver, muscle and kidney but here SSB 
consumption had no detectable effects (Table 2.3.1).  Jürgens et al. (2005) also determined that 
neither sucrose nor fructose consumption increased the relative weight of the liver. Of note, in 
our model the Cal-control group gained weight at a slightly increased pace during the first 
twelve weeks of the study (Figure 2.3.1).   The reason behind this is unclear considering that the 
Cal-control and SSB group consumed a similar amount of total calories (Driescher et al., 2014) 
but it corresponds with the increased relative weight of the liver and visceral fat pads in the Cal-
control group at three months.  However, in all instances this effect tapers off by six months 
where  body and organ weights of all groups are similar.   
In our model SSB consumption did not alter fasting blood glucose levels at three or six months 
(Table 2.3.2).  This result agrees with other studies that used sucrose as sweetener (Diaz-
Aguila et al., 2015; Sheludiakova et al., 2012).  Yet, both these studies observed a decrease in 
insulin sensitivity despite “healthy” blood glucose levels.  Unfortunately, the insulin levels in our 
model were below detectable levels and prevented us from making meaningful conclusions 




regarding insulin sensitivity.  Lozano et al. (2016) observed impaired glucose tolerance without 
a rise in fasting blood glucose levels after rats consumed 25% fructose water for eight months.  
Moreover, others found that fructose consumption was linked to elevated fasting blood glucose 
levels, but again the dosage of the sweetener was disproportionately high and  the study was 
also conducted on female rats (Rebollo et al., 2014).  The latter is an important consideration as 
Vilà et al. (2011) observed that fructose intake elicited more severe effects on glucose tolerance 
and insulin signaling in female rats compared to males.  For our model, SSB consumption 
increased HbA1c levels (IFCC and eAG) but this finding is not clinically relevant although it is 
statistically significant (Table 2.3.2).  We also found that ALT levels were similar between all the 
experimental groups, indicating that liver function is intact (Table 2.3.2).   This finding is 
supported by a short term clinical study (Aerberli et al., 2011).  By contrast, others found that 
HFCS and fructose consumption can induce significant elevations in ALT levels (Figlewicz et al., 
2009).  Although this is contradictory to our finding, this study concluded that the increased ALT 
levels only point to minor tissue injury as the liver histology did not reveal any profound liver 
damage. SSB consumption had no significant effects on uric acid levels.   
To conclude, in agreement to earlier work, our data confirm that moderate SSB consumption 
resulted in  minimal effects on systemic markers for cardio-metabolic health within a six month 
time frame.  With the characterization of the systemic effects completed we next investigated 
the effects of SSB consumption on the liver.   
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Chapter 3: Liver - Proteomics  
3.1 Introduction  
The liver is an important metabolic organ involved in the breakdown, synthesis, storage and 
redistribution of a variety of substrates i.e. carbohydrates, lipids and proteins (Bechmann, 2012).   
Since SSB-induced effects on liver structure and function are still poorly understood, we 
decided to begin our study  on the liver with protein expression profiling.   This entails the 
characterization of the entire protein complement expressed in the liver. As protein expression 
is influenced by the cellular environment, SSB-induced alterations in protein expression should 
provide a more holistic understanding of the effects of long-term SSB intake on hepatocytes 
(Graves & Haystead, 2002).   The field of proteomics is growing rapidly and to our knowledge 
this is the first study to perform hepatic proteomics in the context of SSB intake - we hope that  
the data generated here could guide future cardio-metabolic research. In order to better 
contextualize this part of the study the following sections (3.1.1 – 3.1.4) provide an overview of 
the basic physiological processes involved in the metabolism of a SSB.  
3.1.1  Hepatic glucose metabolism 
The liver plays a central role in glucose homeostasis as it has the ability to either add or remove 
glucose from circulation depending on the overall metabolic state of the organism (Bizeau & 
Pagliassotti, 2005).  This dynamic balance between glucose storage and production allows 
blood glucose levels to be maintained within a narrow homeostatic range (3.9 - 5.6 mM), despite  
temporal changes induced by feeding and fasting  (Roden & Bernoider, 2003).  The liver is 
responsible for the clearance of  60-65% of all consumed glucose (Moore et al., 2012).  
Directly after the consumption of a SSB, i.e. during the absorptive state, blood glucose 
concentrations are high and serve as the main source of energy.  Excess glucose that cannot 
be immediately utilized is stored in the form of glycogen or TGs (Sherwood, 2010).  Due to the 
absorption of nutrients into the hepatic portal vein, the liver is rapidly exposed to much higher 
glucose concentrations compared to other organs (Moore et al., 2012).  When glucose enters 
the hepatic portal vein there is increased uptake by the liver, while storage of glucose is 
stimulated (Moore et al., 2012).  Hepatic glucose uptake is independent of insulin signaling; the 
high blood glucose concentration in the liver sinusoid allows glucose to enter the hepatocytes 
directly by virtue of facilitated diffusion through the glucose transporter (GLUT) 2.  This 




concentration gradient is maintained by rapid phosphorylation of glucose (after entering the 
hepatocyte) to glucose-6-phosphate (G-6-P) (Roden & Bernoider, 2003).  The continuous 
hepatic uptake of glucose decreases blood glucose levels in order to return it to physiological 
levels. 
Figure 3.1.1: Hepatic glucose and fructose metabolism.   
1 – Glucokinase; 2 – Phosphoglucose isomerase; 3 - Phosphofructokinase; 4- Aldolase;               
5 – Pyruvate kinase, 6 – Phosphoenolpyruvate carboxykinase (PEPCK), 7 – Fructose-1,6-
biphosphatase; 8 – Phosphoglucose isomerase; 9 – Glucose-6-phosphatase (G-6-Pase);                           
10- Phosphoglucomutase; 11 -  Glycogen synthase; 12 – Glycogen phosphorylase;                    
13 – Phosphoglucomutase; 14 - Fructokinase; 15 - Frucose-1-phosphoaldose;                               
16 - Glyceraldehydekinase; 17 - Triose phosphate isomerase 
 
 




Intrahepatic glucose can either be metabolized through glycolysis or diverted into storage as 
glycogen molecules depending on the hormonal and the energetic state of the hepatic 
environment (Roden & Bernoider, 2003).  Pancreatic hormones (glucagon and insulin) are 
secreted directly into the hepatic portal vein to rapidly alter the activity of metabolic enzymes,  
thereby adapting metabolic processes according nutrient availability.  Insulin levels are elevated 
during the fed (absorptive) state.  Although insulin is not required for hepatic glucose uptake, it 
directs intrahepatic glucose to the glycogenesis pathway – synthesizing glycogen from 20-30% 
of consumed carbohydrates (Figure 3.1.1 - yellow arrows) (Postic, 2004). Glycogen is also 
stored in skeletal muscle; thereafter excess glucose can also be directed into a lipogenic 
pathway to synthesize de novo lipids (Postic, 2004).  The rate of hepatic glycogen synthesis is 
regulated by glycogen synthase and here insulin promotes its dephosphorylation by protein 
phosphatase-1, leading to its activation (Postic, 2004).  In parallel, glycogen phosphorylase 
(GP) is also dephosphorylated resulting in its inhibition (Postic, 2004) and subsequently less 
glycogen breakdown.  Of note, in diabetic patients glycogen synthesis can be faulty thus 
prohibiting efficient storage and the subsequent lowering of blood glucose levels to within 
physiologic levels (Postic, 2004). 
The post-absorptive state (also known as fasting state) refers to the period roughly four hours 
after the consumption of the previous meal and is marked by a decrease in blood glucose levels 
(Sherwood, 2010).  Stored nutrients are now catabolized to maintain blood glucose levels within 
the physiological range where is can fulfill the body’s and especially the brain’s metabolic 
demands (Sherwood, 2010).  There is therefore a net output of hepatic glucose during the post-
absorptive state that occurs as a result of two pathways, i.e. glycogenolysis and 
gluconeogenesis.  The latter is an interesting reaction as it enables both the liver and the 
kidneys (to a lesser extent) to also produce glucose endogenously (Roden & Bernoider, 2003).  
Glycogenolysis refers to the breakdown of glycogen stores (Figure 3.1.1 - blue arrows) to form 
glucose.  This pathway generally occurs earlier than gluconeogenesis, roughly 2-6 hours after 
dietary intake. Glycogenolysis is enhanced by the activation (phosphorylation) of GP and the 
inhibition of glycogen synthase activity (Postic, 2004).  Gluconeogenesis plays a larger role in 
extended fasting and refers to the de novo synthesis of glucose (Figure 3.1.1 - green arrows) 
from lactate, alanine and other non-carbohydrate precursors (Postic, 2004).  Ultimately free 
glucose is released into the hepatic vein and back into circulation (Roden & Bernoider, 2003).   
The post-absorptive state is also marked by a shift in circulating insulin and glucagon levels.  
Here insulin levels now normalize while glucagon becomes the predominant hormone (Roden & 




Bernoider, 2003).  Glucagon (together with glucocorticoids) can regulate gluconeogenic 
enzymes at the transcriptional level e.g. it promotes the expression of PEPCK, a unidirectional 
and rate-limiting enzyme of the gluconeogenic pathway.  In addition, it can increase expression 
of G-6-Pase that regulates the dephosphorylation of G-6-P to glucose.  Glucagon also inhibits 
the glycolytic enzymes pyruvate kinase and phosphofructo-1-kinase (Roden & Bernoider, 2003).  
Insulin elicits the opposite effect on these hormones (Postic, 2004).  However, in diabetic 
individuals (both type 1 and type 2) increased hepatic glucose output results in hyperglycemia 
during both the fed and fasting states (Postic, 2004).   
3.1.2  Hepatic fructose metabolism  
Fructose has the same chemical formula as glucose, i.e. C6H12O6 but is structurally 
distinguishable by the keto-group attached to the second carbon of fructose compared to 
glucose that has an aldehyde group bound to position 1 of its carbon chain (Tappy & Le, 2010).  
The ingestion of fructose (e.g. from SSBs) induces a modest increase in insulin levels compared 
to glucose consumption, together with minor changes in both blood glucose and fructose 
concentrations.  The absorption of fructose, and free fructose in particular, is usually restricted.  
However, this improves greatly in the presence of glucose (e.g. sucrose or HFCS).  Fructose 
absorption is different from glucose absorption in that it does not require adenosine triphosphate 
(ATP) and is not coupled to sodium uptake (Tappy & Le, 2010).  It is absorbed mainly in the 
enterocytes of the jejunum (through GLUT5 transporter) and then diffuses into the hepatic portal 
bloodstream through GLUT2 (Havel, 2005).   Although GLUT5 is localized on a variety of 
tissues, e.g. adipocytes and skeletal muscle, the bulk of fructose is directed towards the liver 
thus rendering it the primary organ involved in fructose metabolism.  
In the liver fructose is rapidly phosphorylated (by fructokinase) to yield fructose-1-phosphate (F-
1-P) (Havel, 2005) (Figure 3.1.1 – orange arrows).  This is an important step that distinguishes 
fructose metabolism from glucose metabolism since F-1-P can enter the glycolytic pathway 
downstream from phosphofructokinase, the rate-limiting step of glycolysis (Havel, 2005).   
Furthermore, the conversion of fructose to F-1-P takes place independently of insulin levels and 
is not regulated by the negative feedback mechanisms triggered by citrate and ATP that 
regulate glucose metabolism (Tappy & Le, 2010).  Together this allows fructose to be rapidly 
metabolized and in a less controlled manner compared to glucose.  Fructose metabolism yields 
triose phosphates (dihydroxyacetone and glyceraldehyde) that can thereafter follow one of three 
pathways (Havel, 2005).  The largest percentage ( 50%) of triose phosphates is diverted into 




the gluconeogenic pathway to produce glucose.  An additional ( 14%) is directly diverted into 
glycogen storage.  Another portion is metabolized to pyruvate that can enter the tricarboxylic 
acid cycle (TAC) together with glucose-derived pyruvate.  The last  15% is utilized to 
synthesize lactate that is released back into the circulatory system.  Of note, the production of 
glucose and lactate from fructose are interdependent (Tappy & Le, 2010) 





Hepatic lipid content depends on the balance between lipid uptake/synthesis versus lipid 
metabolism and export (Perry et al., 2014) (Figure 3.1.2). Since lipid and carbohydrate 
metabolism are interdependent it is also largely regulated by the same hormones (i.e. insulin, 
glucagon and epinephrine) and metabolic states (i.e. fed, fasted, starved).   
Figure 3.1.2:  Hepatic lipid metabolism.  Hepatic lipid metabolism during 
fasting and fed states.  Adapted from Fabbrini & Magkos (2015). 




During the fed state, hepatic fatty acids (FAs) are synthesized by endogenous lipogenesis 
(Bechmann, 2012), a process that is facilitated by insulin (Horton et al., 2006).   Hepatic de novo 
lipogenesis, a two-phase process, generally occurs during the fed state when glucose is 
abundant and the liver has reached its capacity for glycogen storage. The initial phase entails 
the de novo synthesis of FAs and here acetyl-CoA and malonyl-CoA can serve as substrates 
while acetyl-CoA carboxylase and fatty acid synthase  catalyze the reaction.  The regulation of 
fatty acid synthase in particular is complex as various ligands and hepatic nuclear receptors are 
involved.  The post-prandial insulin spike promotes intrahepatic FA synthesis by increasing the 
expression of fatty acid synthase, providing a possible explanation for elevated hepatic lipid 
deposition observed in the Maersk et al. (2012) clinical intervention study..   
Besides insulin, carbohydrate-responsive element binding protein (ChREBP) and steroid 
regulatory element-binding protein (SREBP)-1c also play an important role in the regulation of 
lipogenesis and linking hepatic glucose and lipid metabolism.  Together these two proteins can 
increase the expression of acetyl-CoA carboxylase and fatty acid synthase, ultimately 
enhancing FA synthesis (Bechmann, 2012). In particular, the SREBP-1c isoform is linked to 
perturbations in TG synthesis/storage and insulin resistance (Postic et al., 2004).  As FAs are 
also associated with oxidative stress and lipotoxicity, the second phase of de novo lipogenesis 
entails storing FAs as TGs.  Here mitochondrial glycerol-3-posphate-aceyltansferase and 
diacylglycerol-acyltransferase catalyze the esterification of three FA chains to a glycerol 
backbone to form one TG molecule, thereby reducing the lipotoxic effect of FAs.  Intrahepatic 
TGs will either remain in the liver as lipid droplets or it can enter the circulation packaged as 
very low-density lipoproteins, a process also facilitated by ChREBP and SREBP-1c (Bechmann, 
2012). Insulin promotes intrahepatic lipid accumulation by preventing the breakdown of FAs and 
TGs (Horton et al., 2006).   
By contrast, glucagon (together with epinephrine) levels increase during the fasting state 
(Horton et al., 2006) and hepatic FAs are taken up into the liver from free circulating FAs and 
thereafter catabolized by the β-oxidation pathway (Bechmann, 2012).  During the fasting state 
lipolysis also occurs in adipocytes and results in a large pool of free FAs in circulation. This 
allows increased FA uptake by hepatocytes (via sarcolemmal FA transport proteins 2 and 5).  
This process is regulated by altering the transcription of FA transport proteins that is mainly 
reliant on peroxisome proliferator-activated receptor-α signaling (Bechmann, 2012). Once FAs 
are taken up by liver cells it can be oxidized to serve as a source of ATP.  FA oxidation takes 
place in mitochondria, peroxisomes or the endoplasmic reticulum (ER), depending on the length 




of the FA chain and other environmental factors. Under physiological conditions most FAs are 
metabolized in the mitochondrion through β-oxidation.  Glucagon and epinephrine compensate 
for the decrease in glucose availability by promoting the transport of activated FAs into 
mitochondria to serve as an energy source.  This is mainly achieved by suppressing the 
synthesis of malonyl-CoA that usually inhibits carnitne acyltransferase I – the latter catalyzes 
the association between fatty acyl-CoA and carnitine, a necessary step to allow FAs into 
mitochondria (Horton et al., 2006).  When the liver is insulin resistant and there is an excessive 
amount of FAs present; subsequently long- and very-long chain FAs will be oxidized in the ER 
and peroxisomes.  This will in turn induce oxidative stress, inflammation and apoptosis 
(Bechmann, 2012).   
The important question is, however, how does SSB consumption impact on metabolic pathways 
here discussed?  Based on the clinical data earlier discussed, it emerges that frequent SSB 
intake can lead to perturbations in hepatic lipid metabolism.  This includes excessive hepatic, 
muscle and visceral lipid deposition (Maersk et al., 2012) together with elevated total 
cholesterol, LDL and plasma TG levels (Black et al., 2006; Maersk et al., 2012; Stanhope et al., 
2015).  Such perturbations contribute to the development of cardio-metabolic diseases, e.g. 
there is a strong association between intrahepatic lipid levels and hepatic insulin resistance 
(Perry et al., 2014).  The literature suggests that fructose in particular is involved in altering lipid 
metabolism (Dekker et al., 2010).  Despite uncertainty regarding the exact mechanisms involved 
it is important to understand hepatic lipid metabolism under physiological and pathophysiologic 
conditions in order to better identify the role(s) of SSB consumption in this context 
3.1.4  Insulin signaling  
During the fed state glucagon levels are relatively low and insulin secretion is increased (Guyton 
and Hall, 2010).  Although hepatic glucose uptake takes place independently of insulin, it is 
important for priming the liver for sudden changes in carbohydrate and lipid homeostasis.  
Insulin acts to lower blood glucose levels by promoting glucose utilization and storage and 
thereby preventing the ‘’toxic’’ effects of hyperglycemia.  This is mainly brought about by 
changes in the expression of genes encoding glycolytic and lipogenic genes (Michael et al., 
2000).  The insulin signaling pathway and its impact on target genes will now be discussed in 
greater detail. 




Pancreatic β-cells secrete insulin directly into circulation to allow it to bind to insulin receptors 
that are situated on the surface of hepatocytes, adipocytes and myocytes. Insulin receptors are 
part of a family of receptors named receptor tyrosine kinases that trigger an intracellular 
signaling cascade in the presence of insulin (Guyton & Hall, 2011).  Insulin receptors consist of 
two extracellular α-subunits and two β-subunits that penetrate the cell membrane.  Insulin binds 
to extracellular α-subunits that initiate auto-phosphorylation by intracellular β-subunits. Insulin 
signaling is a dynamic process regulated by numerous phosphorylation and dephosphorylating 
reactions (Choi & Kim, 2010). The phosphorylation of the tyrosine residues on the insulin 
receptor substrates (i.e. insulin receptor substrate (IRS) 1 – 6, src homology 2, casitas B-
lineage lymphoma and GRB-associated binder-1) follows (Meshkani & Adeli, 2009). 
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) further relays the signal and consists of 
two subunits, regulatory (p85) and catalytic (p110), respectively.  In the absence of insulin the 
p85 subunit inhibits the p110 subunit.  However, when insulin signaling is initiated the activated 
IRS acts as a docking station for PI3K.  This results in the inhibition of p85 that allows for the 
enzymatic activation of the p110 subunit (Cuevas et al., 2001).  PI3K phosphorylates 
phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-triphosphate (PIP3) 
which in turn phosphorylates the 3-phosphoinositide-dependent protein kinases (PDK-1; PDK-2) 
to ultimately activate Akt (Figure 3.1.3) (Choi & Kim, 2010).  Akt activation can be inhibited when 
PIP3 is converted back to PIP2 by phosphatase and tensin homologue deleted on chromosome 
10.  Akt is a central signaling enzyme and altered activity is involved in the pathophysiology of 
several diseases. Literature show a downregulation of Akt in T2DM (Manning & Cantley, 2007).  
The following section explores the downstream targets of AKT in more detail.   
Insulin action is mainly accomplished via the effects of Akt on downstream targets.  Akt is 
involved in the regulation of cellular processes such as metabolism, cell survival, growth and 
proliferation (Manning & Cantley, 2007).  However, for this component of the thesis the focus 
will be placed on Akt-mediated regulation of metabolism.  Akt facilitates the effects of insulin 
when there is a rise in blood glucose levels, i.e. to promote glucose uptake, metabolism and 
storage while inhibiting hepatic glucose production as summarized in Figure 3.1.3 (Manning & 
Cantley, 2007).   




Akt directly promotes glucose uptake in a variety of tissues but not in the liver specifically, e.g. it 
enhances insulin-dependent glucose uptake into skeletal muscle cells by regulating the 
translocation of GLUT4 to the sarcolemma via the activation of 160 kDa substrate (Choi & Kim, 
2010; Manning & Cantley, 2007).  Although Akt signaling does not directly mediate nutrient 
uptake in the liver, it is involved in the regulation of nutrient metabolism and storage (Manning & 
Cantley, 2007).  Akt can accelerate the first step of glucose metabolism (glucose to G-6-P) by 
enhancing the association between mitochondria and hexokinase (Manning & Cantley, 2007).  
Akt activity also determines whether G-6-P will be catabolized via the glycolytic pathway or 
whether it will follow an anabolic pathway and be stored as glycogen.  Here glycolysis is favored 
when Akt phosphorylates hypoxia inducible factor-α  to ultimately increase the transcription of 
glycolytic enzymes.  Alternatively, the storage of G-6-P can be promoted by phosphorylation-
 
Figure 3.1.3: Hepatic insulin signaling pathway and its effect on glucose handling (with the 
focus on Akt as signaling molecule).  Figure adapted from Benadè (2014).  
 Phosphate groups.  
 
 




mediated inhibition of glycogen synthase kinase 3β (GSK-3β) – which usually inhibits glycogen 
synthase.  However, this is now countered and glycogen can be readily synthesized.  Akt also 
reduces hepatic glucose output by phosphorylating peroxisome proliferator-activated receptor-γ 
coactivator 1-α  (PGC-1-α) to attenuate the subsequent expression of gluconeogenic enzymes 
(PEPCK and G-6-Pase), and inhibiting the gluconeogenic transcription factor forkhead box 
protein O1 (FoxO1) (Kitamura, 2013; Postic, 2004). Akt phosphorylates FoxO1 causing it to 
translocate from the nucleus (site of action) to the cytoplasm (Kitamura, 2013).  FoxO1 is 
involved in the regulation of numerous cellular processes including metabolism, e.g. it can 
increase hepatic glucose output by upregulating the expression of glucogenic enzymes 
(Manning & Cantley, 2007).   Thus higher FoxO1 activity is a hallmark of T2DM pathogenesis. 
The inhibition of FoxO1 is pivotal to maintain glycemic homeostasis since it a central modulator 
of hepatic lipid and glucose metabolism (Kitamura, 2013).   Zhang et al. (2006) used a 
transgenic mouse model to establish that constitutively active hepatic FoxO1 is associated with 
increased fasting blood glucose levels regardless of insulin levels, reduced insulin sensitivity 
and impaired glucose tolerance.  The transgenic mice also expressed higher levels of PEPCK, 
G-6-Pase and insulin growth factor binding protein-1, all related to hepatic glucose production.  
In parallel, there was increased transcription of aquaporin 7 and 9.  Aquaporin 7 allows for the 
release of glycerol from adipocytes, while aquaporin 9 promotes its uptake into the liver – a  
necessary substrate for glucose production.  FoxO1 is also responsible for the release of amino 
acids (as substrates for gluconeogenesis) through proteasomal degradation, by altering tyrosine 
transferase and atrogin-1 expression. Furthermore, FoxO1 prevents glycogenesis - important 
step in decreasing blood glucose levels - by suppressing the transcription of glucokinase.  
Amino acids are also released to serve as substrates for gluconeogenesis (Zhang et al., 2006).  
Lastly, FoxO1 has been linked to pancreatic β-cell failure that is central in the pathophysiology 
of T2DM (Guo, 2014).  
3.2 Materials and Methods  
A detailed protocol is provided in Appendix B.   In brief, 100 μg liver tissues (after 6 months of 
treatment) were homogenized (Polytron PT2100, Kinematica, Luzern, Switserland) in 0.5 mL 
extraction buffer.  The lysates were centrifuged for 10 min at 12000 x g (Spectrafuge™ 24D, 
Labnet, Edison NJ) and cooled acetone at -20oC was added to the supernatant in a 1:4 ratio.  
Proteins were allowed to precipitate overnight at -20oC.  On the second day the protein pellets 
were separated and transported to the Central Analytical Facility (Faculty of Medicine and 




Health Sciences, Stellenbosch University) where the rest of the experimental work was 
completed by Dr. Mare Vlok (Laboratory Manager).  Here the protein pellets were ‘cleaned’ and 
the protein concentration determined spectrophotometrically at 280 nm (NanoDrop 
spectrophotometer, Thermo Scientific, Waltham MA) (refer Appendix B for details).  Next the 
proteins were digested in a trypsin solution, dried and resuspended.  Residual digest reagents 
were removed and samples were prepared for liquid chromatography and mass spectrometry 
analysis.  Dionex nano-RSLC Liquid chromatography was performed on a Thermo Scientific 
Ultimate 3000 RSLC and Mass spectrometry was performed using a Thermo Scientific Fusion 
mass spectrometer   Data were acquired and analyzed. 
3.3 Results  
Proteomic analysis was performed on the six month Control, Cal-control and SSB groups (n = 6 
each) and each sample was analyzed in duplicate.    A total of 3, 379 proteins were detected in 
the samples and 3, 156 had similar expression levels between groups at a false discovery rate 
of 0.5%.  The outstanding 222 proteins were uniquely regulated in one or two of the groups 
compared to the remaining group(s).   Here we considered both the effect of the consumption of 
excessive sugar-derived calories (changes in SSB group only) and the consumption of excess 
calories in general (the combined effect of the SSB and Cal-control group).  Of the 34 proteins 
affected in the SSB group, 28 displayed >95% probability reading while 95 of the 106 that 
changed in the SSB/Cal-control combination.  These proteins were further examined - 
summarized in Figure 3.3.1 below.  Tables 3.3.1-3.3.4 provide a brief overview of the function 
and subcellular location of each of the proteins included in the study, together with its full name 










Figure 3.3.1: Proteomic analysis.  The 
Venn diagram indicates the number of 
proteins per group/combination that 
increased versus the remaining group(s).  
● Sugar-induced up/downregulation of 
protein expression. 
● Calorie-induced up/downregulation of 
protein expression. 
● Number of proteins per group that was 





















Name (accession number) Function; location 








Cluster of biliverdin 
reductase B Flavin 
reductase (NADPH) 
(B5DF65) 
Reduces biliverdin to bilirubin with the concomitant oxidation of a 
nicotinamide adenine dinucleotide (NADH) or nicotinamide adenine 
dinucleotide phosphate (NADPH) cofactor; cytoplasm (UniProtKB)  
Significance: decrease in SSB group leads to improved recycling of 
glutathione.  
80% ↓ 70% ↓ 75% ↓ 
 
Cluster of nipsnap1 protein 
(Q5EBA4) 
Involved in pain sensation, cell surface and mitochondrial inner 
membrane (ScaffoldQ+).  
80% ↓ 70% ↓ 75% ↓ 
 
Cluster of tetratricopeptide 
repeat protein 36 (TTC36) 
Possibly involved in protein folding, also known as HSP70-binding 
protein 21 (UniProtKB).  Subcellular location unknown.   
70% ↓ 70% ↓ 70% ↓ 
 
Cluster of sorbin and SH3 
domain-containing protein 2 
(tr|F1LPM3|F1LPM3) 
Involved in the formation of stress fibers and cell adhesion 
(Nakatani, 2011; ScaffoldQ+). Associated with obesity, T2DM (Lin, 
2001), diabetic complications (Nakatani, 2011) and heart infarcts 
(Kakimoto, 2013); perinuclear region of cytoplasm (ScaffoldQ+). 
A decrease could possibly be a protective response.  





Step 5 of methionine salvage pathway (UniProtKB); cytosol 
(Reactome).  
70% ↓ 60% ↓ 65% ↓ 
 
Cluster of uncharacterized 
protein (F1LRJ9) 
Intragolgi protein transport (ScaffoldQ+, STRING); nucleus, cytosol, 
golgi membrane (UniProtKB).  
60% ↓ 60% ↓ 60% ↓ 
 
Cluster of clathrin light chain 
A (sp|P08081|CLCA) 
Intracellular protein transport (clathrin-mediated endocytosis); 
membrane of clathrin-coated endocytic vesicles and trans-Golgi 
network (ScaffoldQ+). 
40% ↓ 80% ↓ 60% ↓ 
 
Table 3.3.1:  Proteins exhibiting a sugar-induced decrease in expression (listed from highest to lowest).   Some of the important 
proteins to take note of are those involved in protein folding and transport (marked blue in the last column) e.g. tetratricopeptide repeat protein 
36. The color code in the final column will be explained in detail in section 3.4.   
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Cluster of tubulin-specific 
chaperone A (TBCA) 
Post-chaperonin tubulin folding pathway (ScaffoldQ+); cytoskeleton 
(UniProtKB).   
60% ↓ 60% ↓ 60% ↓ 
 
Cluster of enoyl-CoA delta 
isomerase 2, mitochondrial 
(ECI2) 
Peroxisomal lipid metabolism (Reactome); peroxisomal matrix 
(ScaffoldQ+). 





Name (accession number) Function; location 







Death-associated protein 1 
(DAP1) 
Negatively regulates autophagy; nucleus and cytoplasm 
(UniProtKB). 




NADPH regeneration and proton transport; mitochondrial inner 
membrane (ScaffoldQ+). 
390% ↑ 90% ↑ 240% ↑ 
 
Prefoldin 1 (D3ZX38) 
Binds specifically to cytosolic chaperonin to promote protein folding; 
ER (Prefoldin complex) (ScaffoldQ+). 
280% ↑ 180% ↑ 230% ↑ 
 
Transgelin (TAGL) 
Form cross-links with actin and possible marker for liver damage; 
cytoplasm (UniProtKB). 
20% ↑ 270% ↑ 145% ↑ 
 
Cluster of protein Snrpd2 
(B5DES0) 
Regulation mRNA splicing and snRNP assembly (Reactome); 
nucleus (UniProtKB). 
180% ↑ 80% ↑ 130% ↑ 
 
Cluster of heterogeneous 
nuclear ribonucleoprotein 
(HNRPF) 
Regulation of RNA splicing and mRNA processing; nucleoplasm 
and cytoplasm (ScaffoldQ+). 




Platelet activation and negative regulation of cell growth 
(ScaffoldQ+); secreted (UniProtKB).  
70% ↑ 90% ↑ 80% ↑ 
 
Acidic leucine-rich nuclear Cell-cycle regulation; nucleus (Reactome). 120% ↑ 30% ↑ 75% ↑  
Table 3.3.2:  Proteins exhibiting a sugar-induced increase in expression (listed from highest to lowest).  Here the expression of ECT 
proteins was significantly upregulated (marked by orange)     The color code in the final column will be explained in detail in section 3.4.   
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phosphoprotein 32 family 
member B (AN32B) 
Cluster of multiple 
coagulation factor deficiency 
2 (Q6GQY2) 
Vesicle mediated protein transport (Reactome; ScaffoldQ+); golgi 
apparatus and ER (ScaffoldQ+). 
70% ↑ 30% ↑ 50% ↑ 
 
Protein mut (D3ZKG1) 
Propionyl-CoA catabolism to succinyl-CoA (intermediate of citric 
acid cycle); mitochondrial matrix (ScaffoldQ+). 
30% ↑ 50% ↑ 40% ↑ 
 
Beta-2-microglobulin (B2MG) 
Positive regulation of T cell-mediated cytotoxicity (stress signaling);    
golgi apparatus (ScaffoldQ+). 
30% ↑ 50% ↑ 40% ↑ 
 
Thymosin β4 (TYB4) 
Regulation of cell migration and actin filament organization for 
tissue repair; cytoskeleton (ScaffoldQ+). 
40% ↑ 40% ↑ 40% ↑ 
 
Cluster of lamina-associated 
polypeptide 2, isoform β 
(LAP2) 
Regulation of transcription; ER membrane (ScaffoldQ+). 40% ↑ 40% ↑ 40% ↑ 
 
Cluster of Hnrpa1 protein 
(Q6P6G9) 
Deoxyribonucleic acid (DNA) strand renaturation and mRNA 
transport; nucleoplasm and cytoplasm (ScaffoldQ+). 





Subunit of Complex II → transfer electrons from succinate to 
ubiquinone; mitochondrial inner membrane (UniProtKB). 
20% ↑ 50% ↑ 35% ↑ 
 
Calcium-regulated heat 
stable protein 1 (CHSP1) 
Inhibit gluconeogenic gene expression; cytoplasm (UniProtKB). 20% ↑ 50% ↑ 35% ↑ 
 
ATP synthase subunit d 
(sp|P31399|ATP5H) 
Maintenance of ATP synthase structure during ATP synthesis; 
mitochondrial inner membrane (UniProtKB). 




protein 4 (sp|Q5XIF3|NDUS4) 
Subunit of Complex I - transfer electrons from NADH to the electron 
transport chain (ETC);  mitochondrial inner membrane (UniProtKB). 
30% ↑ 30% ↑ 30% ↑ 
 
Cluster of 40S ribosomal 
protein S4, X isoform (RS4X) 
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protein subunit β 
(B5DEQ0) 
Involved in ER calcium homeostasis (STRING); ER membrane 
(ScaffoldQ+). 






Partakes in valine, leucine and isoleucine degradation catabolism; 
mitochondria (Horton et al., 2006; ScaffoldQ+). 
ER stress downregulates branched-chain amino acid catabolism (Burrill et 
al., 2015). 




Involved in the assembly and function of cytochrome C oxidase (COX); 
mitochondria (Complex IV) (ScaffoldQ+). 
92% ↓ 100% ↓ 96% ↓ 
 
Protein Tjp3 (D3Z8G7) 
Structural component of tight junctions; between cells (UniProtKB) 
ER stress has been linked to the degradation of tight junctions (Zhou et 
al., 2016). 





Deubiquitination of proteins to prevent protein degradation; ER and golgi 
stacks (UniProtKB). 





Important enzyme in step in the bile acid biosynthetic process before bile 
is released into canaliculi; cytosol and peroxisomes (ScaffoldQ+). 
Could regulate intracellular levels of fatty acids through its effects on acyl-
CoA (UniProtKB). 
90% ↓ 100% ↓ 95% ↓ 
 
Cluster of LUC7-like 
(G3V9R0) 
Involved in RNA splicing; nucleus (ScaffoldQ+). 90% ↓ 100% ↓ 95% ↓ 
 
ATPase inhibitor, Protects cell against ATP-depletion when mitochondrial membrane 90% ↓ 98% ↓ 94% ↓  
Table 3.3.3:  Proteins exhibiting a calorie-induced decrease in expression (listed from highest to lowest).  Excess calorie 
consumption decreased the expression of a wide range of proteins involved in various cellular processes.  The expression of translocon-
associate protein subunit β, a protein involved in ER calcium regulation, was completely suppressed   The color code in the final column 
will be explained in detail in section 3.4.     
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mitochondrial (ATIF1) potential drops below a critical threshold; mitochondrial proton-transporting 
ATP synthase complex (ScaffoldQ+; UniProtKB). 
Enthoprotin (Q6DGF2) 
Initiates the assembly of clathrin for clathrin-coated endocytosis vesicles; 
golgi apparatus (UniProtKB). 
90% ↓ 98% ↓ 94% ↓ 
 
Lymphocyte specific 1 
isoform CRA_a 
(Q4QQV6) 
Involved in signal transduction and chemotaxis; extracellular exosome and 
cell membrane (ScaffoldQ+). 
92% ↓ 91% ↓ 91.5% ↓ 
 
Acyl-protein 
thioesterase 1 (LYPA1) 
Involved in fatty acid metabolism and protein depalmitoylation; cytoplasm 
(ScaffoldQ+, UniProtKB). 
100% ↓ 80% ↓ 90% ↓ 
 
Cluster of isoform 2 of 
myelin basic protein 
(sp|P02688-2|MBP) 
Possibly involved in the formation of transcriptional complexes; nucleus 
(UniProtKB). 
80% ↓ 90% ↓ 85% ↓ 
 
Cluster of clathrin light 
chain B 
(sp|P08082|CLCB) 
Intracellular protein transport; membrane of clathrin-coated endocytic 
vesicles and trans-Golgi network (ScaffoldQ+). 
80% ↓ 80% ↓ 80% ↓ 
 
Cluster of protein 
RGD1565183  
(D3ZJD3) 
Translation - structural component of large ribosomal subunit 
(ScaffoldQ+); nucleolus (UniProtKB). 
80% ↓ 80% ↓ 80% ↓ 
 
Heat shock protein β8 
(HSPB8) 
Chaperone activity (response to temperature stress); golgi apparatus, 
cytoplasm, nucleoplasm (UniProtKB). 
60% ↓ 100% ↓ 80% ↓ 
 
Cluster of annexin A3 
(ANXA3) 
Promotes angiogenesis and involved in immune responses; cytoplams, 
cell membrane, extracellular exomes (ScaffoldQ+; UniProtKB). 
80% ↓ 70% ↓ 75% ↓ 
 
Calponin-3 (CNN3) 
Involved in epithelial cell differentiation and smooth muscle contractions; 
cytoplasm and cytoskeleton (ScaffoldQ+, UniProtKB). 
70% ↓ 80% ↓ 75% ↓ 
 
Phosphohistidine 
phosphatase 1 isoform 
CRA_a (D3ZP47) 
Dephosphorylates proteins and inhibit calcium channels; cytosol and 
extracellular exosome (ScaffoldQ+). 
70% ↓ 80% ↓ 75% ↓ 
 
Cluster of Pdhx 
protein (Q5BJX2) 
Important structural protein of pyruvate dehydrogenase complex; 
mitochondria (Gray et al., 2014; ScaffoldQ+). 
Perturbations in pyruvate metabolism are associated with CVD, obesity 
and T2DM (Gray et al., 2014). 
80% ↓ 70% ↓ 75% ↓ 
 
Ddx17 protein Involved in the regulation of transcription; nucleus (Fuller-Pace & Ali, 80% ↓ 70% ↓ 75% ↓  
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Involved in quinolinate catabolism and nicotinamide adenine dinucleotide 
(NAD+) synthesis (ScaffoldQ+). 
NAD+ plays a role in cellular metabolism and mitochondrial health (Canto 
et al., 2015). 






Catabolizes dimethylglycine to glycine; mitochondrial matrix (Magnusson, 
2015; UniProtKB). 
Dimethylglycine is involved in the regulation of glucose metabolism.  A 
decline in dimethylglycine levels correlates with the development of T2DM 
(Magnusson et al., 2015). 
60% ↓ 70% ↓ 65% ↓ 
 
Cluster of ubiquitin-
60S ribosomal protein 
L40 (RL40) 
Translation - structural constituent of ribosome; cytoplasm and nucleus 
(ScaffoldQ+) 
70% ↓ 50% ↓ 60% ↓ 
 
Cluster of 60S 
ribosomal protein L7 
(B0K031) 





Involved in the production of the antioxidant hydrogen sulfide (H2S).  
Changes in enzyme activity and H2S is indicative of the development of 
T2DM and hyperglycemia-induced epithelial cell damage; cytoplasm and 
mitochondria (Coletta, 2015; UniProtKB). 
70% ↓ 40% ↓ 55% ↓ 
 
Cluster of GM2 
ganglioside activator 
(Q6IN37) 
Regulates the degradation of GM2 gangliosides (UniProtKB); 
mitochondrion (ScaffoldQ+). 
40% ↓ 70% ↓ 55% ↓ 
 
Cluster of isoamyl 
acetate-hydrolyzing 
esterase 1 homolog 
(sp|Q711G3|IAH1) 
Lipid catabolism (lipase) and hydrolase activity; extracellular exosome 
(UniProtKB). 
70% ↓ 40% ↓ 55% ↓ 
 




Aldehyde reductase activity (requires NADPH) and toxin degradation; 
Golgi apparatus and cytoplasm (UniProtKB). 
60% ↓ 50% ↓ 55% ↓ 
 
Cluster of NADH Involved in electron transport from NADH to the ETC; mitochondrial 60% ↓ 50% ↓ 55% ↓  
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subcomplex subunit 6 
(tr|D4A3V2|D4A3V2) 
subunit of complex I of ETC (UniProtKB).  
Cluster of LOC689593 
(B2RYA8) 
ER-associated protein catabolism; cytosol and nucleus (ScaffoldQ+; 
UniProtKB). 






Anti-oxidant properties; mitochondria (STRING). 50% ↓ 40% ↓ 45% ↓ 
 
Cluster of histone H3 
(D3ZJ08) 
Inhibits transcription from RNA polymerase II promoter and involved in 
nucleosome assembly; nucleus (ScaffoldQ+; UniProtKB). 
50% ↓ 40% ↓ 45% ↓ 
 
Cluster of 60S 
ribosomal protein L26 
(tr|G3V6I9|G3V6I9) 
Translation - structural component of large cytosolic ribosomes 
(ScaffoldQ+). 




cytosolic 1B member 1 
(sp|P52847|ST1B1) 




Associated with the acute-phase response and inhibits proteases activity; 
secreted into intracellular space (ScaffoldQ+; UniProtKB). 





Involved in translation - peptidyl-serine phosphorylation, nucleus 
(ScaffoldQ+). 
50% ↓ 30% ↓ 40% ↓ 
 




Partakes in the biosynthesis of coenzyme Q/ubiquinone; mitochondrial 
inner membrane (UniProtKB). 
50% ↓ 30% ↓ 40% ↓ 
 




Proton-transporting ATPase activity, rotational mechanism, mitochondrial 
inner membrane (UniProtKB). 
40% ↓ 30% ↓ 35% ↓ 
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Catalyzes step 8 of glycolytic pathway (Horton et al., 2006), cytosol 
(ScaffoldQ+). 







Synthesis of ketone bodies; mitochondrial matrix (Horton et al., 2006; 
ScaffoldQ+). 
40% ↓ 30% ↓ 35% ↓ 
 
Cluster of 40S 
ribosomal protein SA 
(RSSA) 
Involved in small ribosomal  subunit assembly and maintenance; plasma 
membrane (ScaffoldQ+). 
40% ↓ 30% ↓ 35% ↓ 
 
Cluster of 40S 
ribosomal protein S8 
(tr|M0R7Q5|M0R7Q5) 
Translation - small ribosomal subunit; cytosol and cell membrane 
(ScaffoldQ+; UniProtKB). 
30% ↓ 40% ↓ 35% ↓ 
 
Cluster of protein 
Taf15  (D3ZSS1) 
Involved in binding of nucleotides and the regulation of transcription, 
nucleoplasm (ScaffoldQ+). 





Carbohydrate biosynthetic process, cytosol (ScaffoldQ+). 30% ↓ 40% ↓ 35% ↓ 
 
Cluster of glutathione 
S-transferase-α1 
(GSTA1) 
Protects against oxidative stress and products of lipid peroxidation through 
glutathione peroxidase activity, cytosol and extracellular exome (NCBI; 
UniProtKB). 
20% ↓ 50% ↓ 35% ↓ 
 
Cluster of Glutathione 
S-transferase-α3 
(GSTA3) 
Anti-oxidant properties and involved in the biosynthesis of steroid 
hormones; cytosol and extracellular exome (UniProtKB). 
30% ↓ 30% ↓ 30% ↓ 
 
Cluster of protein 
LOC100912599 
(tr|D3ZCZ9|D3ZCZ9) 
Transports electrons from NADH to ubiquinone; mitochondrial ETC 
complex I (ScaffoldQ+). 
40% ↓ 20% ↓ 30% ↓ 
 
Cluster of Protein 
LOC680161 (D4A6B9) 
Ribosome biogenesis and RNA binding, cytosolic large ribosomal subunit 
(ScaffoldQ+; UniProtKB). 
20% ↓ 40% ↓ 30% ↓ 
 
Cluster of GTPase Nucleotide binding, cytoplasm (UniProtKB). 40% ↓ 20% ↓ 30% ↓  
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Synthesis of bile acids and bile salts; cytoplasm (Reactome; ScaffoldQ+). 30% ↓ 20% ↓ 25% ↓ 
 
Regucalcin (RGN) 
Cellular calcium ion homeostasis, cytoplasm and nucleoplasm 
(ScaffoldQ+). 




domain containing 3 
isoform CRA_a 
(D3ZUX5) 
Involved in maintenance of inner mitochondrial membrane and suppress 
transcription from RNA polymerase II promoter, mitochondria and nucleus 
(UniProtKB). 





Anti-oxidant properties (glutathione transferase activity); cytoplasm 
(UniProtKB). 
20% ↓ 30% ↓ 25% ↓ 
 
Cluster of histone H1.4 
(H14) 
Inhibits transcription from RNA polymerase II promoter and involved in 
nucleosome assembly, nucleus (ScaffoldQ+; UniProtKB). 




Cytoplasm. 20% ↓ 20% ↓ 20% ↓ 
 
Omega-amidase (NIT2) 
Converts potentially toxic metabolic intermediates to beneficial metabolic 
substrates; cytoplasm (UniProtKB). 
20% ↓ 20% ↓ 20% ↓ 
 
Cluster of 40S 
ribosomal protein S18 
(RS18) 





Amino acid catabolism; cytosol (UniProtKB). 20% ↓ 10% ↓ 15% ↓ 
 
 
Stellenbosch University  https://scholar.sun.ac.za




































Cluster of DnaJ 
(Hsp40) homolog 
subfamily B member 1 
(predicted) isoform 
CRA_a (D3ZUU5) 
Chaperone cofactor-dependent protein folding; cytosol, extracellular 
vesicular exosome and nucleus (ScaffoldQ+).  
Marker for ER stress (Tang et al., 2010). 







Cluster of EH domain-
containing protein 1 
(sp|Q641Z6|EHD1) 
Regulates cholesterol homeostasis and lipid droplet storage (Naslavsky et 









Mediates intracellular signal transduction; cytosol, endosome and 
extracellular vesicular exosome (ScaffoldQ+; UniProtKB).   CRKL plays a 
role in the tyrosine kinase signaling pathways, e.g. it binds to IRS of the 
insulin signaling pathway (Cevik, 2016; Hanke & Mann, 2009).  
880% ↑ 530% ↑ 705% ↑ 
 
Cluster of thioredoxin 
domain-containing 
protein 12 
Involved in redox homeostasis and inhibits ER stress-induced apoptosis; 
lumen of ER (UniProtKB). Deng et al. (2010) found it downregulated in the 
liver of a diabetic rat model.  Thus upregulation could possibly be an early 
790% ↑ 460% ↑ 625% ↑ 
 
Table 3.3.4:  Proteins exhibiting a calorie-induced increase in expression (listed from highest to lowest). DnaJ (Hsp40) homolog 
subfamily B member 1 isoform CRA_a is the most important protein to consider  here.  It serves as a marker for ER stress and was not 
expressed in the Control group at all, but was detected in the SSB and Cal-control groups.   The color code in the final column will be 
explained in detail in section 3.4.     
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Function and location unknown. 240% ↑ 350% ↑ 295% ↑ 
 
Cluster of eukaryotic 
translation initiation 
factor 3 subunit D 
(EIF3D) 
Part of eukaryotic translation initiation factor 3 (eIF-3) complex that 
interacts with 40S ribosomes; cytosol (UniProtKB). 







Involved in importing proteins from the mitochondrial inner membrane to 
the mitochondrial matrix (ATP-dependent), chaperone binding; 
mitochondrial inner membrane and matrix (ScaffoldQ+; UniProtKB). 
230% ↑ 160% ↑ 195% ↑ 
 
Ubiquitin fusion 
degradation protein 1 
homolog (UFD1) 
Partakes in the degradation ER-associated degradation (ERAD) and 
ubiquitin fusion degradation of misfolded proteins and the activation of 
certain transcription factors; cytosol and nucleus (UniProtKB). 
160% ↑ 140% ↑ 150% ↑ 
 
Cluster of Aa1018 
(Q7TQ11) 
Structural protein that is involved in receptor-mediated endocytosis and 
immune response; extracellular vesicular exosome (ScaffoldQ+; 
UniProtKB). 
130% ↑ 150% ↑ 140% ↑ 
 
Rat apolipoprotein E 
protein (Q65ZS7) 
Facilitates the binding and uptake of lipoprotein particles (LDLs in 
particular) to clear it out of the plasma (UniProtKB).  
 





Involved in various cellular processes including protein chaperoning; 
cytoplasm and nucleus (UniProtKB).   
90% ↑ 80% ↑ 85% ↑ 
 
Fetuin-B (FETUB) 
Secreted by hepatocytes  and elevated in diabetic mice; extracellular 
region.  Associated with impaired glucose and steatosis (Meex et al., 
2015; Uniport). 
60% ↑ 100% ↑ 80% ↑ 
 
Cluster of bifunctional 
ATP-dependent 
dihydroxyacetone 
Involved in fructose metabolism; cytosol (Horton, 2006; Reactome).  
Alternative name:  Triose kinase (UniProtKB). 
70% ↑ 80% ↑ 75% ↑ 
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Cluster of 40S 
ribosomal protein S26 
(RS26) 
Translation – structural protein of small ribosomal subunit; cytosol and 
nucleus (ScaffoldQ+; UniProtKB). 
 
70% ↑ 80% ↑ 75% ↑ 
 
Cluster of protein Ybx2 
(D4A3P0) 




Involved in mRNA splicing and gene expression; nucleoplasm and 
cytoplasm. (Reactome; UniProtKB). 






Involved in cellular calcium homeostasis and inhibits apoptotic process 
signaling; cytoplasm and extracellular exosome (UniProtKB). 
70% ↑ 40% ↑ 55% ↑ 
 
UBX domain-
containing protein 1 
(UBXN1) 
Negative regulator of protein degradation and nuclear factor kappa B (NF-
κB) signaling; nucleus, cytoplasm and ER (UniProtKB; Wang et al., 2015). 





Involved in the initial phase of cholesterol biosynthesis; cytoplasm, 
nucleoplasm and plasma membrane (Horton, 2006; UniProtKB). 
 












Partakes in the moduation of mRNA stability; cytoplasm and nucleus 
(UniProtKB).  




Involved in cellular redox homeostasis and mitochondrial membrane 
potential.  Mitochondrial thioredoxin is also involved in inhibiting apoptosis; 
mitochondria (UniProtKB).    
50% ↑ 50% ↑ 50% ↑ 
 
Cluster of Involved in mRNA splicing and nucleotide binding; nucleus, nucleoplasm 50% ↑ 50% ↑ 50% ↑  
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and extracellular exosome (ScaffoldQ+; UniProtKB). 
Protein G3bp1 
(D3ZYS7) 
Involved in the assembly of stress granules.  Stress granules that form in 
response to ER stress partake in adjusting protein translation by 
degrading of silencing RNA transcripts   (NCBI; STRING; Wolozin, 2012). 
40% ↑ 50% ↑ 45% ↑ 
 
Cluster of alcohol 
dehydrogenase 1 
(ADH1) 
Reduces alcohol molecules to produce NADH; Cytoplasm (UniProtKB). 40% ↑ 40% ↑ 40% ↑ 
 
SP120 (Q63555) DNA and RNA binding; nucleus (STRING; UniProtKB). 50% ↑ 30% ↑ 40% ↑  
Cluster of elongation 
factor 1-α 
(tr|M0R757|M0R757) 
Translation – assists the binding of aminoacyl-tRNA to the A-site of 
ribosomes; cytoplasm (UniProtKB). 





Involved in ubiquitin-dependent protein degradation process; cytosol and 
nucleoplasm (ScaffoldQ+).  
50% ↑ 30% ↑ 40% ↑ 
 
Cluster of Protein 
LOC100912618 
(tr|D3ZFY8|D3ZFY8) 
Catalyzes the attachment of ubiquitin protein to proteins. Also involved in 
various steps of DNA replication; cytoplasm and nucleus (ScaffoldQ+). 
30% ↑ 50% ↑ 40% ↑ 
 
Cluster of DnaJ 
homolog subfamily A 
member 1 
(sp|P63036|DNJA1) 
Involved in protein transfer into mitochondria whereby it suppresses ER-
associated apoptosis by inhibiting the translocation of Bax into 
mitochondria.  Also inhibits c-Jun amino-terminal kinase (JNK) activity; ER 
and mitochondria (ScaffoldQ+; UniProtKB). 
40% ↑ 30% ↑ 35% ↑ 
 
Cluster of 60S 
ribosomal protein L12 
(RL12) 
Translation - assembly and maintenance large ribosomal subunit; cytosol 
(ScaffoldQ+; UniProtKB). 
40% ↑ 30% ↑ 35% ↑ 
 





Mitochondrial electron transport, NADH to ubiquinone; mitochondrial ETC 
complex I (ScaffoldQ+). 
40% ↑ 30% ↑ 35% ↑ 
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Cluster of 60S 
ribosomal protein L17 
(RL17) 
Translation – structural component of large ribosomal subunit; cytosol and 
nucleus (ScaffoldQ+; UniProtKB). 




mine-binding protein 1 
(PEBP1) 
Involved in the dephosphorylation of proteins and serine protease 
inhibition; cytoplasm, nucleus and extracellular exosome (ScaffoldQ+; 
UniProtKB).  
10% ↑ 30% ↑ 20% ↑ 
 
Cluster of non-specific 
lipid-transfer protein 
(sp|P11915|NLTP) 





3.4 Discussion  
Figure: 3.4.1:  Schematic depiction of main proteomic findings.  We theorize that SSB consumption leads to hepatic ER stress through 
three possible mechanisms.  Here ER stress first  induces a cellular adaptation, followed by an alarm phase that will eventually result in 
apoptosis.  In addition, such stress  may also alter substrate metabolism.  The color blocks below each ‘event’ provide the accession 
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As we had relatively limited insight into the effects of SSB consumption on the liver, we decided 
to perform a proteomic analysis. Each protein with a unique expression profile in the SSB or 
SSB and Cal-control groups was identified and its function and subcellular location was 
determined (Table 3.3.1-3.3.4) in order to detect any meaningful patterns.  As Stanhope (2015) 
explained, SSB consumption could induce metabolic perturbations through direct or indirect 
(calorie-related) mechanisms.  For this reason we tabulated sugar- and calorie induced changes 
separately.  Although the calories triggered  more significant effects on protein expression 
compared to the sugar per se, we pooled the data in this section since SSB consumption would 
lead to a combined (sugar- and calorie-induced) effect.   Evidence emerged that moderate but 
frequent SSB consumption can lead to ER stress.  ER stress can be triggered by a variety of 
cellular stressors e.g. disproportionate levels of reactive oxygen species (ROS), imbalance in 
calcium homeostasis or the accumulation of misfolded proteins (Senft & Ronai, 2015; Tang et 
al., 2010).  Here we detected altered expression of proteins with antioxidant capacity e.g. 
peroxiredoxin-5, thioredoxin and glutathione S-transferase isoforms, as well as proteins that 
alter the availability of NADPH and consequently influence glutathione levels (Figure 3.4.1 B).  
There was also a decrease in several proteins involved in protein folding and transport together 
with proteins regulating ER and cellular calcium  handling, respectively (Figure 3.4.1 B).    
ER stress triggers a series of events in order to restore cellular homeostasis and salvage the 
cell.  These events can roughly be divided into three phases (i.e. adaptation, alarm and 
apoptosis) based on their order and purpose (Xu et al, 2005).  The main ‘event’ during the 
adaptation phase is the induction of the unfolded protein response (UPR).  The UPR has two 
main functions, i.e. to enhance protein folding and to suppress the synthesis of new proteins 
(note: although the mass of protein synthesis decrease, the synthesis of proteins involved in the 
stress response are upregulated, hence we refer to this as selective translation) (Tang et al., 
2010). Here we found that at least five proteins involved in protein folding are upregulated.  With 
regards to protein translation, the expression of a multitude of ribosomal proteins and proteins 
involved in ribosomal biogenesis or the initiation of translation were significantly altered (Figure 
3.4.1 D).  Another adaptation associated with ER stress is increased protein degradation 
through the ubiquitin proteasome pathway, also known as ER associated degradation (ERAD) 
(Bravo et al., 2012; Doroudgar et al., 2015; Xu, 2005).  Several proteins involved in protein 
degradation through ERAD were upregulated (Figure 3.4.1 D).  The final adaptive mechanism is 
enhancing mitochondrial function and oxidative phosphorylation.  The ER and mitochondria are 
connected - both physically and functionally (Malhotra & Kaufman, 2011).  During this early 




response to ER stress mitochondrial bioenergetics are augmented to increase subsequent ATP 
production and relieve ER stress (Bravo et al., 2012).  Our proteomic analysis revealed the 
upregulation of proteins that form part of the ETC e.g. succinate dehydrogenase (ubiquinone 
iron-sulfur subunit) that is responsible for electron transport at complex II.  The promotion of 
mitochondrial metabolism in response to transient ER stress was also observed in mammalian 
adrenal glands and gonads (Prasad et al., 2016).  
If ER stress persists, the cell enters the alarm phase. In contrast to the adaptation phase, 
mitochondrial metabolism fails during the alarm phase (Bravo et al., 2012) and we found a 
significant decrease in several proteins involved in oxidative phosphorylation (Figure 3.4.1 E). 
This may indicate that even moderate SSB consumption is sufficient to induce the alarm phase 
in the liver.  Another important ‘event’ during the alarm phase is the activation of stress-related 
signaling pathways e.g. NF-κB and JNK (known as the ER overload response) (Xu et al., 2005), 
however, there is no clear evidence of stress signaling in our model.  DnaJ homolog subfamily A 
member 1, a known inhibitor of JNK, was significantly upregulated.  A downstream 
consequence of the stress-signaling is the activation of autophagy (Senft & Ronai, 2015; Xu et 
al., 2005).  We did not detect an increase of proteins involved in autophagy.  On the contrary, 
the expression of death-associated protein 1 (negative regulator of autophagy) was significantly 
upregulated.  Perhaps this suggests that the ER overload response and autophagy are initiated 
late in the alarm phase.   Prolonged ER stress will eventually trigger apoptosis in the final stage 
(Tang et al., 2010).  As far as we can ascertain, phase 3 has not yet manifested in our model.  
The proteomics data also revealed that glucose, fructose and lipid metabolism are potentially 
altered due to SSB consumption (Figure 3.4.1 G).  For example, phosphoglycerate mutase 1 
(an enzyme of the glycolytic pathway) and Pdhx protein (structural protein of the pyruvate 
dehydrogenase complex) are significantly downregulated, perhaps indicating that glucose 
metabolism is suppressed.  The most significant changes were observed in proteins involved in 
lipid metabolism.   On the whole it seems as if proteins involved in lipid/fatty acid catabolism are 
decreased while lipid/cholesterol synthesis and storage is promoted.  It is unclear whether the 
variation of metabolic proteins is induced by the SSB per se or whether it is also a downstream 
consequence of ER stress, or a combination of both  Although ER stress can trigger metabolic 
changes these are not yet clearly understood.  For example, there is evidence that ER stress 
can both enhance and suppress gluconeogenesis (reviewed by Bravo et al., 2013).  Similarly, 
there is an undeniable link between ER stress and lipid metabolism, but the exact mechanisms 
and consequences of this interaction remain unclear.     




To our knowledge no other study has performed a proteomic analysis in the liver in response to 
long-term SSB consumption.  There is, however, an investigation of hepatic protein expression 
in hamsters consuming a high fructose diet (Zhang et al., 2008).   In contrast to our study, they 
observed an upregulation in the expression peroxiredoxin- and glutathione S-transferase 
isoforms and deemed it a protective mechanism.  This inconsistency is perhaps due to unique 
properties of fructose compared to sucrose or due to the fact that the fructose was consumed in 
solid form and not liquid as in our model.  In another study, hepatocytes cultured in high glucose 
medium displayed increased expression of proteins responsible for protein folding (e.g. heat-
shock proteins) (Chen et al., 2013).  The authors speculated that this may be a response to 
unfolded proteins in the ER (and thus ER stress). The expression of proteins involved in redox 
control was also altered.  These glucose-induced effects reflect the findings of our study. There 
are also a few studies that performed proteomic analysis in the context of insulin 
resistance/diabetes.  For example, Morand et al. (2005) studied the expression of ER-related 
proteins in insulin resistant hamsters on a high fructose diet and found the expression of 
chaperone proteins and other proteins involved in protein folding were altered.  Similar to our 
results the expression of some of these proteins were downregulated (a possible cause of ER 
stress) while others were upregulated (as you would expect during the adaptation phase).  This 
finding suggests that although ER stress triggers a sequence of cellular responses, these are 
much more fluid than depicted in Figure 3.4.1. This may explain our observation that proteins 
involved in various “phases” are implicated.   They also observed a significant increase in 
apolipoprotein E levels (Morand et al., 2005).  Another study corroborates the positive 
association between insulin resistance and ER stress.  Here the expression of a variety of ER 
stress markers were measured (i.e. GRP-78, PERK, IRE1a, XBP1, and CHOP) (Balakumar et 
al., 2016).  Additionally, they observed that the change elicited by a high fructose and a high fat 
diet, respectively, were similar both in nature and intensity.  This supports our finding that SSB-
induced perturbations can be mainly attributed to the excess calories and not the sugar per se.  
Others found that the onset of diabetes in Goto-Kakizaki rats triggered an increase in the 
expression of mitochondrial proteins, particularly those involved in oxidative phosphorylation, 
while antioxidants were suppressed (Deng et al., 2010).  These data are very similar to our 
observations (Figure 3.4.1 D).  In contrast to our model, the Goto-Kakizaki rats also expressed 
elevated levels of proteins involved in glycolysis and β-oxidation.  The similarity between our 
data and that of insulin resistant/diabetic models may indicate that moderate but frequent SSB 
consumption induced early diabetic characteristics in our model despite the fact that it is not yet 
reflected in the fasting blood glucose levels.  Furthermore, these studies support the idea that 




ER stress and mitochondrial metabolism may be implicated in the onset of early hepatic 
pathophysiology.   
In summary, our data indicate that moderate long-term SSB consumption may induce hepatic 
ER stress with subsequent effects on the mitochondria, protein synthesis and metabolism.  
There is some evidence that this is weighted more towards a calorie-induced effect versus a 
sugar-induced one since most of the proteins that were altered in the SSB group were also 
altered in the Cal-control group.  The next chapter investigates possible causes and 
consequences of ER stress based on the above mentioned theoretical framework.   
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Chapter 4: Understanding ER stress 
4.1 Introduction   
The purpose of this chapter is to build on the data generated in the proteomic analysis.  Here 
we investigated oxidative stress as a possible underlying cause of ER stress.  Additionally, we 
investigated perturbations of glucose and lipid metabolism since it is poorly understood in the 
context of ER stress. Lastly we hoped to determine whether the ER overload response is 
triggered in our model since the proteomic data in were inconclusive in the regard.  Section 
4.1.1-4.1.4 provides a theoretical background for the experimental work that follows.   
4.1.1 Oxidative stress 
Over-nutrition is closely linked with oxidative stress, a parameter that plays an important role in 
cardio-metabolic disease onset (Matsuda, 2013).  Oxidative stress refers to a state where 
excess ROS molecules induce physiological dysfunction by reacting with, and damaging, 
proteins, DNA and lipids (Araki & Nishikawa, 2010).  While relatively small amounts of ROS are 
essential for proper functioning of the cell, the presence of excessive amounts is detrimental 
(Styskal et al., 2012).  It is widely assumed that hyperglycemia aggravates ROS, yet clinical 
studies exploring the association between acute glycemic load and oxidative stress produced 
inconsistent and inconclusive results (reviewed by Choi et al., 2008).  Others confirmed a 
positive association between chronic hyperglycemia (diagnosed diabetes or based on HbA1c 
measurements) and oxidative stress (Aouacheri et al., 2015; Araki & Nishikawa, 2010).   
Theoretically, hyperglycemia should have significant effects on mitochondrial ROS production 
(Rolo & Palmeira, 2006).  Here the glucose is metabolized to form ETC donors, NADH and 
flavin adenine dinucleotide (FADH2), thereby enabling the production of ATP.  Under 
physiological conditions NADH and FADH2 donate electrons to protein complex I and protein 
complex II, respectively.  These electrons are then transferred through the ETC (Figure 4.1.1) 
until it reaches complex IV.  Here the electrons leave the ETC to reduce oxygen to water.  In 
parallel, complexes I, III and IV also pump protons across the inner membrane of mitochondria 
to generate a trans-membrane voltage gradient that drives ATP generation through ATP 
synthase.  Frequent SSB consumption may, result in an excess availability of NADH and 
FADH2.  Electrons now enter the ETC at a faster pace causing a shift in ATP/adenosine 
diphosphate (ADP) ratio and hyperpolarization of the mitochondrial inner membrane (Rolo & 




Figure 4.1.1:  Mitochondrial superoxide production induced by hyperglycemia.  
Glucose metabolism ultimately leads to the production of NADH and FADH2 (steps 1-
4).  NADH and FADH2 donate electrons to the complex I and complex II of the 
electron transfer chain ETC, respectively.  Hyperglycemia results in an excess 
availability of NADH and FADH2 (5) which cause congestion and untimely electron 
leakage.  Each of these electrons bind to an oxygen molecule to generate superoxide 
(6-7). Diagram from Benadè (2014). 
 
Palmeira, 2006).  Subsequently, complex III can become partially congested resulting in 
electron accumulation and leakage at coenzyme Q that can bind to molecular oxygen to yield 
superoxide (Rolo & Palmeira, 2006).   
 
Although mitochondria are considered the main source of intracellular ROS, there are other 
processes and enzymes that also contribute to oxidative stress e.g. NADPH oxidase (NOX), 
xanthine oxidase , endothelial nitric oxide synthase and angiotensin II (reviewed by Giacco & 
Brownlee, 2010; Johnson et al., 2009, Panigrahy, 2016).  Xanthine oxidase activity is linked to 
CVD as it generates superoxide that reacts with nitric oxide, thereby interfering with the 
relaxation of vascular smooth muscle and promoting the aggregation of platelets.  Additionally, it 
promotes the generation of peroxynitrite anions that can deactivate several signaling enzymes 
(Bocci et al., 2011).  However, data suggest that besides mitochondrial ROS, NOX likely plays 




the most noteworthy role in the context of SSB consumption and the onset of cardio-metabolic 
diseases, e.g. NOX are overexpressed in Zucker fatty rats that are often used as models for 
obesity and T2DM (Shen, 2010).  NOX is a family of enzymes located in the membranes of 
organelles.  NOX interacts with other transmembrane proteins to capture NADPH from within 
the organel and convert it to superoxide that is released back into the cytosol.  In addition, NOX 
further exacerbates oxidative stress by weakening the antioxidant capacity of the cell, i.e. by 
depleting NADPH that is required in the regeneration of the antioxidant reduced glutathione 
(Johnson et al., 2009).  How does this relate to SSB consumption?  Frequent SSB intake is 
associated with increased body fat e.g. fructose consumption can trigger visceral fat deposition 
(Aeberli et al., 2011).  Here the release of adipokines from adipocytes can dysregulate NOX 
activity (Matsuda & Shimomura, 2013).  Another mechanism by which SSB consumption, or 
fructose consumption in particular, can enhance NOX activity is via uric acid (Johnson et al., 
2009). The notion that fructose intake leads to oxidative stress is supported by animal studies 
although the precise underlying mechanisms remain unclear (Chandramohan & Pari, 2014).   
In the literature one of the primary links between oxidative stress and cardio-metabolic diseases 
is the increase in NOGP activity.  The NOGPs are alternative pathways for glucose metabolism, 
but inappropriate activation of the NOGPs may have detrimental cardio-metabolic 
consequences (reviewed by Poornima et al., 2006).  Oxidative stress induces DNA strand 
breakage (Matsuda & Shimomura, 2013) that activates poly(ADP-ribose) polymerase (PARP). 
The latter is located within the nucleus and plays a central role in DNA repair by inducing the 
accumulation of ADP-ribose polymers.  DNA damage also triggers the translocation of the 
glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) from the cytosol to the 
nucleus to facilitate the DNA repair.  In the nucleus ADP-ribose polymers modify the structure of 
GAPDH thereby inhibiting subsequent glycolytic activity (Du et al., 2003).  The glycolytic 
intermediates upstream of GAPDH accumulate and divert into the NOGPs, which will be 
discussed in the following section (Ceriello & Testa, 2009).   
Although this is the most documented example of how oxidative stress can contribute to cardio-
metabolic complications, there are also other mechanisms that may play a role (refer Figure 
4.1.2).  For example, as discussed in Chapter 3, redox imbalance may induce ER stress and 
subsequent detrimental consequences (Senft & Ronai, 2015).  Oxidative stress can also 
contribute to the development of T2DM in a more direct manner, e.g. by interfering with insulin 
secretion by inhibiting the activity of the insulin gene promoter and insulin mRNA expression 
(Panigrahy, 2016, Tangvarasittichai, 2015).  ROS can also halt insulin signaling, induce 




Figure 4.1.2:  The role of ROS in cardio-metabolic diseases.  ROS may induce 
damage in various organ systems that contribute to the development and perpetuation of 
cardio-metabolic conditions.   
 
pancreatic β-cell apoptosis and suppress the expression of the insulin gene through NF-κB and 
JNK signaling, respectively (Lazo-de-la-Vega-Monroy & Fernández-Mejía, 2013).  In severe 
cases, oxidative stress can also suppress hepatic glucose uptake by decreasing the availability 
of sarcolemmal GLUT2 in hepatocytes thereby causing chronic hyperglycemia.  Oxidative stress 
can induce apoptosis of hepatocytes by upregulating the pro-apoptotic factor Bax, while 









4.1.2       Non-oxidative glucose metabolism 
In section 4.1.1 we explained how ROS can suppress the activity of the glycolytic enzyme 
GAPDH, which may cause upstream glycolytic intermediates to accumulate and divert into 
alternative metabolic pathways – the NOGPs.  Here glucose enters the polyol pathway, while G-
6-P is channeled into the pentose phosphate pathway .  F-6-P is diverted into the hexosamine 
biosynthetic pathway (HBP) where O-linked β-N-acetyl glucosamine moieties (O-GlcNAc) are 
attached to proteins. Lastly, elevated glyceraldehyde-3-phosphate leads to increase protein 
kinase C (PKC) activity and the synthesis of advance glycation end products (AGE) (Figure 
4.1.3).  Besides the role of oxidative stress, we found that SSB consumption reduced the 
expression of the glycolytic enzyme phosphoglycerate mutase 1 (PGM1 in Figure 4.1.3).  
Phosphoglycerate mutase 1 catalyzes the 8th reaction in the glycolytic pathway thus its 
decrease could further increase NOGP activity.  In the light of this, we decided to evaluate the 
activity of the NOGPs in our model.    
Research suggests that all but one of the NOGPs play a central role in the mechanisms 
underlying cardio-metabolic conditions and diabetic complications (reviewed by Poornima et al., 
2006).  Here the pentose phosphate pathway may elicit protective instead of detrimental effects 
although the precise mechanisms are not yet fully understood.  The other four pathways and 
their role in SSB-induced cardio-metabolic disease will now be discussed. 





Figure 4.1.3: Increased NOGP activity. (1) Oxidative damage to DNA leads to the inhibition of 
glycolytic enzyme, GAPDH while (2) ER stress possibly suppresses the expression of PGM1. 
Together this may result in (3): the accumulation of upstream glycolytic metabolites which then 
divert into NOGPs and induce cardio-metabolic complications.  Adapted from Benadè (2014). 









AGEs are formed when glucose and other glycation agents are attached to proteins, lipids and 
nucleotides (Bucala et al., 1995).  This can happen though two possible pathways, both 
promoted by oxidative stress.  The first is marked by the modification of proteins, amine-
containing lipids and nucleic acids by reactive triosphosphates like glyceraldehyde-3-phosphate 
that accumulated under hyperglycemic conditions.  The second, the Maillard pathway, relies on 
the attachment of the carbonyl groups from reducing sugars to the animo acids of targeted 
proteins. This reaction is reversible and the product is known as a Schiff base.  These are then 
processed to form Amadori/Heyns products and ultimately AGEs after further modification 
(Refer Figure 4.1.4) (reviewed by Takeuchi & Makita, 2001). Methylglyoxal derivatives produced 
Figure 4.1.4: AGE formation from glycolytic moieties.  Adapted from Takino (2015). 




form glyceraldehyde-3-phosphate and carboxymethyl-lysine produced form glucose are the 
most well-known and studied AGEs (Gavin, 2001; Vlassara & Uribarri, 2014).     
Hyperglycemia is considered to be a primary endogenous trigger for AGE synthesis.  New 
research, however, suggests that AGEs might also be a cause of hyperglycemia and T2DM and 
not only a result of it.  For example, a clinical trial demonstrated that insulin resistance, 
inflammation and oxidative stress can be reversed by following a low AGE diet (Uribarri et al., 
2011).  This finding was recently confirmed in an obese cohort during a year-long controlled 
trial.  Participants who consumed a diet low in AGEs had significantly improved insulin 
sensitivity, together with lowered oxidative stress and inflammation compared to baseline 
measurements and a control group (Vlassara et al., 2016).  The link between increased AGE 
levels and cardio-metabolic perturbations is well studied both in vitro and in vivo (reviewed by 
Hueschmann et al., 2006; Nowotny, 2015).   
AGEs induce damage by modifying signaling proteins and transcription factors (Brownlee, 
2005).  This is particularly linked to insulin resistance and impaired insulin secretion.  For 
example, Tahara et al. (2012) found that increased serum AGE levels correlate with insulin 
resistance based on HOMA-IR data.  However, the exact molecular mechanism behind this is 
still not clear.  Some possible mechanisms include increased expression of TNF-α that inhibits 
insulin signaling, PKC-mediated pathways, glycation of insulin and increased JNK-mediated 
IRS-1 inhibition (reviewed in Nowotny et al., 2015; Vlassara, 2011).  Insulin secretion is 
diminished by the cytotoxic effect of AGEs on pancreatic β-cells (Lim et al., 2008).  
Methylglyoxal, in particular, is responsible for dysregulated apoptosis as it alters the expression 
of Bcl2, Bax and caspase (Tajes et al., 2014)  
AGEs also accumulate within the extracellular matrix.  This can lead to tissue stiffness that has 
significant effects on cardiovascular health e.g. it can cause stiffening of the heart valves 
(reviewed by Essop, 2016).  Changes in the extracellular matrix also alter signaling between the 
matrix and the cell, leading to cellular dysfunction (reviewed by Brownlee, 2005). Lastly, the 
interaction between AGEs and receptors for AGEs (RAGE) can also be detrimental (Neeper et 
al., 1992).  Under physiological conditions, AGEs normally bind to AGE-receptor1 (AGE-R1) 
that leads to degradation of AGEs.  AGE-peptides can then be excreted through urine, thereby 
protecting the organism against oxidative stress.  However, when there is an excessive amount 
of AGEs present, AGE-R1 receptors become depleted.  Consequently AGEs bind to RAGEs 
instead (Vlassara & Uribarri, 2014).  AGE-RAGE interactions trigger signaling cascades that 




may lead to NF-κB-induced inflammation (Balakumar et al., 2010).  This interaction is also 
associated with downstream generation of ROS.  Although the expression of AGE-R1 and 
RAGEs is usually regulated by AGE and ROS levels, the expression of RAGEs remain relatively 
high in diabetics, while the expression of protective AGE-R1 receptors are suppressed.  This is 
possibly the result of chronic oxidative stress (Vlassara & Uribarri, 2014).    




PKC refer to a cluster of proteins with more than 11 isoforms.  PKC alters cell signaling and 
gene regulation by modifying transcription- and co-factors through the addition of a phosphate 
group, thereby either enhancing or suppressing its activity (Newton, 1995).  PKC isoforms are 
divided into three groups (i.e. conventional, novel and atypical) based on the combination of co-
factors required for activation.  When glyceraldehyde-3-phosphate accumulates it can be used 
to produce diacylglycerol  that serves as a co-factor for the activation of conventional (α, βI, βII 
and γ) and novel PKC isoforms (δ, ε, η and θ) (Shiba et al., 1993) (Figure 4.1.5).    
Dysregulated PKC activity is linked to pathophysiology in a range of organ systems. For 
example, PKCβ activity robustly correlates with cardio-metabolic diseases (Geraldes & King, 
2010).  This isoform is expressed in various organs such as the liver, skeletal muscle and the 
kidney with exceptionally high levels found in adipose tissue and the brain. The expression of 
PKCβ is increased by the consumption of large amounts of fatty foods.  ROS mediates the  
activation of PKCβ independent of the presence of Ca2+ and phospholipids (reviewed by Mehta, 
Figure 4.1.5: PKC activation in response to high glucose availability.  Adapted 
from Joseph, 2014. 




2014). As PKCβ is particularly implicated in the context of a Westernized diet and cardio-
metabolic conditions – it will be the focus of this section.      
Animal models are often used to investigate the link between PKCβ and cardio-metabolic 
conditions e.g. PKCβ knockout mice are lean and characterized by significantly lower levels of 
body fat compared to wild-type mice. Moreover, such mice were also protected against insulin 
resistance and hepatic steatosis despite consuming a high fat diet for 12 weeks (Huang et al., 
2009).  In another animal model it was observed that PKCβ is associated with the inhibition of 
IRS-1 serine residue (Hennige et al., 2010).  Additionally, this study found that PKCβ also 
inhibits the expression of genes involved in lipid metabolism (e.g. PGC-1-α, acyl-CoA oxidase 
and hormone-sensitive lipase) and is linked to intrahepatic lipid deposition (Hennige et al., 
2010).  It can also trigger inflammation via JNK and NF-κB (Butcher & Galkina, 2013), 
aggravate oxidative stress (H2O2 production) and induce mitochondrial damage by triggering the 
opening of mitochondrial permeability transition pore (Pinton et al., 2007). In the heart PKCβ 
(together with PKCδ) modulates various factors involved in cardiovascular health e.g. nitric 
oxide synthase, endothelin-1 and  sarco/endoplasmic reticulum Ca2+-ATPase (reviewed by  
Brownlee, 2005; Giacco & Brownlee, 2010).  Inappropriate regulation of such factors can lead to 
restricted blood flow and impaired relaxation of the cardiac muscle.   A recent in vitro study 
performed in our laboratory also showed that PKCβ elcited an inhibitory effect on myocardial 
insulin-dependent glucose uptake (Joseph et al., 2014).   Moreover, others showed that the 
protective properties of exercise in the context of cardio-metabolic diseases are possibly due to 
the inhibition of PKCβ expression in both murine liver and skeletal muscle (Rao, 2013).  To 
conclude, PKCβ clearly plays a pivotal role in the onset and perpetuation of cardio-metabolic 
diseases and its value as therapeutic target should not be disregarded.  
  




4.1.2.3   HBP  
 
 
The HBP is a nutrient-sensing pathway responsible for the regulation of a range of cellular 
processes (Hanover et al., 2010).  After G-6-P is converted to F-6-P early in glucose 
metabolism, F-6-P then has two possible fates – it can continue in the glycolytic pathway or be 
channel into the HBP (Brownlee, 2001).  In healthy individuals only  2-5% of intracellular 
glucose will enter the HBP where glutamine:fructose-6-phosphate-amidotransferase is the rate-
limiting enzyme that regulates HBP flux (Schleischer & Weigert, 2000).  If F-6-P enters the HBP, 
glutamine acts as amino donor to convert F-6-P to glucosamine-6-phosphate (GlcN-6-P) (refer 
Figure 4.1.6).  GlcN-6-P follows a series of enzymatic reactions to finally produce uridine 5’-
diphospho N-acetyl glucosamine (Kornfeld, 1967).  O-GlcNAcylation takes place when the N-
acetyl glucosamine moiety binds to the hydroxyl group of the threonine or serine residues of 
proteins (this happens in a similar fashion as protein phosphorylation) to form O-GlcNAc 
products.  It is a dynamic process regulated by O-GlcNAc transferase that catalyzes the 
attachment of the O-GlcNAc moiety, and O-GlcNAcase that removes O-GlcNAc residues from 
Figure 4.1.6 Protein O-GlcNAcylation via the HBP.  Adapted from Joseph, 2014. 




the target protein (Torres & Hart, 1984). O-GlcNAcylation plays a major role in a range of 
cellular processes such as transcription and signaling (Lefebvre et al., 2010).   
O-GlcNAcylation regulates various cellular processes by modifying transcription factors and 
RNA polymerase II (reviewed by Hart, 2014).  Under physiological conditions protein O-
GlcNAcylation has beneficial results, however, the level of O-GlcNAcylation change rapidly and 
become maladaptive in response to stress (Lefebvre et al., 2010).  Hyperglycemia is associated 
with an inappropriate increase in HBP flux that leads to pathological changes in the expression 
of various proteins. Transcription factors, signaling molecules and enzymes are targeted in 
particular and many are linked to cardio-metabolic diseases (Vaidyanathan  & Wells, 2014). For 
example, a mouse model revealed that overexpression of O-GlcNAc transferase in the liver is 
associated with insulin resistance and a perturbed lipid profile (Yang et al., 2008).  This is likely 
due to the deactivation through O-GlcNAcylation of various signaling molecules of the insulin 
signaling pathway including Akt1/2, IRS-1/2, the catalytic subunit of PI3K and the β-subunit of 
the insulin receptor.  This may provide some insight into the link between the HBP and hepatic 
insulin resistance (reviewed by Lefebvre et al., 2010; Zhang et al, 2014).  O-GlcNAc 
modification also plays a crucial role in hepatic metabolism as it regulates the expression of 
important gluconeogenesic genes (PEPCK and G-6-Pase) via transcription factor FoxO1 
(Housley et al., 2008).  Here FoxO1 O-GlcNAcylation corresponds with elevated FoxO1 activity, 
perhaps due to enhanced DNA binding capacity or increased co-factor affinity (Kuo et al., 2008).  
Anthonisen et al. (2010) established a link between O-GlcNAc modification and increased 
expression of lipogenic enzymes.  Hepatic energy production is also compromised since O-
GlcNAcylation of mitochondrial proteins alters membrane potential and other mitochondrial 
parameters (Banerjee et al., 2015).   
Besides its effects on hepatic metabolism and insulin sensitivity, O-GlcNAcylation is also 
associated with various other cardio-metabolic perturbations. For example, there is robust 
evidence from animal and cell culture studies that O-GlcNAc modification also induce peripheral 
insulin resistance (skeletal muscle and adipose tissue) (reviewed by Vaidyanathan  & Wells, 
2014).  Moreover, insulin synthesis and secretion are also altered by the O-GlcNAcylation of two 
pancreatic transcription factors: pancreas homeobox protein 1 and neurogenic differentiation 
factor 1 (Andrali et al., 2007; Gao et al., 2003). In the cardiovascular system O-GlcNAcylation is 
associated with vascular occlusions and cardiomyocyte dysfunction (reviewed by Giacco & 
Brownlee, 2010).  Greater O-GlcNAcylation is also linked to low grade inflammation through 
upregulation of the NFκB pathway, although it can exert anti-inflammatory properties in specific 




contexts (Baudoin & Issad, 2015).  Together, there is a growing collection of literature 
associating O-GlcNAc modification to the pathological patterns in gene expression observed in 
T2DM and other cardio-metabolic diseases.  However, more research is necessary to fully 
understand the effects of O-GlcNAcylation on energy homeostasis and health in general. 




The polyol pathway refers to the endogenous conversion of glucose to fructose in a two-step 
process (depicted in Figure 4.1.7). The first rate-limiting step in this pathway is catalyzed by 
aldose reductase (AR) and yields sorbitol that is in turn converted to fructose by sorbitol 
dehydrogenase (Giacco & Brownlee, 2010).  The polyol pathway plays an important role in 
reducing toxic aldehydes in the cell to inactive alcohols.  Under physiological conditions only 
 3% of glucose enters this pathway, but under hyperglycemic conditions this can increase to    
> 30%.  Such a high flux has detrimental consequences (reviewed by Tang et al., 2012).   
Early studies show that a polyol flux exacerbates oxidative stress via three possible 
mechanisms.  Firstly, AR requires NADPH as a cofactor to convert excess glucose to sorbitol.  
This leads to the depletion of intracellular NADPH and subsequently decrease the ability of the 
cell to regenerate an important antioxidant, i.e. reduced glutathione (Cheng & Gonzalez, 1986). 
The polyol pathway is also associated with increased  ROS production. When sorbitol 
dehydrogenase converts sorbitol into fructose, NAD+ is concomitantly converted to NADH that 
Figure 4.1.7:  Two-phased polyol pathway.  Adapted from Joseph, 2014. 




serves as a co-factor for NOX.  This allows increased NOX activity and therefore ROS 
production (Morre et al., 2000).  Lastly, fructose can be converted to the powerful glycating 
agents fructose-3-phosphate and 3-deoxyglucosone, thereby increasing the synthesis of AGEs 
that worsens oxidative stress (Hamada et al.,1996).   
More recently preclinical studies established an association between elevated polyol flux and 
cardio-metabolic diseases.  For example, Lanaspa et al. (2013) observed that intrahepatic 
fructose production (via the polyol pathway) leads to the development of MetS and intrahepatic 
lipid deposition. Increased activity of the polyol pathway is also evident in a diabetic mouse 
model (MRK mice) (Gallagher et al., 2016) where such mice displayed a 2.5  increase in 
sorbitol levels in skeletal muscle together with a 1.7  decrease in reduced glutathione 
compared to wild-type mice.  Increased polyol pathway activity is also robustly linked to diabetic 
complications (reviewed by Grewal et al., 2016).  Another study found that genetically modified 
mice overexpressing human AR experienced cardiac dysfunction when aged (Son, 2012).  They 
further showed that the overexpression of AR leads to worse outcomes after ischemia and 
reperfusion.  Here they measured infarct area, percentage fractional shortening and the 
expression of acyl-CoA oxidase, pyruvate dehydrogenase kinase 4 and PPAR-α mRNA (genes 
involved in glucose and FA oxidation).  Others found that AR expression influenced caspase-
dependent apoptosis (Zhang et al., 2014).  Moreover, excess sorbitol that is not converted to 
fructose can lead to osmotic stress and subsequent cell damage since cell membranes are 
impermeable to sorbitol (Behl et al., 2016).  Together these data show that the polyol pathway 
(particularly AR activity) is an important factor in the onset of cardio-metabolism diseasesand 
that the clinical usage of AR inhibitors may offer therapeutic potential in this regard. 
4.1.3 Meta-inflammation 
Meta-inflammation (MI) refers to a low-grade inflammatory response that is triggered by 
metabolic damage associated molecular patterns and is implicated in the development of 
cardio-metabolic diseases (refer Figure 4.1.8) (Kitamura et al., 2013).  MI is different from 
classic inflammation in various ways, e.g. the latter is generally an acute, local response while 
MI is systemic and chronic.  MI leads to the infiltration of macrophages and cytotoxic T-
lymphocytes into insulin-dependent tissues specifically, but does not cause structural and 
functional damage to the infiltrated tissue as with the classic response. Another hallmark of MI is 
a high level of circulating pro-inflammatory cytokines like TNF-α, ROS and IL-6 (reviewed by 
León-Pedroza, 2015).  The ER overload response (discussed in section 3.4) might be a 




possible cause or consequence of MI as similar signaling pathways are involved.  In the light of 
that, this section will provide a brief overview of MI.  
Early experimental work indicated an association between metabolic conditions and 
inflammation.  For example, the pro-inflammatory cytokine TNF-α is overexpressed  in an obese 
rodent model as well as in an obese clinical cohort (Hotamisligil, 2006).  A possible explanation 
may be that systemic MI sprouts from inflammation triggered in visceral adipose tissue (Murano 
et al., 2008).  As visceral fat increases due to unhealthy dietary choices, some adipocytes may 
become more distally located from the nearest blood vessel as a result of adipose hypertrophy 
and hyperplasia.  This can lead to a hypoxic state that will result in adipocyte necrosis if 
prolonged.  An inflammatory response is initiated as phagocytes infiltrate such tissues in order 
to remove necrotic cells.  Immune cells infiltrating such tissues are also a source of pro-
inflammatory cytokines - thus there is a continuous signal for further tissue infiltration.  
Moreover, adipocyte hypertrophy and hyperplasia are associated with ROS generation that can, 
in turn, lead to an elevation in TNF-α and leptin levels (Murano et al., 2008).   
Perturbations in metabolic homeostasis e.g. hyperglycemia can induce a chronic low-grade 
inflammatory response by releasing metabolic damage associated molecular patterns that bind 
to toll-like receptors on  membranes of immune cells (Lemaitre, 2008).  For example, AGEs can 
bind to the toll-like receptor 4 on macrophages to initiate a pro-inflammatory signaling cascade. 
Here the translocation of NF-κB to the nucleus is central to this response as it promotes the 
transcription of pro-inflammatory factors.  Such immune cells ultimately migrate to insulin-
dependent tissues, thereby spreading the inflammatory state (reviewed by León-Pedroza, 
2015).  Besides AGEs, other NOGPs like PKC and the HBP can also play a role in MI onset and 
perpetuation (Baudoin & Issad, 2015; Butcher & Galkina, 2013) 
MI contributes to the onset and progression of T2DM through several mechanisms. TNF-α 
interferes with the insulin signaling pathway by inhibiting the activity of IRS, Akt or GLUT2/4 via 
various intracellular pathways such as JNK and NF-κB (refer to the ER overload response in 
section 3.4) to cause insulin resistance (Hotamisligil et al., 1993; Uysal et al., 1997).  Obese 
mice that lack TNF-α (whole body knock-out) are protected from developing insulin resistance 
(Uysal et al., 1997).  MI also plays a role in β-cell injury as T2DM worsens.  Here the islets of 
Langerhans become inflamed  thus inducing insulitis – a condition that can cause an excessive 
release of pro-inflammatory factors such as TNF-α, IL-6, IL-8 and macrophage chemo-attractive 




Figure 4.1.8:  The onset and perpetuation of meta-inflammation and its role in 




protein.  Besides T2DM, MI is also associated with hypertension and atherosclerosis (reviewed 
by León-Pedroza, 2015, Schwartz & Reaven, 2006).    
 
4.2 Materials and Methods  
4.2.1 Oxidative stress analyses  
Oxidative stress is one of the possible causes of ER stress (refer to section 3.4).  We 
investigated various markers of oxidative stress in the hope to corroborate that oxidative stress 
is the underlying mechanism driving ER stress in this model as it seem the most probable in the 
context of SSB consumption.  All oxidative stress analyses were performed in collaboration with 




Dr. Dirk Bester at the Oxidative Stress Research Unit, Cape Peninsula University of 
Technology. 
4.2.1.1  Glutathione redox analysis  
This protocol was adapted from Asensi et al. (1999).  In brief a tissue homogenizer 
(ProScientific Pro200 homogenizer, Oxford, CT) was used to homogenize liver samples ( 200 
μg) on ice in 2mL Buffer A (50 mM NaPO4, 1 mM EDTA, pH 7.5).  For GSSG analysis an 
additional 10 μL 1-methyl-2-vinyl-pyridinium trifluoromethane sulfonate (30 mM in 0.1 M 
hydrochloric acid) was added to every 1 mL Buffer A.  Thus reduced (GSH) and oxidized 
(GSSG) samples were prepared separately.  Samples were centrifuged (Boeco M240, Boeco, 
Hamburg, Germany) at 15, 000   g for 5 min and the supernatants were diluted (10–40 ) and 
used for analysis.  A standard curve was prepared using GSH (3 μM) and GSSG (1.5 μM)] 
stock solutions and Buffer A.  All other reagents were also made up in Buffer A.  50 μL of each 
standard and sample (each in triplicate) were added to the microtiter plate.  Next, a multi-pipette 
(Multichannel Research, Eppendorf, Hamburg, Germany) was used to add 50 μL 0.3 mM 
5,5’Dithiobis-(2-nitrobenzoic acid) to each well followed by 50 μL glutathione reductases 
(0.02U/μL).  The plate was incubated for 5 min at room temperature after which 50 μL NADPH 
(1mM) was added to each well.  The absorbance was measured directly afterwards using a 
Multiskan spectrum platereader (Thermo Electron corporation, Waltham, MA)  that was 
programmed to obtain a reading every 30 sec for a total period of 5 min.   
For systemic glutathione redox analysis, EDTA whole blood (BD, Franklin Lakes, New Jersey).  
was used. Here 5% metaphosphoric acid was added to the samples in a 1:4 ratio whereafter 
samples were vortexed for 20 sec (DragonLab Mx-S, Dragon Laboratory Instruments, Beijing, 
China) and centrifuged at 10, 000   g for 10 min. The supernatant was further diluted with 
Buffer A and 50 μL was loaded as the sample in the microtiter plate. 
4.2.1.2   Oxygen radical absorbance capacity (ORAC) 
Liver samples were homogenized in Buffer A as described above.  Thereafter it was centrifuged 
at 12, 000   g for 10 min (Boeco M240, Boeco, Hamburg, Germany).  The supernatant was 
collected and deproteinized by centrifuging 50 μL of 0.25 M perchloric acid (PCA) and 50 μL 
supernatant together at 14, 000   g for 15 min.  The resultant supernatants were diluted (2-4 ) 
and 12 μL were added to a black 96-well plate. Of note, all samples should be loaded in 
triplicate and the first two and last columns of the plate should not be used.  A trolox stock 




solution (500 μM) is used for a standard series with final concentrations 0, 83, 167, 250, 333 
and 417 μM.  12 μL of the standard series was added to the appropriate wells.  Next, 138 μL of 
fluorescein (working solution) was added to each well using a multi-pipette (Multichannel 
Research, Eppendorf, Hamburg, Germany).  The last step was to add 50 μL (25 mg/mL) 2,2’-
Azobis (2-methylpropionamidine) dihydrchloride to each well after which the plate was read on a 
Fluoroskan ascentfluorometer (Thermo Electron Corporation, Waltham, MA) - readings were 
taken every min for 2 hr.   
Blood samples was collected in EDTA vacutainers (Guangzhou Improve Medical Instruments, 
Guangzhou, China) and centrifuged (Spectrafuge™ 16M, Labnet, Edison NJ) at 1, 300   g for 
30 min to collect the plasma.  The plasma (50 μL) was subsequently treated with 50 μL 0.5 M 
PCA, thereafter the same steps as in the case of tissues were followed.  This protocol was 
adapted from Prior et al., (2003) and Cao & Prior (1998). 
4.2.1.3    Thiobarbituric acid reactive substances (TBARS) 
Liver samples were homogenized in Buffer A as in previous experiments.  The supernatant (50 
μL) was vortexed (DragonLab Mx-S, Dragon Laboratory Instruments, Beijing, China) together 
with 6.25 μL butylated hydroxytoluene (4mM in ethanol) and 50 μL ortho-phosporic acid (0.2M).  
TBA reagent (6.25 μL; 0.11M in 0.1M NaOH) was added and the samples were vortexed again 
for 10 sec.   The samples were placed in a heating bath for 45 minutes at 90°C followed by 2 
min on ice and 5 min at room temperature.  N-Butanol (500 μL) and saturated NaCl (50 μL) 
were added to each sample before another 10 sec bout of vortex.  Samples were centrifuged 
(Boeco M240, Boeco, Hamburg, Germany) at 13, 700   g for 2 min and 300 μL of the top phase 
were added to the wells.  The plate was read at A532-A572. Systemic TBARS were measured 
by using 50 μL plasma instead of 50 μL homogenate supernatant. 
4.2.1.4  Conjugated dienes (CDs) 
Liver samples ( 100 μg) were homogenized in 2 mL methanol and 1 mL chloroform was added 
to the lysates.  Lysates were vortexed briefly (DragonLab Mx-S, Dragon Laboratory Instruments, 
Beijing, China) before it was centrifuged (Eppendorf 5810R, Eppendorf, Hamburg, Germany) at 
3, 000   g for 1 min to allow for separation.   Of note, for samples that did not separate 100 μL 
saturated NaCl was added and the samples were re-centrifuged.  The bottom layer of the 
samples were pipetted into fresh microtubes and left open overnight at 4°C to dry out.  On the 
second day 700 μL cyclohexane was added to each of the microtubes which were then 




vortexed.  Subsequently, 200 μL of sample was added to a 96-well plate that was read in a 
plate reader (Multiskan spectrum, Thermo Electron corporation, Waltham, MA) .  Cyclohexane 
was used as a blank and all samples were assayed in triplicate.   
Plasma assays were done in a similar fashion; however here the initial phase of sample 
preparation entailed 100 μL plasma in 405 μL methanol and chloroform in a 2:1 ratio.  
4.2.2 NOGP analyses 
4.2.2.1  AGE 
To determine the level of AGEs in the liver samples the OxiSelectTM AGE Competitive ELISA kit 
(Cell Biolabs, San Diego CA) was used and executed according to the protocol provided.  The 
kit determines the quantity of the AGE proteins in the samples by comparing it to an AGE-
bovine serum albumin (BSA) standard curve.  A 96-well plate was incubated overnight at 4°C 
with an AGE conjugate coating.  On the second day the plate was blocked for an hour at room 
temperature before 50 μL the sample/standard are added to the wells.  Each sample/standard 
was assayed in duplicate.  The samples were incubated in the wells for 10 min on a belly 
dancer (Stovall Life Science, Greensboro, NC) and then anti-AGE antibody was added to each 
well.  After incubation (1 hr at room temperature), the contents of the wells were removed and 
100 μL diluted secondary antibody-HRP was added to each well.  Of note, the wells were 
washed with a wash buffer between steps.  After a final incubation step, the substrate solution 
was added and time was allowed for color development before ( 10 min) the reaction was 
terminated with the stop solution.  A microplate reader (El 800 KC Junior Universal Microplate 
reader, Bio-Tek Instruments, Winooski VT) was used to read the absorbance at 450 nm.  
4.2.2.2   PKCβII and O-GlcNAc 
PKCβII and O-GlcNAc expression were determined using standard Western blotting techniques 
as described before (Joseph et al., 2014; Mapanga et al., 2012).  Here the first step was protein 
extraction, i.e. liver samples ( 100 μg) were placed in 2 mL microtubes with 1 mL radio immune 
precipitation buffer (RIPA buffer) and homogenized (Polytron PT2100, Kinematica, Luzern, 
Switserland) in 15 sec bouts until all of the tissue was disrupted.  RIPA buffer contained 
protease inhibitors (pepstatin [10 µg/ml], leupeptin [1 µg/ml], apoprotein [1 µg/ml] and 
phenylmethylsulfonyl fluoride [1 mM]), phosphatase inhibitors (activated Na3VO4 [1 mM], NaF 
[1mM]) and a trypsin inhibitor (benzamidine [1 µg/ml]).  The O-GlcNAc extractions also 




contained Pugnac (1 µM) to prevent the removal of O-GlcNAc modifications.  The samples were 
kept on ice throughout the entire procedure. The homogenates were centrifuged (Spectrafuge™ 
16M, Labnet, Edison NJ) at 14, 000   g for 10 min (4°C) and the supernatants (lysate) were 
collected and stored at -80°C.   
Next the protein concentration was determined using the Direct Detect® Infrared Spectrometer 
(Merck KGaA, Darmstadt, Germany) with RIPA buffer as a blank. Here 2 μL lysate is added to 
the wells on cards (provided) that slot into the machine.  After a drying cycle the amide bonds in 
protein chains are measured to determine protein concentration.  Samples were prepared by 
diluting the determined amount of lysate in RIPA and Laemmli sample buffers.  Thereafter the 
samples were boiled for 5 min at 95°C and vortexed briefly (Scientific industries, Bohemia NY).  
Finally the samples were centrifuged at 14, 000   g for 10 sec (Spectrafuge™ 24D, Labnet, 
Edison NJ) and stored at -20oC for future use. 
The samples were separated by gel electrophoresis at 100 V ( 90 min).  Here polyacrylamide 
gels were cast in accordance with the protocol recommended by the Tris-glycine extended 
Stain-Free™ FastCast™ Acrylamide Kit, 10% #161-0183 (BIO-RAD, Hercules CA). The 
Transfer Blot (Trans-Blot® Turbo™, transfer system, BIO-RAD, Hercules CA) was used to 
transfer gels unto polyvinylidine fluoride membranes (BIO-RRAD pre-defined 7 min, mixed 
molecular weight protocol).  Membranes were soaked in methanol for 30 sec and left to dry 
completely.  For O-GlcNAc membranes were blocked in 5% BSA prepared in Tris-buffered 
saline and Tween 20 (TBS-T) for 20 min and then incubated overnight in primary O-GlcNAc 
antibody (CTD110.6, Santa Cruz Biotechnology, Santa Cruz CA) diluted in TBS-T (1:500) at 
4°C.  On the second day, it was incubated for an hour in secondary anti-mouse HRP-linked 
antibody (Cell Signaling Technology®, Danvers MA) (also diluted in TBS-T [1:2000]) at room 
temperature.  For PKCβII, membranes were blocked for an hour in 5% fat free milk and probed 
with a primary PKCβII antibody (Abcam, Cambridge  MA) prepared in 5% BSA (1:1000) 
followed by incubation in secondary HRP-conjugated anti-rabbit antibody (Cell Signaling 
Technology®, Danvers MA) (1:4000 in TBS-T). After every step, the membranes were washed 
for 3   5 minutes in TBS-T.  Finally, 600 μL ECL (BIO-RAD, Hercules CA) was squirted over the 
membrane to allow imaging of protein bands.   All Western blots were imaged with Image Lab™ 
Software version 4.0 (BIO-RAD, Hercules CA) and total protein was used for normalization. 




4.2.2.3   Polyol Pathway  
D-sorbitol is an intermediate of the polyol pathway and can be used as a marker for activation of 
this pathway; hence a colorimetric D-sorbitol assay kit (Abcam, Global Biotech Company, San 
Francisco CA) was used.  Here a sorbitol standard was serially diluted to generate a standard 
curve.  The standard and the samples (50 μL) - prepared in accordance with the kit’s instruction 
manual - were then added (in duplicate) to a 96-well plate.  A reaction mixture containing assay 
buffer, enzyme mix, developer and a probe was prepared and 50 μL was added to each well. 
After an incubation period of 60 min at 37°C the absorbance was measured at 560 nm on a 
microplate reader (El 800 KC Junior Universal Microplate reader, Bio-Tek Instruments, Winooski 
VT).   
4.2.3 Inflammation and stress signaling 
TNF-α and IκB were selected as markers for inflammation and stress signaling as it would 
indicate whether the ER overload response has been initiated in this model.  Western blotting 
techniques as described in the previous sections were used to measure the expression of both 
markers.  Both sets of membranes were blocked in 5% BSA before overnight incubation with 
the respective primary antibody. The specific antibodies used were anti-TNF-α (Abcam, 
Cambridge MA) and IκB-α antibody (Cell Signaling Technology®, Danvers MA) diluted 1:1000 
in TBS-T, both paired with secondary HRP-conjugated anti-rabbit antibody (Cell Signaling 
Technology®, Danvers MA) (1:4000 in TBS-T).  For a detailed protocol refer to Appendix C. 
4.2.4 Histology  
Based on the proteomic data we were interested to see whether SSB consumption led to the 
deposition of lipid droplets in the liver.  Unfortunately, we could not use standard staining 
techniques for lipid detection such as Oill-Red-O or SudanIV due to the lack of frozen tissues.  
Instead we hoped to identify lipid droplets on Hematoxylin and Eosin (H & E) stained sections 
based on morphological characteristics. These data will be combined with previously collected 
data to gain a better understanding of SSB induced perturbations in lipid metabolism.  An H & E  
stain lso allows the detection of other structural changes.  ER stress has also been linked to 
tissue fibrosis (Lenna & Trojanowska, 2012; Tanjore et al., 2013).  In the light of this a Masson’s 
Trichrome stain was performed.  




All histological staining techniques were performed by Mr. Reggie Williams (Technical 
Supervisor, Department of Anatomical Pathology, Faculty of Medicine and Health Sciences, 
Stellenbosch University) The liver samples were fixed in formalin and embedded (Leica EG1160 
embedding center, Wetzlar, Germany) in paraffin before transverse sectioning (Leica RM2125 
RTS microtome, Wetzlar, Germany).  The tissue slides were stained with H & E and Masson’s 
Trichrome stains (refer below) to allow for qualitative evaluation of hepatic histology.  A Nikon 
microscope (Nikon Eclipes E400, Tokyo Japan) was used at 10  and 40  magnification to 
examine the slides and images were created with NIS Elements (Imaging software version 4.10, 
Tokyo Japan).  
4.2.4.1 H & E 
Slides were de-paraffinized (two changes of xylene, 5 min each) and hydrated (two changes of 
100% alcohol, 5 min each).  Thereafter the slides were placed in 95% alcohol (2 min) and 70% 
alcohol (2 min) before being briefly rinsed in distilled water (dH2O).  Slides were stained in 
Mayer hematoxylin (Science World, Vancouver, BC) solution (8 min) and washed in warm tap 
water for 10 min.  Next the slides were rinsed in dH2O and 95% alcohol, 10 dips each.  Eosin-
phloxine B solution (Science World, Vancouver, BC) was used to counterstain the slides for 30 
sec before dehydration steps were followed (95% and two changes of 100 % alcohol, 5 min 
each).  Slides were cleared in two changes of xylene (5 min each) and mounted with a xylene-
based mounting medium (Science World, Vancouver, BC) (Avwioro, 2011).   
4.2.4.2 Masson’s Trichome 
Slides were de-paraffinized and hydrated with dH2O (as described above) before rinsed (in 
dH2O) and stained with hematoxylin for 5 min.  Running tap water was used to wash the slides 
until it turned dark blue ( 3 min) whereafter it was rinsed in dH2O. Slides were stained in filtered 
with Fuschsin Ponceau Orange G stock solution (Sigma-Aldrich, St. Louis, MO) for  15 min and 
rinsed with acetic acid water. This was followed by a 5 min mordant step in 5% phosphotungstic 
acid before staining in light green solution (Kimix Chemicals, Cape Town, South Africa) for  20 
min. Slides were placed in acetic acid water for 5 min.  Finally slides were dehydrated with 
alcohol, cleared in xylene and mounted in DPX mountant (Science World, Vancouver, BC).    




4.2.5 Statistical analysis 
Statistica 13.0 (StatSoft Inc., Dell Software, Tulsa, OK) was used for statistical analyses.  The 
differences between the experimental groups of normally distributed data were evaluated with 
one-way ANOVAs and non-parametric data was tested with Kruskal-Wallis ANOVA and median 
tests. A p-value < 0.05 was considered to be significant. Outliers and extremes were detected 
using box plots with an outlier coefficient of 2.2 and Levene’s tests were used to test for 
homogeneity of variances. All the data are presented on Graphpad Prism 5.01 (Graphpad 
Software Inc., San Diego CA) as mean ± SD.  
 
4.3 Results  
4.3.1 Oxidative stress 
ROS production (especially mitochondrial-derived) can be induced by energy-imbalance and 
hyperglycemia.  The rise in ROS levels can lead to oxidative stress and subsequent molecular 
damage.  A combination of assays that measured antioxidant defense systems and markers for 
ROS-induced damage were used to determine both systemic and hepatic oxidative states.   
4.3.1.1  Glutathione redox analysis  
Reduced glutathione is an important scavenger of ROS molecules and its ratio to oxidized 
glutathione is an indicator of the oxidative state of the sample.  A decrease in this ratio would be 
a sign of increased oxidative stress.   
No significant changes were found in liver samples at three months (Figure 4.3.1).  However, at 
six months the SSB group exhibited an increase compared to the Control group (P < 0.05).  
This increase is also found in relation to the Cal-control group, although it is not statistically 
significant.  No significant changes were detected for plasma samples between any of the 
groups at three or six months.   








Figure 4.3.1: Oxidative state evaluated by reduced to oxidized glutathione in liver (A) and 
plasma (B) samples.  N ≥ 5 for all groups (liver and plasma).  Data are displayed as mean ± 
SD and significance is shown as * P < 0.05. 




4.3.1.2   ORAC 
This experiment measured the capacity of the tissue or system (blood samples) to absorb ROS 
as a defense mechanism against ROS-induced tissue damage.  This is achieved by determining 
the rate of oxidative breakdown of fluorescein (fluorescent molecule).  The SSB treatment did 
not alter the absorbance capacity of the SSB group compared to any of the controls in the liver 






Figure 4.3.2: Tissue-specific (A) and systemic (B) ORAC.  N ≥ 5 for all groups.  Data are 
displayed as mean ± SD and significance is shown as * P < 0.05. 
A 
B 




4.3.1.3    TBARS 
Malondialdehyde (MDA), a product of lipid peroxidation, was measured by using a TBARS 
assay.  SSB consumption did not induce any significant changes in MDA levels in the liver 
samples at three or six months (Figure 4.3.3).  However, plasma samples showed a different 
trend:after three months MDA levels in both the SSB and Control group were increased 
compared to the Cal-control group (P < 0.05 and P < 0.005, respectively) but by six months this 
change was no longer detected.  MDA is only a good marker if a substantial amount of lipid 
peroxidation has occurred.  For this reason we also measured CD levels that will allow the 
detection of early phases of lipid peroxidation.  
  
Figure 4.3.3: MDA levels as an indicator of lipid peroxidation.  N ≥ 5 for all groups. Data 
are displayed as mean ± SD and significance is shown as * P < 0.05, **P < 0.005. 
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B 




4.3.1.4  CDs 
CDs serve as an early marker for lipid peroxidation.  No changes were detected in the liver or 
blood samples at either of the time points, indicating that there was no ROS-induced lipid 




Figure 4.3.4: Early lipid peroxidation evaluated by changes in CD levels.  CD levels were 
measured in (A) the liver and (B) the plasma.  N ≥ 5 for all the groups. Data are displayed as 
mean ± SD.  
A 
B 




4.3.2 NOGP analyses 
Based on the proteomic analysis and established literature we suspected that moderate SSB 
intake may suppress glycolysis.  This would cause glycolytic intermediates to shunt into the 
NOPGs that are linked to insulin resistance, exacerbated oxidative stress, inflammation and 
diabetic complications. NOGPs are the umbrella term that generally refers to the polyol 
pathway, the HBP, PKC activation and AGE formation.  We expected to observe a significant 
increase in these pathways.   
4.3.2.1  AGE 
A commercial enzyme-linked immunosorbent assay kit was used to detect and measure AGE 
protein adducts in order to determine the effect of SSB consumption on AGE formation.  Here 
an increase was observed in the SSB group compared to the Cal-control (P < 0.05) at three 
months (but not the Control group) and no changes were seen at the six-month time point 




Figure 4.3.5: Quantification of AGE in liver samples.  N ≥ 5 for all groups. Data are 
displayed as mean ± SD and significance is shown as * P < 0.05. 




4.3.2.2   PKCβII and O-GlcNAc 
Western blotting techniques were used to evaluate the relative protein expression of PKCβII, an 
isoform implicated in cardio-metabolic perturbations (Figure 4.3.6 A on the following page).  At 
three months there were no significant differences between the SSB group and either of the 
control groups.  At six months there was an increase in hepatic PKCβII expression in the SSB 
group compared to the Cal-control group (P < 0.005), but not the Control group.  The degree of 
O-GlcNAcylated proteins was also determined as it is indicative of HPB activity.  However, no 
significant differences were observed between any of the groups after three or six months 
(Figure 4.3.6 B).  
4.3.2.3  Polyol pathway 
 D-sorbitol levels are indicative of polyol pathway activity and were therefore assessed by using 
a commercially-available kit.  The results did not show any significant changes between the 





Figure 4.3.7: Measurement of D-sorbitol as a marker for polyol pathway activation. N ≥ 5 
for all groups. Data are displayed as mean ± SD.  







4.3.2.3   Polyol Pathway  
4.3.3 Inflammation 
Western blotting techniques were used to evaluate the levels of hepatic TNF-α and IκB following 
SSB consumption.  No changes were observed in TNF-α expression for any of the groups at 
three or six months.  However, this was not the case for the IκB results.  Although SSB 
Figure 4.3.6: Evaluation of hepatic PKC expression (A) and O-GlcNAcylated proteins (B) 
N ≥ 5 for all groups. Total protein was used to normalize the data.  Data are displayed as mean 
± SD and significance is shown as **P < 0.005. 
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treatment did not trigger any significant changes, it is noteworthy that IκB levels in Cal-control 
samples (three and six months) are almost completely degraded compared to the Control (P < 
0.005) and SSB (P<  0.05) groups, respectively (Figure 4.3.8) 
 
 
 Figure 4.3.8: Assessment of inflammatory markers in livers of SSB-consuming rats.  A – 
TNF-α with n ≥ 5 for all the groups; B - IκB where an n = 6 was employed for all groups. Total 
protein was used to normalize the data. Data are displayed as mean ± SD and significance is 
shown as * P < 0.05; **P < 0.005. 
39 kDa 39 kDa 
17 kDa 17 kDa 
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4.3.4   Histology 
4.3.4.1 H & E  
H & E is considered the ‘’gold standard’’ histological stain to detect pathology.  All basophilic 
structures in the cell such as cytoplasmic proteins stain pink with eosin, while acidic structures  
stain blue with hematoxylin.  These include structures like the nuclei and ribosomes that contain 
large amounts of nucleic acids.  In the figures (4.3.9 and 4.3.10) hepatic acini were identified by 
the presence of the portal tract (the cluster of the hepatic portal vein, hepatic artery and bile 
duct).  The hepatocytes closest to the portal tract (zone 1) receives the most oxygenated blood 
and is the first to be exposed to the metabolites and absorbed from the gastrointestinal system 
into the portal track. These cells are thus primarily responsible for oxidative metabolic processes 
like oxidative phosphorylation and fatty acid β-oxidation.  A low magnification (10 ) was used to 
detect overall architectural changes in the liver although no significant changes were observed 
at any time point.  We used a higher magnification (40 ) to examine hepatocyte ultrastructure.  
Although some exhibited larger nuclei and other cells were binucleated, this reflects normal 
features of hepatocytes. The slightly granulated appearance of the cytoplasm is due to the 
presence of ribosomes (free and in the rough ER). Upon higher magnification the SSB and Cal-
control hepatocytes (6 months) displayed intracellular unstained areas.  This could possibly be 
washed out glycogen stores; however, the regular shape suggests that it is more likely 
accumulating lipid droplets.  This was not observed in the Control group and thus likely 
represents a caloric-induced effect (analyses were guided by a Histology expert [Dr. C. Chase] 
and .Wheater’s Functional Histology, 2006).     
4.3.4.2 Masson’s trichrome  
A Masson’s trichrome stain is used to detect connective tissue and collagen.  Here the collagen 
stains green, the nuclei black, the cytoplasm red and erythrocytes yellow to orange.  The portal 
tract is surrounded by a framework of connective tissue.  For our samples we did not detect 
abnormal amounts of collagen in any of the groups at three or six months (Figure 4.3.11 and 
4.3.12).  Although our model did not manifest any hepatic fibrosis it is arguable that the time 
period of the model was too short and that the SSB treatment could still cause fibrosis in the 
long-term. 
 






























Figure 4.3.9: H&E stain of three-month liver samples.  The hepatic portal tract is visible in 
each of the 10x magnification images.  A - terminal portal venule, B – bile duct, C – hepatic 







































Figure 4.3.10: H&E stain of six-month liver samples.  Arrows point to unstained areas in 
hepatocytes – putative lipid droplets. N = 3 per treatment group. 





























Figure 4.3.11: Masson’s trichrome stain of three-month liver samples.  The collagenous 
network surrounding the portal tract is clearly visible.  No inappropriate fibrosis is observed in 
any of the samples.  N = 3 for all groups.   






























Figure 4.3.12: Masson’s trichrome stain of six-month liver samples.  At six months there is 
still no signs of liver fibrosis in any of the groups (n = 3).  




4.4 Discussion  
We evaluated systemic and hepatic oxidative stress markers to determine whether it could be 
one of the underlying causes of ER stress in our model.  Here four different tests were 
considered and on the whole SSB intake did not increase either systemic or hepatic oxidative 
stress.  Lozano et al. (2016) found similar results after rats consumed 25% fructose water for 
eight months.  In this instance in situ ROS production was detected with fluorescent 
dihydroethidine dye in liver sections, while lipid peroxidation was measured with a TBARS kit in 
tissue homogenates while systemic oxidative stress was determined using a total antioxidant 
capacity and TBARS assays.  However, some interesting trends emerged when considering the 
experiments separately.  ORAC measurements are indicative of the capacity of the antioxidants 
to protect the cell against ROS molecules.   At three months the hepatic ORAC reading for both 
the Cal-control and SSB groups are decreased (although only Cal-control versus control in 
significant) (refer Figure 4.3.2).  This suggests that excessive calorie intake, regardless of 
source, can weaken the antioxidant defense system.  At six months the decline in antioxidant 
capacity has been remedied, possibly by the increased hepatic GSH/GSSG ratio in the Cal-
control and SSB group (SSB versus control significant) (Figure 4.3.1).  It is important to keep in 
mind that the ORAC assay is very specific for ROS molecules and does not detect reactive 
nitrogen specifies. It is therefore possible that these data do not necessarily reflect the complete 
redox state. Yet, it is reassuring that a similar biphasic pattern was observed in the analysis of 
kidney samples isolated at the same time points from the same experimental model (Marinus et 
al., 2016).  Here our laboratory showed that the SSB group exhibited a reduced antioxidant 
capacity at three months, but that this was rectified and enhanced by six months, signifying a 
compensatory effect. However, the overall consequences of oxidative stress were more severe 
in the kidney and manifested in lipid peroxidation.  Another finding worth noting is that the Cal-
control group displayed significantly decreased plasma MDA levels at three months compared 
to the other groups (Figure 4.3.3).  This is an unexpected finding since previous work  linked a 
high fat diet to increased lipid oxidation (Lozano et al., 2016).  We are unclear regarding the 
significance of our finding and further studies are required to confirm whether this is indeed the 
case. Based on these data there are no convincing evidence that oxidative stress underlies 
SSB-induced ER stress.  We recommend that future studies investigate cellular and ER calcium 
handling as putative targets of dysregulation and speculate that it may be a probable cause of 
SSB-induced ER stress.   




Next we investigated the NOGPs.  Elevated NOGP activity is not only strongly linked to cardio-
metabolic complications, but could indicate that moderate SSB consumption suppressed the 
glycolytic pathway.  We hypothesized that enhanced sugar consumption would induce a 
collective increase in hepatic NOGP activity, but we observed varying results.  PKCβII 
expression is markedly increased at three and six months (yet not statistically) in the SSB group 
compared to the other groups (Figure 4.3.6).  In support, we also observed elevated PKCβII 
expression in heart tissues of our model (Driescher, 2014).  PKCβII is a downstream target of 
mitochondrial ROS and NOX-signaling (Joseph, 2014) and although we could not measure 
mitochondrial ROS, preliminary data show that SSB consumption could increase NOX activity in 
the liver (six months) (Benadè, 2014) and kidney (Marinus et al., 2016).  Another study 
conducted on cardiomyocytes of diabetic animals argue that PKC is indeed the key modulator of 
hyperglycemia-induced perturbations (Davidoff, 2004), thus possibly explaining why we 
observed the most conclusive effect in PKCβII expression.   
The SSB group also displayed a slight increase in hepatic AGE levels at three months, but this 
tapered down by six months (Figure 4.3.5).  This finding corresponds (in part) to the pattern 
observed in the heart tissue, although in this instance the decrease observed at six months was 
more severe. The activity of the HPB remained unaltered (Figure 4.3.6).  It was a surprising 
finding since previous work from our group and others provide robust evidence that the HBP is 
involved in hyperglycemia/insulin resistance-induced damage (Fricovsky et al., 2012; Na et al., 
2013; Rajamani et al., 2011).  However, all these studies focused on the heart; therefore it is 
possible that the HBP does not play such a prominent role in the context of the liver.  Finally, 
polyol pathway activity was similar between all groups at three and six months (Figure 3.2.7). Of 
note, Lanaspa et al. (2013) found that the polyol pathway was upregulated in rats consuming 
glucose-sweetened beverages and that this directly translated to hepatic lipid accumulation.  
Although the polyol pathway activity was seemingly unaltered in our model we detected lipid 
droplets in the six month samples (histological analysis).  Based on this finding, we speculate 
that the polyol pathway is activated in a punctuate fashion, but went undetected due to the 
limited time points used in this study.  Since we detected minimal significant changes in the 
NOGPs, we conclude that moderate SSB consumption does not have a marked inhibitory effect 
on the glycolytic pathway. 
We used histological staining techniques (H & E and Masson’s Trichrome) to assess lipid 
deposition, fibrosis and overall structural quality of the liver samples (Figure 4.3.9-4.3.12).  In 
agreement with Figlewicz et al., (2009) and Lozano et al. (2016) there was no structural damage 




in any of the samples.  At six months, however, the H & E stains revealed an increase in 
intracellular lipid droplets in the SSB and Cal-control group.  This is in agreement with others 
who also observed a moderate increase in hepatic lipid stores of fructose- and sucrose-
consuming rats (Jürgens et al., 2005).  This is further supported by our earlier experimental 
work where the results from a commercial triglyceride kit revealed that hepatic triglyceride levels 
were significantly higher at six months in SSB-consuming rats compared to water-consuming 
rats (Benadè, 2014).  Together these data corroborate the proteomic data indicating that SSB 
consumption promotes hepatic lipid storage.  This effect seems to be time dependent, since we 
detected no differences at three months, thus prolonged SSB consumption may induce 
significant lipid accumulation in the liver.  We did not detect signs of fibrosis (Masson’s 
Trichrome slides) after three or six months, despite the fact that ER stress is been linked to 
fibrosis in the literature.   
Finally we hoped to determine whether the moderate SSB consumption triggered stress 
pathways associated with ER stress (known as the ER overload response) since there was 
insufficient support for this response in the proteomic data.   Here we determined the expression 
levels of TNF-α and IκB as the former is considered a master regulator of inflammation while IκB 
is directly linked to NF-κB activity.  IκB bind to NF-κB in the cytosol to prevent its translocation to 
the nucleus.  In this manner increased IκB levels will attenuate NF-κB activation. By contrast, 
lower IκB levels (by degradation process) are linked to NF-κB activation.  In our model moderate 
SSB consumption did not alter hepatic TNF-α and IκB expression, although IκB levels were 
significantly reduced in the Cal-control group at three and six months (Figure 4.3.8).  This is 
likely a fat-specific response and hence not directly relevant to this study.  Additionally, 
circulating CRP levels were below the detectable range in  blood samples.  Together this 
suggests that frequent but moderate SSB (and high sugar) intake do not initiate the ER overload 
response.  This finding is in agreement with earlier pre-clinical studies (Figlewicz et al., 2009; 
Lozano et al., 2016).  By contrast, some of our preliminary data showed an SSB-induced 
increase in hepatic JNK activity after six months.  Therefore, more research is required to fully 
elucidate whether the ER overload response is triggered and how its downstream effects will 
manifest in response to moderate SSB consumption.  
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Chapter 5: Concluding remarks  
Cardio-metabolic diseases such as T2DM and CVD cause  19 million deaths annually (WHO 
factsheet #355, 2015).  The prevalence of cardio-metabolic diseases is increasing rapidly 
especially in low- and middle-income countries, e.g. the amount of obese children in Africa has 
doubled over the past 25 years (WHO Fact sheet #311, 2016) while the IDF predicts that Africa 
will suffer a 93% increase in the incidence of T2DM between 2014 and 2035 (IDF Diabetes 
Atlas, 2014).  In South Africa the statistics are just as condemning: currently  15% of all adult 
males and ≥ 30% of females are obese (BMI ≥ 30 kg/m2),  27.5% suffer from hypertension, 
 35% display elevated cholesterol levels and  12.5% exhibit fasting blood glucose levels 
associated with diabetes.  Researchers rightfully refer to cardio-metabolic diseases as a global 
pandemic (Grundy, 2007; Lewis & Hennekens, 2016; Skrha, 2014).  In parallel, there has been 
a global increase in sugar consumption (Lustig et al., 2012).  In the US the average sugar 
consumption is ≥ 36 teaspoons/capita/day (conversion 100 calories = 6 teaspoons). The 
average South African consumes 12-18 teaspoons of sugar per day (converted from Lustig et 
al., 2012).  Although this seems moderate compared to the US, it is still more than double the 
amount recommended by the WHO (≤ 6 teaspoons per day).  A significant portion of  excess 
sugar intake is derived from SSBs (US Department of Agriculture & US Department of Health 
and Human Services, 2010) and SSB consumption continues to increase globally (Basu et al., 
2013). 
Despite the large volume of epidemiological data supporting the link between SSB consumption 
and the onset of cardio-metabolic diseases, there are currently insufficient clinical data to 
confirm causality (Stanhope, 2015).  As a result, the health effects of frequent SSB intake 
remains disputed.   Moreover, the available clinical studies produced inconsistent results in 
several of the parameters that were measured (refer to section 1.2.3.4) – thus hindering the 
deduction of  coherent, plausible pathophysiological mechanisms.  In the light of this, the CMRG 
established a unique rat model for long-term moderate SSB consumption which allows for in-
depth molecular and functional analyses.  Unlike most other animal models that simply diluted 
SSB/sugar into the rodents’ drinking water, we administered SSB by gavaging.  Moreover, we 
supplied the actual SSB (in moderate amounts) unlike the majority of studies that used fructose, 
glucose or sucrose in excessive amounts.  This allowed us to improve on some drawbacks of 
previous studies, i.e. not being able to regulate how much each rat consumed, controlling for 
inappropriately high sugar dosages compared to overall caloric intake, and by evaluating the 




effects of an actual SSB.  By using a relatively low dosage we aimed to generate data that will 
be far more applicable to the majority of the population and also to detect the earliest 
perturbations underlying ultimate onset of disease – before the onset of significant functional 
changes.  
Hindsight is always 20/20.  Despite our attempts to improve  on previous study protocols, the 
current study is not without its own limitations.  We recommend that future studies conduct 
expression proteomics on samples from more than one time point as this will aid in the 
interpretation of ambiguous results.  The mitochondrial bioenergetics data were particularly 
difficult to interpret and in this respect  high-resolution mitochondrial respirometry should provide 
valuable insight.  Furthermore, we recommend that post-translational protein modifications 
should also  be taken into consideration instead of focusing solely on hepatic protein expression 
levels.  We further recommend that various markers of ER stress should be evaluated to 
corroborate the link between moderate SSB intake and ER stress.  Lastly, we recommend that 
the SSB intervention should be assessed over a longer time period in order to even better 
understand the consequences of long-term SSB intake.   
This study generated two main findings: 
 Moderate long-term SSB intake induced minimal changes in systemic markers of cardio-
metabolic complications together with no significant body weight alterations and 
functional changes in the liver; 
 SSB consumption did, however, induce hepatic ER stress as an early metabolic 
perturbation – this effect is driven mainly through increased  caloric intake rather than 
the SSB per se.  
What is the verdict? Is it safe to consume SSBs on a regular basis?  Findings from the current 
study support a firm ‘’no’’ as a response to this question.  Due to the caloric make-up of SSBs, it 
almost inevitably leads to excessive calorie intake with downstream intracellular effects.  Here 
our data revealed that even moderate SSB consumption triggers hepatic ER stress and 
subsequent intracellular responses despite minimal phenotypic and functional changes.  Of 
concern, the SSB-induced shift in the hepatic protein expression profile resembles the signature 
found in insulin resistant/diabetic models.  Thus a key, broader public message derived from 
this thesis is that SSB consumption contributes to the onset of cardio-metabolic diseases 
without the manifestation of any early phenotypic/functional “warning signs”.  We propose that 




focusing on easily identifiable and measurable markers of ER stress may provide a novel 
biomarker to detect risk at a much earlier stage in this context.     
Don’t drink Jive* – stay alive!   (*or any other SSB) 
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Appendix B: Proteomics  
Sample preparation 
Liver tissue (100 μg) was placed in 0.5 mL extraction buffer (triethylammonium bicarbonate 
[TEAB, Sigma; 100 mM], Urea [8 M], Tween20 [0.5%], NaCl [100 mM], EDTA [2 mM] and 
triscarboxyethyl phosphine (TCEP, Fluka; 5-10 mM]) and homogenized (Polytron PT2100, 
Kinematica, Luzern, Switserland) for 3   15 sec bursts. Thereafter the samples were 
centrifuged (Spectrafuge™ 24D, Labnet, Edison NJ) for 10 min at 12000 x g and 400 μL 
supernatant was collected into fresh microtubes.  Acetone cooled to -20oC (1.6 mL) was added 
to each sample.  The content was mixed and the tubes were left overnight at -20oC.  On the 
second day the samples were centrifuged (Spectrafuge™ 24D, Labnet, Edison NJ) once more 
(12000 xg for 10 min) and the pellets were collected and sent to the Central Analytical Facility 
(Faculty of Medicine and Health Sciences, Stellenbosch University) where the rest of the 
experimental work was completed under supervision of Dr. Mare Vlok (Laboratory Manager).   
The supplied pellets were dissolved in 100 mM TEAB containing 4 M guanindine-hydrochloride 
(Sigma-Aldrich, St. Louis, MO) and 1% octylglucopyranoside by sonication for 5 min. The 
protein suspension was centrifuged at 12 000   g for 10 min (Spectrafuge™ 24D, Labnet, 
Edison NJ). The supernatant was removed and the proteins were precipitated once more with 5 
volumes acetone cooled to -20oC (overnight). The next day proteins were pelleted by 
centrifugation (Spectrafuge™ 24D, Labnet, Edison NJ)  12 000   g for 10 minutes before being 
dissolved in 100 mM TEAB containing 4M guanindine-hydrochloride. Proteins concentration 
was determined spectrophotometrically at 280 nm using a NanoDrop spectrophotometer 
(Thermo Scientific, Waltham, MA). 
In-solution digest 
All reagents used were analytical grade or equivalent. Samples were reduced by adding 50 mM 
TCEP; Fluka in 100 mM TEAB (final concentration 5mM TCEP) for 30 min at room temperature. 
Following reduction, cysteine residues were modified to methylthio-cysteine using 200 mM 
methane methylthiosulphonate (MMTS; Sigma-Aldrich, St. Louis, MO) in 100 mM TEAB (final 
concentration 20 mM) for 30 min. After modification the samples were diluted to 98 μL with 100 
mM TEAB. Proteins were digested by adding 5 μL trypsin solution (1μg/ μL) (Promega 
Corporation, Fitchburg, WI) followed by an 18 hr incubation at 37°C. The samples were dried 




down and resuspended in 100 μL 2% acetonitrile (Sigma-Aldrich [Fluka], St. Louis, MO): water 
and 0.1% formic acid (FA; Sigma-Aldrich, St. Louis, MO). 
Desalting  
Residual digest reagents were removed using an in-house manufactured C 18 stage tip 
(Empore Octadecyl C 18 extraction discs; Sigma-Aldrich (Supelco), St. Louis, MO. The 20 μL 
sample was loaded onto the stage tip after activating the C 18 membrane with 30 μL methanol 
(Sigma-Aldrich, St. Louis, MO) and equilibration with 30 μL 2% acetonitrile:water; 0.05% TFA. 
The bound sample was washed with 30 μL 2% acetonitrile: water, 0.1% formic acid before 
elution with 30 μL 50% acetonitrile: water; 0.1% formic acid. The eluate was evaporated to dry 
and dried peptides were dissolved in 20 μL 2% acetonitrile:water; 0.1% FA for liquid 
chromatography and mass spectrometry analysis. 
Liquid chromatography 
Dionex nano-RSLC Liquid chromatography was performed on a Thermo Scientific Ultimate 
3000 RSLC equipped with a 0.5 cm   300 μm C18 trap column and a 35 cm   75 μm in-house 
manufactured C18 column (Luna C18, 3.6 μm; Phenomenex, Torrance, CA) analytical column. 
The solvent system used was loaded: 2% acetonitrile:water; 0.1% FA; Solvent A: 2% 
acetonitrile:water; 0.1% FA and Solvent B: 100% acetonitrile:water. The samples were loaded 
onto the trap column using loading solvent at a flow rate of 15 μL/min from a temperature 
controlled autosampler set at 7oC. Loading was performed for 5 min before the sample was 
eluted onto the analytical column. Flow rate was set to 500 nL/min and the gradient generated 
as follows: 2.0% -10%B over 5 min; 5% -25% B from 5 -50 min using Chromeleon non-linear 
gradient 6, 25%-45% from 50-65 min, using Chromeleon non-linear gradient 6. Chromatography 
was performed at 50°C and the outflow delivered to the mass spectrometer through a stainless 
steel nano-bore emitter. 
Mass spectrometry  
Mass spectrometry was performed using a Thermo Scientific Fusion mass spectrometer 
equipped with a Nanospray Flex ionization source (Thermo Scientific, Waltham, MA). The 
sample was introduced through a stainless steel emitter. Data were collected in positive mode 
with spray voltage set to 2 kV and ion transfer capillary to 275°C. Spectra were internally 
calibrated using polysiloxane ions at m/z = 445.12003 and 371.10024. MS1 scans were 
performed using the orbitrap detector set at 120 000 resolution over the scan range 350-1650 




with AGC target at 3 E5 and maximum injection time of 40 minutes. Data was acquired in profile 
mode. MS2 acquisitions were performed using monoisotopic precursor selection for ion with 
charges +2-+6 with error tolerance set to +/- 0.02 ppm. Precursor ions were excluded from 
fragmentation once for a period of 30 seconds. Precursor ions were selected for fragmentation 
in HCD mode using the quadrupole mass analyzer with HCD energy set to 32.5%. Fragment 
ions were detected in the orbitrap mass analyzer set to 15 000 resolution. The AGC target was 
set to 1E4 and the maximum injection time to 45 minutes. The data was acquired in centroid 
mode.  
Data analysis  
The raw files generated by the mass spectrometer were imported into the Proteome Discoverer 
v1.4 (Thermo Scientific, Waltham, MA) and processed using the SequestHT algorithm here 
included in Proteome Discoverer. Data analysis was structured to allow for methylthio as a fixed 
modification as well as NQ deamidation (NQ), oxidation (M). Precursor tolerance was set to 10 
ppm and fragment ion tolerance to 0.02 Da. The database used was the Rattus rattus database 
obtained from Uniprot Knowledge Base (The UniProt Consortium, 2014). The raw files 
generated were also converted to Mascot generic format (mgf) and the files interrogated using 
the Myrimatch algorithm through SearchGUI. Search parameters were set as for Sequest HT 
search. The results files were important into Scaffold 1.4.4 and identified peptides validated 
using the X!Tandem search algorithm included in ScaffoldQ+ (Proteome Software, Portland, 
OR). Peptide and protein validation were done using the Peptide and Protein Prophet 
algorithms. Protein quantitation was performed by first performing a ANOVA analysis and 
applying the Hochberg-Benjamini correction (significant when P < 0.00275 after correction). The 
proteins showed to be statically different were marked for fold change calculations. Two 
replicates, 1-3A Rep1 and 2-3A Rep1 deviated significantly from the other replicates and were 
excluded from the quantitation analysis.  
 
  




Appendix C: Western blotting techniques  
Protein extraction from tissues 
Preparation of RIPA buffer  
Base ingredients 
 Tris-HCl (buffering agent prevents protein denaturation) 
 NaCl (salt prevents non-specific protein aggregation)  
 NP-40 (non-ionic detergent to extract proteins; 10% stock solution in H2O) or use Triton 
X-100 
 Na-deoxycholate (ionic detergent to extract proteins; 10% stock solution in H2O; protect 
from light). Adjust the pH to 9, then boil, cool, and re-adjust the pH to 9. Repeat this 
process until the solution becomes colorless 
Note: Do not add Na-deoxycholate when preparing lysates for kinase assays. Ionic detergents 
can denature enzymes, causing loss of activity.  
 
RIPA protease inhibitors 
 Phenylmethylsulfonyl fluoride (PMSF) (200 mM stock solution in isopropanol; store at 
room temperature) 
 EDTA (calcium chelator; 100 mM stock solution in H2O, pH 7.4) 
 Leupeptin (store frozen in aliquots, 1 mg/mLin H2O) 
 Aprotinin (store frozen in aliquots, 1 mg/mLin H2O) 
 Pepstatin (store frozen in aliquots, 1 mg/mLin methanol) 
 
RIPA phosphatase inhibitors 
 Activated Na3VO4 (200 mM stock solution in H2O; see sodium orthovanadate activation 
protocol). 
 NaF (200 mM stock solution: store at room temperature) 
Note: Do not add phosphatase inhibitors when preparing lysates for phosphatase assays. 





 RIPA trypsin inhibitors 
 Benzamidine (200 mM stock solution -dissolve in ddH2O – store at -20ºC) 
Note: When blotting for O-GlcNAc, Pugnac should be added to prevent the removal of 
O-GlcNAc modifications. Make 200 µM stock solution 
 
Sodium orthovanadate activation protocol 
1. Sodium orthovanadate should be activated for maximal inhibition of protein 
phosphotyrosyl-phosphatases. 
2. Prepare a 200 mM solution of sodium orthovanadate. 
3. Adjust the pH to 10 using either 1 N NaOH or 1 N HCl. The starting pH of the sodium 
orthovanadate solution may vary depending on different lots of the chemical. The 
solution will become yellow in color at pH 10. 
4. Boil the solution until it turns colorless (~ 10 min). 
5. Cool to room temperature. 
6. Re-adjust the pH to 10 and repeat steps 3 and 4 until the solution remains colorless 
and the pH stabilizes at 10. 
7. Store the activated sodium orthovanadate as aliquots at -20°C. 
8. This procedure de-polymerizes the vanadate, converting it into a more potent 
inhibitor of protein tyrosine phosphatases. 
 
Procedure:  
Prepare 100 mLmodified RIPA buffer as follows:  
 Add 790 mg Tris base to 75 mLdistilled water (ddH2O). Then add 900 mg NaCl and stir 
the solution until all solids are dissolved. Using HCl, adjust the pH to 7.4. 
 Add 10 mLof 10% NP-40 to the solution. 
 Add 2.5 mLof 10% Na-deoxycholate and stir until solution is clear. 




 Add 1 mLof 100 mM EDTA to the solution. Adjust the volume of the solution to 100 
mLusing a graduated cylinder.  
 Ideally, the remaining protease and phosphatase inhibitors should be added to the 
solution on the same day for running of the assay. Therefore, it is best to aliquot the 
buffer in 10 mLaliquots without the protease inhibitors and store at 2-8°C. 
 RIPA with inhibitors - on day of use, thaw the required amount of RIPA buffer and add the 
appropriate volume of protease inhibitors to the buffer. 
 
For 10 mLRIPA add: 
10 μL aprotonin; 10 µL of leupeptin; 50 µL of PMSF, Na3VO4, and NaF and benzamidine, 100 
μL pepstatin and 50 µL Pugnac. 
  
NB: these are the volumes for 10 mLof RIPA, but with the exception of PMSF, the diluted 
inhibitors are stable in aqueous solution for up to 5 days.  Add PMSF last; PMSF have a half-life 
of 30 minutes in aqueous solution. 
  
The final concentrations in the modified RIPA buffer should be:  
Tris-HCl: 50 mM, pH 7.4 Leupeptin: 1 µg/mL 
NP-40: 1% Aprotonin: 1 ug/ml 
Na-deoxycholate: 0.25% Pepstatin: 10 ug/ml 
NaCl: 150 mM Na3VO4: 1 mM 
EDTA: 1 mM NaF: 1 mM 
PMSF: 1 mM PUGNAc: 1µM 








 Cut tissue samples into small pieces and place into a 2 mLmicrotube. 
 Pour RIPA buffer into the microtubes containing the tiny pieces of tissue samples – (aim 
to make homogenates that are 1:2 w/v tissue: lysis buffer). 
 Using a dounce homogenizer (Ultra-Turrax homogenizer, IKA, China), homogenize the 
tissue until a fine slurry is obtained. 
 Transfer the homogenates to fresh pre-chilled 2 mLmicrotubes and keep on ice. 
 Once the foam has dissipated (1 hour) collect the content of the microtube and transfer 
it into a clean tube. 
 Centrifuge (Spectrafuge™ 24D, Labnet, Edison NJ) at 17 226   g. for 15 min at 4ºC. 
 Transfer the supernatants (protein lysates) to clean pre-chilled microtubes. 
 Perform Direct Detect® protein determination and then freeze samples at -80ºC.  
 
Direct Detect®  protein determination 
 Apply 2 µL of sample solution (position 2-4) and sample buffer blank (position 1) on the 
card. 
 Select the appropriate calibration curve on the machine  
 Insert the card vertically into the slot in the top of the sampling accessory. 
 The card notch should face towards the center of the instrument (align arrows on card 
and instrument). 
 Instrument dries samples, then measures each spot. 
 Acquire spectra. 
 Statistical data displayed for all 3 samples. 
 User can select which data points to exclude, if any. 
 User has option to print a report of current data, or export as a .CSV file. 
 Compare results to internal Amino Acid Analysis verified BSA standard or create your 
own standard curve. 








Laemmli’s loading buffer 
ddH20 3.8 mL 
0.5 M Tris-HCl, pH 6.8 1.0 mL 
Glycerol 0.8 mL 
10% (w/v) SDS 1.6 mL 
0.05% (w/v) Bromophenol blue 0.4 mL 
 
Materials: 
0.5 mL microtubes 
Sharp tweezers or a syringe needle 
β-mercaptoethanol 
Ice 
Heating block set to 95οC (or beaker of water on hot plate) 
Vortex (Scientific industries, Bohemia NY) 
Microtube centrifuge (Spectrafuge™ 24D, Labnet, Edison NJ)  
 
Method 
 Make a working solution of Laemmli’s sample buffer – 850 µL Laemmli’s stock buffer 
solution together with 150 µL β-mercaptoethanol (work in fume hood). Vortex (Scientific 
industries, Bohemia NY) thoroughly. 
 Calculate the appropriate volume of each sample to give equal loading protein amounts 
(e.g.: 50 μg protein/sample) and calculate the number of sample sets needed. 




 Label microtubes for each sample. 
 Add the appropriate amount of working solution of Laemmli’s and RIPA buffer, as 
calculated, to each appropriate tube (work in fume hood). 
 Add the appropriate volume of each protein sample to respective microtubes. 
 Close samples and punch small hole in lid with tweezers or syringe needle. 
 Heat samples on heating block for 5 minutes. 
 Centrifuge (Spectrafuge 24D Labnet, Edison NJ) each tube at 17, 226   g (briefly for 
10 sec) and place on ice immediately. 




Polyacrylamide gel electrophoresis (PAGE) gels were casted according to the protocol provided 
by the Tris-glycine extended (TGX) Stain-Free™ FastCast™ Acrylamide Kit, 10% #161-0183 
(BIO-RAD, Hercules CA). 
 
 Add 7.5 µL of protein marker (BIO-RAD, unstained Precision Plus Protein™ standard, 
Hercules CA) to the first lane on the far left of each precast gel (BIO-RAD, Hercules CA). 
 Add the appropriate amount of sample slowly into respective lanes using the gel-loading 
tips. 
 Place the green lid with appropriate leads (black to black: red to red) on top of the tank 
and connect to the power pack (Power PAC 1000, BIO-RAD, Hercules CA). 
 Add running buffer to just below the line indicated on the tank. 
 
Running buffer: 10x SDS (1L) 
 10 g SDS 
 30.3 g Tris-base 




 144.1 g glycine 
Dissolve in 800.mL ddH2O, adjust volume to 2 L. Make 1x running buffer by adding 100 mL 10  
running buffer to 900 mL ddH2O. 
 
 Run at 100V (constant), 400 mA for 85-90 min to allow samples to migrate through gel. 
 Switch off power and disconnect electrodes. Remove gel plates from the tank and 
immediately proceed to the electro-transfer step. 
 Image gels to evaluate sample migration as well as visualizing total protein content of 
each sample (Image Lab™ Software version 4.0, BIO-RAD, Hercules CA). 
 
Transfer using Transfer Turbo and Chemi-Doc:  
 Open the transfer pack (Trans-Blot® Turbo™, transfer pack, BIO-RAD, mini format,   0.2 
μm PVDF, single application, Hercules CA) and place the blotting paper marked 
“bottom” on bottom of the Transfer Blot (Trans-Blot® Turbo™, transfer system, BIO-RAD, 
Hercules CA) cassette on top. Gently roll out any air bubbles.  
 Place the gel on top of the membrane with the low molecular weight protein side facing 
towards the center of the cassette and again gently roll out any trapped air bubbles.  
 Then place the blotting paper marked “top” from the transfer pack over the gel and roll 
out air bubbles (align the blotting paper tabs in the same manner as when it came out of 
the transfer pack). 
 Place lid on top and lock in place. 
 Place the cassette in the Transfer Blot (Trans-Blot® Turbo™, transfer system, BIO-RAD, 
Hercules CA ) and set to transfer for 7 min (unless stated otherwise), this will allow the 
protein to be transferred from the gel onto the membrane. 
 Check that protein has transferred and then place in methanol for 30 sec then leave to 
dry completely. 
 Rinse membrane 3 x 5 min with TBS-T. 
 




10  TBS Buffer: 
 48.4 g Tris 
 160 g NaCl 
Dissolve in 1.5 L ddH2O. Set pH to 7.6 with HCl and adjust volume to 2 L. 
1  TBS-T buffer: 
 100 mL 10  TBS buffer 
 900 mL ddH2O 
 1 mL Tween 
 
 Block for 1 hr in 5% BSA (TNF-α, IκB ) or 5% milk (PKCβII) made up in TBS-T.  O-
GlcNAc must be blocked in 5% BSA, but only for 20 min.  
 Wash 3 x 5 minutes in TBS-T (unless stated otherwise). 
 Place membrane in 50 mL Falcon tube (BD Bioscience, Bedford MA) containing 5 mL of 
primary antibody  
O-GlcNAc (CTD110.6, Santa Cruz Biotechnology, Santa Cruz CA); 1:500 dilution; in 
TBS-T  
PKCβII (Abcam, Cambridge  MA);  
anti-TNF-α (Abcam, Cambridge MA),1:1000 dilution; in 5% BSA   
IκB-α  (Cell Signaling Technology®, Danvers MA) diluted 1:1000 in TBS-T 
 Place on rotator in 4ºC walk-in fridge overnight. 
 
DAY 2: 
 Remove membrane from primary antibody (save antibody – freeze at -20ºC). 
 Wash 3 x 5 minutes in TBS-T. 
 Prepare secondary antibodies by diluting in 5 mL TBS-T in a 50 mL Falcon tube (BD 
Bioscience, Bedford MA).  




PKCβII, IκB-α, TNF-α: Secondary HRP-conjugated anti-rabbit antibody (Cell Signaling 
Technology
®
, Danvers MA); 1:4000; in TBS-T 
O-GlcNAc: anti-mouse monoclonal secondary antibody (anti-mouse IgG, HRP-linked, Cell 
Signaling Technology
®
, Danvers MA); 1:2000; in TBS-T  
 Place on roller for 1 hour at room temperature. 
 Pour off secondary antibody into tube and freeze for later use. 
 Wash membrane 3 x 5 minutes in TBS-T. 
 NB: in order to image your stain free blot the imaging steps below must be followed 
before the addition of the ECL.  For this it is necessary that the gel was activated prior to 
electrophoretic transfer.  The images that are taken after the addition of the ECL is 
known as chemiluminescent blots.   
 Take ECL reagents (BIO-RAD, Hercules CA) A & B from fridge and equilibrate to room 
temperature. 
 Prepare ECL substrate in a 1:1 ratio of A:B. Use foil-covered microtubes to prepare 
solution as ECL is light sensitive. 
 Pour off the TBS-T from membrane and add ECL, spreading evenly over the surface of 
the membrane by gentle tilting. If MW of protein is known, just add ECL to this area to 
save on the amount of ECL as it is very costly. 
 Swirl gently for 2 minutes. 
 Place membrane on tray of  the ChemiDoc (BIO-RAD, ChemiDoc™, XRS+ system, 
Hercules CA) taking care to remove any visible bubbles. 
 
Image analysis on Chemi-Doc: 
 Select “Image Lab™ Software version 4.0 (BIO-RAD, Hercules CA), quantification 
analysis” program from desktop on computer. 
 The ‘’start’’ page will pop up – can choose an existing protocol or create a new one. 
 All protocol settings can be modified by selecting the item on the left under “Protocol Set 
Up”. 
 For self-poured gels: Select “Blot” and then select “Chemi” from drop-down window. 




 Next, set the imaging area to 12 x 9 cm (W x L). 
 Specify the optimum exposure e.g. “intense bands”.  
 Default color is auto selected – you can change this if required. 
 Select “Lane and Band Detection”. 
 Select either “Low” or “High” for intense or faint bands or use the “custom” slider to set 
exact sensitivity. 
 Select “Analyze MW” then select MW standard used, the appropriate lane and the 
regression method (linear, semi-log) - if using Bio-Rad marker you can analyze against 
this (a stain-free marker was used in order to activate and visualize total protein content 
before the gel was transferred to the membrane). The stain-free gel does not require a 
loading control as the total protein content is visualized and analysed for normalization. 
Gels are visualized to calculate total protein content (Image Lab™ Software version 4.0, 
BIO-RAD, Hercules CA) 
 Generate a report: Specific output, then provide a customized name and specify whether 
to be printed or displayed. 
 Save the protocol summary.  
 Load the gel into the imager and position it on the stage using the “position gel” option – 
this will produce a live image of the gel’s position –adjust by opening the top door of 
Chemi-doc- adjust the zoom settings and position to obtain image exactly as required. 
 When gel is correctly positioned, click on “Run Protocol”. 
 Once protocol has run, the images and report will be displayed with all selected analyses 
applied. 
 Save the images required to an appropriate folder in ‘’Documents’’. 










Quantitative analysis (Total protein normalization) 
 Create a multichannel image with the stain-free blot in “Channel 1” and the 
chemiluminescent blot in “Channel 2”.  The multichannel image  option can be found in 
the “File” tab.  Click OK 
 Click on the “RGB” icon to deselt the overlay option  
 Use the “Lane and Bands” tool to detect the lanes on your stain-free image.  The lanes 
should be wide enough to include the entire band width.  Additionally the lanes should all 
have similar widths and should not touch each other.  The disk size should be set to 70 
to subtract the background.  
 Copy and paste the lanes over to the chemiluminescent blot – adjust the lanes if 
necessary.   
 Choose “Detect Bands” on the “Band” tab to detect all bands on the chemiluminescent 
blot.  Adjust the bands as needed  
 Select “Normalization” in the Analysis Tool Box.  Select the stain-free gel as the 
normalization channel.  “Total Lane Protein” must be selected.   
 Go to the “MW Protein Standard” in the Analysis Tool Box.  On the stain-free gel tick the 
box below the MW standard lane (protein ladder) 











Stellenbosch University  https://scholar.sun.ac.za
